Sod1-modulating compositions and methods of use thereof

HK40137386APending Publication Date: 2026-09-11ADARX PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124952
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-21
Filing Date
2026-06-17
Publication Date
2026-09-11
Patent Text Reader

Abstract

Aspects of the present disclosure provide compounds, compositions and methods for modulating the expression or activity of superoxide dismutase 1 (SOD1). In some aspects, the compounds, compositions, and methods of the present disclosure are useful for reducing the expression of SOD1 mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the present disclosure are useful for reducing the expression of SOD1 protein in a cell or animal.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480035024.2 (22) Application Date 2024.05.24 (30) Priority Data 63 / 504,692 2023.05.26 US 63 / 510,090 2023.06.23 US 63 / 613,687 2023.12.21 US (85) PCT International Application Entering National Phase Date 2025.11.25 (86) PCT International Application Application Data PCT / US2024 / 031069 2024.05.24 (87) PCT International Application Publication Data WO2024 / 249328 EN 2024.12.05 (71) Applicant: Adalx Pharmaceuticals, Inc. Address: USA (72) Inventors: Li Zhen, Zhu Rui, Hugh-Jing, Huang Chengbo (74) Patent Agency: Beijing J&J Intellectual Property Agency Co., Ltd. 11227 Patent Attorney: Zhang Shanshan (51) Int.Cl. C12N 15 / 113 (2006.01) A61K 31 / 713 (2006.01) (54) Invention Title: SOD1 Regulation Composition and Method of Use Thereof (57) Abstract: This disclosure provides compounds, compositions, and methods for regulating the expression or activity of superoxide dismutase 1 (SOD1). In some aspects, the compounds, compositions, and methods of this disclosure can be used to reduce the expression of SOD1 mRNA in cells or animals. In some aspects, the compounds, compositions, and methods of this disclosure can be used to reduce the expression of SOD1 protein in cells or animals. Claims 9 pages, Description 151 pages, CN 121335980 A 2026.01.13 CN 1 21 33 59 80 A 1. A compound comprising a modified oligonucleotide of 14 to 30 linked nucleosides, said modified oligonucleotide having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 adjacent nucleobases comprising any nucleobase sequence of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. 2. A compound comprising a modified oligonucleotide of 14 to 23 linked nucleosides, said modified oligonucleotide having a nucleobase sequence comprising any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. 3. A compound comprising a modified oligonucleotide having a nucleobase sequence selected from SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223.4. The compound of any one of claims 1-3, wherein the modified oligonucleotide is at least 80%, at least 85%, at least 90%, or at least 95% complementary to SEQ ID NO: 1 or 2. 5. The compound of any one of claims 1-4, wherein the modified oligonucleotide comprises at least one modification selected from modified nucleoside linkages, modified sugars, and modified nucleobases. 6. The compound of any one of claims 1-5, wherein the compound is double-stranded. 7. A compound comprising a first modified oligonucleotide of 14 to 23 linked nucleosides, the first modified oligonucleotide having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides comprising any nucleobase sequence of SEQ ID NO: 11-223; and a second modified oligonucleotide of 14 to 23 linked nucleosides, the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. 8. A compound comprising a first modified oligonucleotide of 14 to 23 linked nucleosides, the first modified oligonucleotide having a nucleobase sequence comprising any one of SEQ ID NO: 11-223; and a second modified oligonucleotide of 14 to 23 linked nucleosides, the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. 9. A compound comprising a first modified oligonucleotide having a nucleobase sequence selected from the group consisting of any one of SEQ ID NO: 11-223; and a second modified oligonucleotide of 19 to 23 linked nucleosides, the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. 10. The compound of any one of claims 7-9, wherein the first modified oligonucleotide has at least 80%, at least 85%, at least 90%, or at least 95% complementarity or identity in length with SEQ ID NO: 1 or 2. 11. The compound of any one of claims 7-10, wherein the first modified oligonucleotide has at least one, at least two, or at least three mismatches with the region of the same length as the first modified oligonucleotide in SEQ ID NO: 1 or 2. 12. The compound of any one of claims 7-11, wherein the first modified oligonucleotide has at least one, at least two, or at least three mismatches with the region of the same length as the first modified oligonucleotide in SEQ ID NO: 1 or 2.13. The compound of any one of claims 7-11, wherein the complementary region between the first modified oligonucleotide and the second modified oligonucleotide is 19 to 23 linked nucleosides. 14. The compound of any one of claims 7-11, wherein the complementary region between the first modified oligonucleotide and the second modified oligonucleotide is 21 to 23 linked nucleosides. Claims 1 / 9 page 2 CN 121335980 A 15. The compound of any one of claims 7-11, wherein the first modified oligonucleotide and the second modified oligonucleotide are completely complementary. 16. The compound of any one of claims 7-15, wherein the first modified oligonucleotide comprises at least one modification selected from modified nucleoside linkages, modified sugars, and modified nucleobases. 17. The compound of any one of claims 7-16, wherein the second modified oligonucleotide comprises at least one modification selected from the group consisting of modified nucleoside interlinks, modified sugars, and modified nucleobases. 18. The compound of any one of claims 5, 16, and 17, wherein the modified nucleoside interlink is a thiophosphate nucleoside interlink or a methylphosphonate nucleoside interlink. 19. The compound of claim 18, wherein the thiophosphate nucleoside interlink or the methylphosphonate nucleoside interlink is located at the 3' end of the first modified oligonucleotide or the second modified oligonucleotide, or at the 5' end of the first modified oligonucleotide. 20. The compound of any one of claims 5, 16, and 17, wherein the modified sugar comprises a modification selected from the group consisting of halogens, alkoxy groups, and bicyclic sugars. 21. The compound of claim 20, wherein the modified sugar comprises a 2'-F modification. 22. The compound of claim 20, wherein the modified sugar comprises a 2'-OMe modification. 23. The compound of any one of claims 7-15, wherein each nucleoside of the first modified oligonucleotide comprises a modified sugar. 24. The compound of any one of claims 7-15, wherein each nucleoside of the second modified oligonucleotide comprises a modified sugar. 25. The compound of claim 23 or 24, wherein the modified sugar comprises a modification selected from the group consisting of halogens, alkoxy groups, and bicyclic sugars, or combinations thereof. 26. The compound of claim 25, wherein the modified sugar comprises a modification selected from the group consisting of LNA, cEt, 2'-MOE, 2'-F, 2'-OMe, and 2'-deoxy, or combinations thereof.27. The compound of claim 26, wherein the first modified oligonucleotide comprises no more than ten 2'-F sugar modifications. 28. The compound of claim 27, wherein the second modified oligonucleotide comprises no more than five 2'-F sugar modifications. 29. The compound of any preceding claim, comprising a conjugation group. 30. The compound of claim 29, wherein the conjugation group is attached to the 5' end of the modified oligonucleotide. 31. The compound of claim 29 or 30, wherein the conjugation group comprises a targeting portion. 32. The compound of claim 31, wherein the targeting portion comprises one or more ligands selected from one or more tropomyosin receptor B (TrkB) ligands, one or more type 1 cannabinoid receptor (CB1) ligands, one or more α4β1 / 7 integrin ligands, and one or more N-methyl-D-aspartate receptor (NMDA) ligands. 33. The compound of claim 32, wherein the modified oligonucleotide is the second modified oligonucleotide. 34. The compound of claim 33, wherein one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, or one or more NMDA ligands are attached to the 5' end of the modified oligonucleotide. (Claims 2 / 9, Page 3, CN 121335980 A) 35. The compound of claim 33, wherein one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, or one or more NMDA ligands are attached to the 3' end of the modified oligonucleotide. 36. The compound of claim 33, wherein one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, or one or more NMDA ligands are attached to both the 5' and 3' ends of the modified oligonucleotide. 37. The compound of any one of claims 32-36, wherein: the one or more TrkB ligands are selected from any one of formulas I-XX, XXV, and XXX; the one or more CB1 ligands are of formula XXVI; the one or more α4β1 / 7 integrin ligands are selected from any one of formulas XXVII, XXVIII, XXXI, and XXXII; and the one or more NMDA ligands are of formula XXIX. 38. The compound of any one of claims 29-37, wherein the conjugating group comprises one or more lipids. 39. The compound of claim 38, wherein the modified oligonucleotide is the second modified oligonucleotide.40. The compound of claim 38 or 39, wherein the one or more lipids are attached to the nucleoside-to-nucleotide link of the modified oligonucleotide. 41. The compound of claim 40, wherein the nucleoside-to-nucleotide link of the modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV. 42. The compound of any one of claims 32-41, wherein the modified oligonucleotide comprises: one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, or one or more NMDA ligands; and one or more lipids. 43. The compound of claim 42, wherein the modified oligonucleotide is the second modified oligonucleotide. 44. The compound of claim 42, wherein the one or more TrkB ligands, the one or more CB1 ligands, the one or more α4β1 / 7 integrin ligands, or the one or more NMDA ligands are attached to the 5' end of the modified oligonucleotide. 45. The compound of claim 42, wherein one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, or one or more NMDA ligands are attached to the 3' end of the modified oligonucleotide. 46. The compound of claim 42, wherein one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, or one or more NMDA ligands are attached to the 5' and 3' ends of the modified oligonucleotide. 47. The compound of claim 42, wherein: the one or more TrkB ligands are selected from any one of formulas I-XX, XXV, and XXX; the one or more CB1 ligands are of formula XXVI; the one or more α4β1 / 7 integrin ligands are selected from any one of formulas XXVII, XXVIII, XXXI, and XXXII; and the one or more NMDA ligands are of formula XXIX. 48. The compound of any one of claims 42-47, wherein the one or more lipids are attached to the nucleoside internucleotide of the modified oligonucleotide. 49. The compound of claim 48, wherein the nucleoside internucleotide of the modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV. 50. The compound of any one of claims 1-49, wherein the modified oligonucleotide comprises one or more substituted or unsubstituted alkyl or alkenyl groups. 51. The compound of claim 50, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups...The alkyl or alkenyl group comprises a saturated or unsaturated C4-C30 hydrocarbon chain. 52. The compound of claim 51, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise a saturated or unsaturated C5-C20 hydrocarbon chain, optionally wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise a saturated or unsaturated C14-C20 hydrocarbon chain. 53. The compound of claim 52, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise a saturated or unsaturated C16 hydrocarbon chain, a saturated or unsaturated C17 hydrocarbon chain, a saturated or unsaturated C18 hydrocarbon chain, or a saturated or unsaturated C22 hydrocarbon chain. 54. The compound of any one of claims 50-53, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups are attached to an internucleotide link of the modified oligonucleotide. 55. The compound of claim 54, wherein the internucleotide link of the modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV. 56. The compound of any one of claims 1-6, wherein the modified oligonucleotide comprises a 5'-phosphonate modification. 57. The compound of any one of claims 7-55, wherein the first modified oligonucleotide comprises a 5'-phosphonate modification. 58. The compound of claim 56 or 57, wherein the 5'-phosphonate modification is a 5'-vinylphosphonate modification or a 5'-ethylidenephosphonate modification. 59. A compound comprising: a first modified oligonucleotide containing a 5'-phosphonate modification, wherein the first modified oligonucleotide is at least 80% complementary to the region of SEQ ID NO: 1 or 2; and a second modified oligonucleotide containing one or more ligands. 60. The compound of claim 59, wherein the first modified oligonucleotide comprises a 5'-terminal nucleoside containing the 5'-phosphonate modification. 61. The compound of claim 59 or 60, wherein the 5'-phosphonate modification is a 5'-vinylphosphonate modification or a 5'-ethylidenephosphonate modification. 62. The compound of any one of claims 59-61, wherein the 5'-phosphonate modification is a 5'-vinylphosphonate modification. 63. The compound of any one of claims 59-61, wherein the 5'-phosphonate modification is a 5'-ethylidenephosphonate modification. 64. The compound of any one of claims 59-63, wherein the second modified oligonucleotide comprises one or more ligands selected from one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, and one or more NMDA ligands.65. The compound of claim 64, wherein one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, or one or more NMDA ligands are attached to the 5' end of the second modified oligonucleotide. 66. The compound of claim 64, wherein one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, or one or more NMDA ligands are attached to the 3' end of the second modified oligonucleotide. 67. The compound of claim 64, wherein one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, or one or more NMDA ligands are attached to both the 5' and 3' ends of the second modified oligonucleotide. 68. The compound of claim 64, wherein: the one or more TrkB ligands are selected from any one of formulas I-XX, XXV, and XXX; the one or more CB1 ligands are of formula XXVI; the one or more α4β1 / 7 integrin ligands are selected from any one of formulas XXVII, XXVIII, XXXI, and XXXII; and the one or more NMDA ligands are of formula XXIX. 69. The compound of any one of claims 59-68, wherein the second modified oligonucleotide comprises one or more TrkB ligands. 70. The compound of claim 69, wherein the one or more TrkB ligands are selected from any one of formulas I-XX, XXV, and XXX. 71. The compound of claim 69 or 70, wherein the second modified oligonucleotide comprises one TrkB ligand. 72. The compound of claim 69 or 70, wherein the second modified oligonucleotide comprises at least two TrkB ligands. 73. The compound of claim 72, wherein the at least two TrkB ligands are identical. 74. The compound of claim 72, wherein the at least two TrkB ligands are different. 75. The compound of any one of claims 59-68, wherein the second modified oligonucleotide comprises one or more CB1 ligands. 76. The compound of claim 75, wherein the one or more CB1 ligands are of formula XXVI. 77. The compound of claim 75 or 76, wherein the second modified oligonucleotide comprises one CB1 ligand. 78. The compound of claim 75 or 76, wherein the second modified oligonucleotide comprises at least two CB1 ligands. 79. The compound of claim 78, wherein the at least two CB1 ligands are the same. 80. The compound of claim 78, wherein the at least two CB1 ligands are different.81. The compound of any one of claims 59-68, wherein the second modified oligonucleotide comprises one or more α4β1 / 7 integrin ligands. 82. The compound of claim 81, wherein the one or more α4β1 / 7 integrin ligands are selected from any one of claims XXVII, XXVIII, XXXI, and XXXII. 83. The compound of claim 81 or 82, wherein the second modified oligonucleotide comprises one α4β1 / 7 integrin ligand. 84. The compound of claim 81 or 82, wherein the second modified oligonucleotide comprises at least two α4β1 / 7 integrin ligands. 85. The compound of claim 84, wherein the at least two α4β1 / 7 integrin ligands are identical. 86. The compound of claim 84, wherein the at least two α4β1 / 7 integrin ligands are different. 87. The compound of any one of claims 59-68, wherein the second modified oligonucleotide comprises one or more NMDA ligands. 88. The compound of claim 87, wherein the one or more NMDA ligands are of formula XXIX. 89. The compound of claim 87 or 88, wherein the second modified oligonucleotide comprises one NMDA ligand. 90. The compound of claim 87 or 88, wherein the second modified oligonucleotide comprises at least two NMDA ligands. 91. The compound of claim 90, wherein the at least two NMDA ligands are identical. 92. The compound of claim 90, wherein the at least two NMDA ligands are different. 93. The compound of any one of claims 59-92, wherein the second modified oligonucleotide comprises one or more lipids. 94. The compound of any one of claims 59-93, wherein the second modified oligonucleotide comprises one or more substituted or unsubstituted alkyl or alkenyl groups. 95. The compound of claim 94, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C4-C30 hydrocarbon chains. 96. The compound of claim 95, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C5-C20 hydrocarbon chains, optionally wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C14-C20 hydrocarbon chains. 97. The compound of claim 96, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C16 hydrocarbon chains, saturated or unsaturated C17 hydrocarbon chains, saturated or unsaturated C18 hydrocarbon chains, or saturated or unsaturated C22 hydrocarbon chains.98. The compound of any one of claims 94-97, wherein one or more substituted or unsubstituted alkyl or alkenyl groups are attached to the nucleoside internucleotide of the second modified oligonucleotide. 99. The compound of claim 98, wherein the nucleoside internucleotide of the second modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV. 100. The compound of any one of claims 59-99, wherein the first modified oligonucleotide has a length of 14 to 30 linked nucleosides. 101. The compound of any one of claims 59-100, wherein the second modified oligonucleotide has a length of 14 to 30 linked nucleosides and has a region complementary to the first modified oligonucleotide. 102. The compound of any one of claims 59-101, wherein the first modified oligonucleotide has a nucleobase sequence comprising at least 14 adjacent nucleobases of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. (Claims 6 / 9, page 7, CN 121335980 A) 103. The compound of any one of claims 59-102, wherein the second modified oligonucleotide has a nucleobase sequence comprising at least 14 adjacent nucleobases of any one of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. 104. The compound of any one of claims 59-103, wherein the first modified oligonucleotide is selected from any one of IA Ref ID NO in Table 3. 105. The compound of any one of claims 59-104, wherein the second modified oligonucleotide is selected from any one of the IS Ref ID NOs in Table 3. 106. A compound comprising a first modified oligonucleotide selected from any one of the IA Ref ID NOs in Table 3, and a second modified oligonucleotide of 14 to 21 linked nucleosides that are completely complementary to the first modified oligonucleotide. 107. A compound comprising a first modified oligonucleotide selected from any one of the IA Ref ID NOs in Table 3, and a second modified oligonucleotide selected from any one of the IS Ref ID NOs in Table 3. 108. A compound comprising a first modified oligonucleotide selected from any one of the IA Ref ID NOs in Table 3, and a second modified oligonucleotide selected from any one of the IS Ref ID NOs in Table 3. 109. The compound of claim 106, 107, or 108, comprising a conjugating group.110. The compound of claim 109, wherein the conjugation group is attached to the 5' end of the modified oligonucleotide. 111. The compound of claim 109 or 110, wherein the conjugation group comprises a targeting portion. 112. The compound of claim 111, wherein the targeting portion comprises one or more ligands selected from one or more tropomyosin receptor B (TrkB) ligands, one or more type 1 cannabinoid receptor (CB1) ligands, one or more α4β1 / 7 integrin ligands, and one or more NMDA ligands. 113. The compound of claim 112, wherein the modified oligonucleotide is the second modified oligonucleotide. 114. The compound of claim 112 or 113, wherein the one or more TrkB ligands, the one or more CB1 ligands, the one or more α4β1 / 7 integrin ligands, or the one or more NMDA ligands are attached to the 5' end of the modified oligonucleotide. 115. The compound of claim 112 or 113, wherein one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, or one or more NMDA ligands are attached to the 3' end of the modified oligonucleotide. 116. The compound of claim 112 or 113, wherein one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, or one or more NMDA ligands are attached to the 5' and 3' ends of the modified oligonucleotide. 117. The compound of any one of claims 112-116, wherein: the one or more TrkB ligands are selected from any one of formulas I-XX XXV and XXX; the one or more CB1 ligands are of formula XXVI; the one or more α4β1 / 7 integrin ligands are selected from any one of formulas XXVII, XXVIII, XXXI and XXXII; and the one or more NMDA ligands are of formula XXIX. 118. The compound of any one of claims 1-117, wherein the compound is in a pharmaceutically acceptable salt form. 119. The compound of claim 118, wherein the pharmaceutically acceptable salt is a sodium salt. 120. The compound of claim 118, wherein the pharmaceutically acceptable salt is a potassium salt. 121. A composition comprising any of the compounds of the preceding claims and a pharmaceutically acceptable carrier. 122. A composition for use in a therapy comprising any of the compounds of the preceding claims. 123. A method for treating, preventing, or improving an individual's SOD1-related disease, condition, or disorder, comprising administering to the individual...124. A method of administering a compound of any one of claims 1-120 or a composition of claim 122 to an individual. 125. The method of claim 123 or 124, wherein the disease, condition, or ailment is a neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death. 126. The method of any one of claims 123-125, wherein administration of the compound inhibits or alleviates or improves neurodegenerative diseases, ALS or its symptoms such as loss of motor function or neuronal death. 127. A method of inhibiting SOD1 expression in cells, comprising contacting the cells with a compound targeting SOD1 to inhibit SOD1 expression in the cells. 128. The method of claim 127, wherein the cells are in the brain of an individual. 129. The method of claim 128, wherein the individual suffers from or is at risk of suffering from a neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death. 130. A method for alleviating or inhibiting a neurodegenerative disease in an individual, the neurodegenerative disease including ALS or its symptoms such as loss of motor function or neuronal death, the method comprising administering to the individual a compound targeting SOD1, thereby alleviating or inhibiting the individual's neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death. 131. The method of claim 130, wherein the individual suffers from or is at risk of suffering from a neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death. 132. The method of any one of claims 123-131, wherein the compound is a compound targeting SOD1. 133. The method of any one of claims 123-132, wherein the compound is a compound of any one of claims 1-120 or a composition of claim 122. 134. The method of claim 133, wherein the compound or the composition is administered parenterally. 135. The method of claim 133, wherein the compound or the composition is administered intrathecally. 136. Use of a compound targeting SOD1 for the treatment, prevention, or improvement of diseases, conditions, or disorders related to SOD1. 137. The use of claim 136, wherein the disease, condition, or disorder is a neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death. 138. The use of claim 136 or 137, wherein the compound is a compound targeting SOD1.139. The use of any one of claims 136-138, wherein the compound or the modified oligonucleotide is a compound of any one of claims 1-120 or a composition of claim 122. Claims 8 / 9 Page 9 CN 121335980 A 140. Use of a compound targeting SOD1 in the manufacture of a medicament for treating, preventing, or improving diseases, conditions, or disorders related to SOD1. 141. The use of claim 140, wherein the disease is a neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death. 142. The use of claim 140 or 141, wherein the compound is a compound targeting SOD1. 143. The use of any one of claims 140-142, wherein the compound or the modified oligonucleotide is a compound of any one of claims 1-120 or a composition of claim 122. 144. The method or use as claimed in any of the preceding claims, wherein the compound or the composition is administered to an individual approximately every three months to approximately once a year. 145. The method or use as claimed in any of the preceding claims, wherein the compound or the composition is administered to an individual about once every three months, about once every six months, or about once a year. 146. A method for delivering a therapeutic oligonucleotide to the brain of a subject, comprising administering to the subject the compound of any one of claims 1-120 or a stereoisomer, tautomer, prodrug, or salt thereof, or the composition of claim 122. 147. The method of claim 146, wherein the therapeutic oligonucleotide is delivered to one or more brain regions selected from the group consisting of: striatum, cerebellum, brainstem, hippocampus, frontal cortex, and spinal cord. 148. A method for treating or improving a disease, condition, or symptom of a subject, comprising administering to the subject the compound of any one of claims 1-120 or a stereoisomer, tautomer, prodrug, or salt thereof, or the composition of claim 122. 149. The method of claim 148, wherein the disease, condition, or symptom of the subject is a central nervous system (CNS) disease, condition, or symptom of the subject. 150. The method of claim 148 or 149, wherein the disease, condition, or symptom is Alzheimer's disease or a symptom thereof. 151. The method of any one of claims 146-150, wherein the administration is intrathecal or intraventricular (ICV) administration. 152. A method of delivering one or more cargo molecules into the living cells or tissues of a subject, comprising administering to the subject a compound of any one of claims 1-120 or a composition of claim 122.153. The method of claim 152, wherein the cell or tissue is a CNS cell or tissue. Claims 9 / 9 pages 10 CN 121335980 A SOD1 regulating composition and method of use thereof

[0001] Cross-reference to related applications

[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 504,692, filed May 26, 2023, U.S. Provisional Application No. 63 / 510,090, filed June 23, 2023, and U.S. Provisional Application No. 63 / 613,687, filed December 21, 2023, under Title 35, Section 119(e) of the United States Code. The disclosure of each prior application is considered a part of this application and is incorporated herein by reference in its entirety. Summary of the Invention

[0003] This disclosure provides compounds, compositions, and methods for regulating the expression or activity of superoxide dismutase 1 (SOD1). In some embodiments, the compounds, compositions, and methods can be used to reduce the expression of SOD1 mRNA in cells or animals. In some embodiments, the compounds, compositions, and methods can be used to reduce the amount of SOD1 protein in cells or animals.

[0004] In some embodiments, the animal suffers from a CNS-related disease, condition, or disorder. In some embodiments, the disease, condition, or disorder is a neurodegenerative disease, including amyotrophic lateral sclerosis (ALS) or its symptoms such as loss of motor function or neuronal death. Certain compounds, compositions, and methods provided herein are intended to alleviate CNS-related diseases, conditions, or disorders or their symptoms, or neurodegenerative diseases or their symptoms, including ALS or its symptoms such as loss of motor function or neuronal death, in animals. In some embodiments, the compounds and compositions provided herein are potent and tolerable and inhibit the expression of SOD1, and can be used to treat, prevent, improve, or slow the progression of: CNS-related diseases, conditions, or disorders or their symptoms, or neurodegenerative diseases or their symptoms, including ALS or its symptoms such as loss of motor function or neuronal death.

[0005] In some embodiments, the compound and composition include one or more features that effectively increase potency. In some embodiments, the compound and composition include one or more features that effectively increase tolerability. In some embodiments, the compound and composition include one or more features that effectively target the compound or composition to cells or tissues. In some embodiments, the compound and composition are more potent, have a longer duration of action, or have greater therapeutic value than disclosed compounds. Detailed Description

[0006] It should be understood that the foregoing description and the following embodiments are illustrative and explanatory only, and are not intended to limit the scope of the invention.The embodiments for which protection is sought. Section headings used herein are for organizational purposes only and are not construed as limiting the subject matter described.

[0007] As of the date of filing of this application, all references or portions thereof (including, but not limited to, patents, patent applications, articles, books, papers and GenBank, NCBI and other sequence reference records) cited herein are expressly incorporated by reference in their entirety.

[0008] It should be understood that even when shown in context with a modified compound, the sequence shown in each SEQ ID NO contained herein is independent of any modification to the sugar moiety, internucleotide link or nucleobase. Thus, a compound defined by SEQ ID NO may independently contain one or more modifications to the sugar moiety, internucleotide link or nucleobase. Oligomeric compounds referred to by compound number or Ref ID NO indicate a combination of nucleobase sequences, chemical modifications and motifs. Specification 1 / 151 pages 11 CN 121335980 A

[0009] In this document, unless otherwise expressly stated, the use of the singular includes the plural. For example, the article “a” and “an” are used herein to refer to one or more (i.e., at least one) grammatical object of the article. For instance, “element” means one or more elements, such as multiple elements. As used herein, unless otherwise stated, the use of “or” means “and / or”. Furthermore, the use of the term “including” and other forms such as “includes” and “included” is not restrictive and is interchangeable with the phrase “including but not limited to”.

[0010] Definitions Unless otherwise stated, the following terms have the following meanings: “superoxide dismutase 1” and the term “SOD1” are used interchangeably to refer to any nucleic acid or protein that is SOD1. Exemplary nucleotide and amino acid sequences of SOD1 can be found at, for example, nucleotides 5001 to 14310 of GenBank accession numbers NM_000454.5 (incorporated herein as SEQ ID NO: 1) and NG_008689.1 (incorporated herein as SEQ ID NO: 2). Further instances of SOD1 sequences are readily available from publicly available databases such as GenBank, UniProt, and OMIM. Further information about SOD1 can be found, for example, at www.ncbi.nlm.nih.gov / gene / ?term=SOD1. As used herein, SOD1 also refers to variations of the SOD1 gene, including variants available in SNP databases. Many sequence variations within the SOD1 gene have been identified and can be found, for example, in NCBI dbSNP and UniProt (see, e.g.,The term "SOD1 mRNA" can be found at www.ncbi.nlm.nih.gov / snp / ?term=SOD1. "SOD1 mRNA" refers to the mRNA encoding the SOD1 protein. SOD1 can be referred to using uppercase or lowercase letters.

[0011] "SOD1 specific inhibitor" refers to any agent capable of specifically inhibiting the expression or activity of SOD1 RNA and / or SOD1 protein at the molecular level. For example, SOD1 specific inhibitors include nucleic acids (including oligonucleotides), peptides, antibodies, small molecules, and other agents capable of inhibiting the expression of SOD1 RNA and / or SOD1 protein.

[0012] "2'-O-methoxyethyl" or "2'-MOE" refers to 2'-O(CH2)2-OCH3 modification. A 2'-O-methoxyethyl modified sugar is a modified sugar in which the 2'-OH group on the ribose ring is replaced by 2'-O(CH2)2-OCH3.

[0013] “5’ start site” means the nucleotide in the target nucleic acid or region that is aligned with the 3’ nucleotide of the antisense oligonucleotide.

[0014] “3’ stop site” means the nucleotide in the target nucleic acid or region that is aligned with the 5’ nucleotide of the antisense oligonucleotide.

[0015] “about” means within ±10% of a value. For example, if the statement “the compound achieves about 70% SOD1 inhibition” implies that the SOD1 level is inhibited in the range of 60% to 80%. When about appears before a series of values ​​or ranges, it should be understood that “about” may modify each value in the series or range.

[0016] “administer or administering” means the manner in which the compound or composition provided herein is introduced into an individual to perform its intended function. Examples of administration methods that may be used include, but are not limited to, intrathecal (IT) administration, intraventricular (ICV) administration, parenteral administration, such as subcutaneous administration, intravenous administration, intramuscular administration, intra-arterial administration, intraperitoneal administration, or intracranial administration, such as intrathecal or intraventricular administration.

[0017] "Improvement" means improvement or reduction of at least one indicator, sign, or symptom of a related disease, condition, or disorder. In some embodiments, improvement includes delaying or slowing the progression or severity of one or more indicators of the disorder or disease. The progression or severity of the indicator can be determined by subjective or objective measures known to those skilled in the art.

[0018] "Animal" means human or non-human animal, including but not limited to mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including but not limited to monkeys and chimpanzees.

[0019] "Antisense oligonucleotide" or "antisense strand" means an oligonucleotide containing a region complementary to a target nucleic acid (e.g., SOD1 RNA or a region thereof).

[0020] "Complementarity" of an oligonucleotide means when the nucleobase sequence of such oligonucleotide or one or more regions thereof is present. (Specification 2 / 151, page 12 CN)When the nucleotide sequence of column 121335980 A is aligned in the opposite direction to the nucleotide sequence of another oligonucleotide or nucleic acid or one or more regions thereof, the two nucleotide sequences are complementary. Unless otherwise specified, complementary nucleotide sequences as described herein are limited to the following pairs: adenine (A) and thymine (T), adenine (A) and uracil (U), and cytosine (C) and guanine (G). Complementary oligonucleotides and / or nucleic acids do not need to have nucleotide complementarity at each nucleoside and may contain one or more nucleotide mismatches. In contrast, “perfectly complementary” or “100% complementary” with respect to oligonucleotides means that such oligonucleotides have nucleotide matches at each nucleoside without any nucleotide mismatches.

[0021] “Composition” or “pharmaceutical composition” means a mixture of substances suitable for administration to an individual. For example, a composition may contain one or more compounds or salts thereof and a sterile aqueous solution.

[0022] "Co-administration" means administering two or more compounds in any manner, wherein the pharmacological effects of both are manifested in a patient. Co-administration does not require the two compounds to be administered as a single pharmaceutical composition, in the same dosage form, via the same route of administration, or simultaneously. The effects of the two compounds do not need to be manifested simultaneously. The effects only need to overlap over a period of time, without being concurrent. Co-administration includes administering the one or more compounds in parallel or sequentially.

[0023] "Conjugation group" means a group of atoms attached to an oligonucleotide. The conjugation group is optionally attached to the oligonucleotide via a conjugation linker. The conjugation group can, for example, alter the distribution, targeting, or half-life of the compound incorporating the conjugation group. Conjugation groups include lipids (or lipophilic moieties), ligands, and other targeting moieties.

[0024] "Conjugation linker" means a group of atoms containing at least one bond that links the conjugated portion to the oligonucleotide.

[0025] "Identity" with respect to an oligonucleotide means that the nucleotide sequence of such oligonucleotide or one or more regions thereof matches the nucleotide sequence of another oligonucleotide or nucleic acid or one or more regions thereof. The identity of an oligonucleotide with another oligonucleotide or nucleic acid does not require that every nucleobase match, and may contain one or more different nucleobases. In contrast, “complete identity” or “100% identity” with respect to an oligonucleotide means that such an oligonucleotide has the same nucleobases at every relative position along its length as another oligonucleotide or nucleic acid.

[0026] “Individual” means a human or non-human animal selected for treatment or therapy.

[0027] “Inhibition of expression or activity” with respect to a target nucleic acid or protein means reducing or blocking the expression or activity of such a target relative to the expression or activity in an untreated or control sample, and does not necessarily indicate complete elimination of expression or activity.

[0028] As used herein, the term “nucleoside linkage” is a covalent linkage between adjacent nucleosides in an oligonucleotide.As used herein, “modified nucleoside interlinking” means any nucleoside interlinking other than phosphodiester nucleoside interlinking. “Thiophosphate nucleoside interlinking” is a modified nucleoside interlinking in which a non-bridging oxygen atom of the phosphodiester nucleoside interlinking is replaced by a sulfur atom.

[0029] Representative nucleoside interlinkings having chiral centers include, but are not limited to, alkylphosphonates and thiophosphates. As further described below, modified oligonucleotides containing nucleoside interlinkings having chiral centers can be prepared into modified oligonucleotide groups containing stereorandom nucleoside interlinkings, or into modified oligonucleotide groups containing thiophosphate interlinkings with a specific stereochemical configuration. Unless otherwise indicated, the chiral nucleoside interlinkings of the modified oligonucleotides described herein may be stereorandom or have a specific stereochemical configuration.

[0030] The compounds of this disclosure may also contain atomic isotopes in non-natural proportions at one or more atoms constituting such compounds. For example, the compounds may be radiolabeled with radioactive isotopes such as tritium (3H), iodine-125 (125I), or carbon-14 (14C). All isotopic variations of the compounds disclosed herein (whether or not radioactive) are covered within the scope of this disclosure.

[0031] The term "isotopic variant" refers to a therapeutic agent (e.g., the compounds disclosed herein and / or modified oligonucleotides) that contains an isotope in a non-natural proportion at one or more atoms constituting such a therapeutic agent. In some embodiments, the "isotopic variant" of the therapeutic agent contains one or more isotopes in non-natural proportions, including but not limited to hydrogen (H), deuterium (2H), tritium (3H), carbon-11 (11C), carbon-12 (12C), carbon-13 (13C), carbon-14 (14C), nitrogen-13 (13N), nitrogen-14 (14N), nitrogen-15 (15N), oxygen-14 (14O), oxygen-15 (15O), oxygen-16 (16O), oxygen-17 (17O), oxygen-18 (18O), fluorine-17 (17F), fluorine-18 (18F), phosphorus-31 (31P), phosphorus-32 (32P), phosphorus-33 (33P), sulfur-32 (32S), sulfur-33 (33S), sulfur-34 (34S), sulfur-35 (35S), sulfur-36 (36S), chlorine-35 (35Cl), chlorine-36 (36Cl), chlorine-37 (37Cl), bromine-79 (79Br), bromine-81 (81Br), iodine-123 (123I), iodine-125 (125I), iodine-127 (127I), iodine-129 (129I), and iodine-131 (131I). In some embodiments, the "isotope variants" of the therapeutic agent contain non-natural ratios.Examples include one or more isotopes, including but not limited to hydrogen (H), deuterium (2H), tritium (3H), carbon-11 (11C), carbon-12 (12C), carbon-13 (13C), carbon-14 (14C), nitrogen-13 (13N), nitrogen-14 (14N), nitrogen-15 (15N), oxygen-14 (14O), oxygen-15 (15O), oxygen-16 (16O), oxygen-17 (17O), oxygen-18 (18O), fluorine-17 (17F), fluorine-18 (18F), phosphorus-31 (31P), phosphorus-32 (32P), phosphorus-33 (33P), sulfur-32 (32S), sulfur-33 (33S), sulfur-34 (34S), sulfur-35 (35S), sulfur-36 (36S), chlorine-35 (35Cl), chlorine-36 (36Cl), chlorine-37 (37Cl), bromine-79 (79Br), bromine-81 (81Br), iodine-123 (123I), iodine-125 (125I), iodine-127 (127I), iodine-129 (129I), and iodine-131 (131I).

[0032] It should be understood that in therapeutic agents (e.g., the compounds disclosed herein and / or modified oligonucleotides), any hydrogen may be, for example, 2H, or any carbon may be, for example, 13C, or any nitrogen may be, for example, 15N, or any oxygen may be, for example, 18O, where feasible according to the judgment of a person skilled in the art. In some embodiments, the "isotope variants" of the therapeutic agent contain a non-natural proportion of deuterium (D).

[0033] "Lipid" or "lipophilic moiety" refers to aliphatic, cyclic (such as alicyclic) or polycyclic (such as polyalicyclic) compounds, such as steroids (e.g., sterols) or straight-chain or branched aliphatic hydrocarbons. The term lipid includes cholesterol, retinoic acid, cholic acid, adamantaneacetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O (hexadecyl)glycerol, geranyloxyhexyanol, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecanyl, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, ibuprofen, naproxen, dimethoxytriphenylmethyl, or phenoxazine. The term lipid includes saturated or unsaturated C4-C30 hydrocarbon chains (e.g., C4-C30 alkyl or alkenyl). In some embodiments, the lipophilic moiety contains a saturated or unsaturated C5-C20 hydrocarbon chain (e.g., a straight-chain C5-C20 alkyl or alkenyl group). In some embodiments, the lipophilic moiety contains a saturated or unsaturated C14-C20 hydrocarbon chain (e.g., a straight-chain C14-C20 alkyl or alkenyl group). In some embodiments, the lipophilic moiety contains a saturated or unsaturated C6-C18 hydrocarbon chain (e.g., a straight-chain C6-C18 alkyl group).(Alkyl or alkenyl). In some embodiments, the lipophilic moiety contains a saturated or unsaturated C16 hydrocarbon chain (e.g., a straight-chain C16 alkyl or alkenyl). In some embodiments, the lipophilic moiety contains a saturated or unsaturated C17 hydrocarbon chain (e.g., a straight-chain C17 alkyl or alkenyl). In some embodiments, the lipophilic moiety contains a saturated or unsaturated C18 hydrocarbon chain (e.g., a straight-chain C18 alkyl or alkenyl). In some embodiments, the lipophilic moiety contains a saturated or unsaturated C22 hydrocarbon chain (e.g., a straight-chain C22 alkyl or alkenyl).

[0034] “Mismatch” or “non-complementary” means that when the first oligonucleotide / nucleic acid is aligned with the second oligonucleotide / nucleic acid in an antiparallel orientation, the nucleobase of the first oligonucleotide or nucleic acid is not complementary to the corresponding nucleobase of the second oligonucleotide or nucleic acid. For example, a nucleobase (including but not limited to universal nucleobases, inosine, and hypoxanthine) is capable of hybridizing with at least one nucleobase but is still mismatched or non-complementary with respect to the nucleobase with which it hybridizes. As another example, when the first and second oligonucleotides are aligned in an antiparallel orientation, the nucleobases in the first oligonucleotide / nucleic acid that cannot hybridize with the corresponding nucleobases of the second oligonucleotide / nucleic acid are mismatched or non-complementary nucleobases.

[0035] "Modified oligonucleotide" means an oligonucleotide in which at least one sugar, nucleobase, or nucleoside bond is modified.

[0036] "Regulation" refers to altering or adjusting a characteristic in a cell, tissue, organ, or organism. For example, regulating SOD1 RNA (4 / 151 pages, CN 121335980 A) may be intended to increase or decrease the level of SOD1 RNA and / or SOD1 protein in a cell, tissue, organ, or organism. "Regulator" causes a change in a cell, tissue, organ, or organism. For example, an SOD1 compound may be a regulator that reduces the amount of SOD1 RNA and / or SOD1 protein in a cell, tissue, organ, or organism.

[0037] “Motif” refers to the pattern of linkages between unmodified and modified sugar portions, nucleotides, and / or nucleosides in an oligonucleotide.

[0038] “Nucleic acid” refers to a molecule composed of monomeric nucleotides. Nucleic acids include, but are not limited to, ribonucleic acid (RNA), deoxyribonucleic acid (DNA), single-stranded nucleic acids, and double-stranded nucleic acids.

[0039] “Nucleobase” refers to a heterocyclic portion capable of pairing with a base of another nucleic acid. As used herein, “naturally occurring nucleobase” is adenine (A), thymine (T), cytosine (C), uracil (U), and guanine (G). “Modified nucleobase” is a naturally occurring nucleobase that has been chemically modified. “Universal base” or “universal nucleobase” is a nucleobase other than naturally occurring nucleobases and modified nucleobases that can pair with any nucleobase.

[0040] "Nucleobase sequence" refers to the sequence of adjacent nucleobases in a nucleic acid or oligonucleotide that is independent of any sugar or nucleoside bond.

[0041] “Nucleoside” means a compound comprising a nucleobase and a sugar moiety. The nucleobase and sugar moiety are each independently unmodified or modified. “Modified nucleoside” means a nucleoside comprising a modified nucleobase and / or a modified sugar moiety. Modified nucleosides include abase-free nucleosides lacking a nucleobase.

[0042] “Oligomer” means a compound comprising one or more oligonucleotides and optionally one or more additional features (such as conjugation groups or terminal groups). Examples of oligoomers include single-stranded and double-stranded compounds, such as oligonucleotides, antisense oligonucleotides, RNA interference compounds (RNAi compounds), oligonucleotides targeting microRNAs, site-based compounds (e.g., mRNA processing or translation blocking compounds and splicing compounds). RNAi compounds include double-stranded compounds (e.g., short interfering RNA (siRNA) and double-stranded RNA (dsRNA)) and single-stranded compounds (e.g., single-stranded siRNA (ssRNA), single-stranded RNAi (ssRNAi), short hairpin RNA (shRNA), and microRNA mimics) that function at least in part through the RNA-induced silencing complex (RISC) pathway, thereby causing sequence-specific degradation and / or chelation of target nucleic acids through a process called RNA interference (RNAi). The term “RNAi compound” is intended to be equivalent to other terms used to describe nucleic acid compounds capable of mediating sequence-specific RNA interference, such as interfering RNA (iRNA), iRNA agent, RNAi agent, short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically modified siRNA, etc. Additionally, the term “RNAi” is intended to be equivalent to other terms used to describe sequence-specific RNA interference.

[0043] “Oligomer duplex” means a duplex formed by two oligomers having complementary nucleobase sequences. Each oligomeric compound of an oligoduplex may be referred to as a “double-stranded oligomeric compound”. The oligonucleotide of each oligomeric compound of an oligoduplex may include a non-complementary pendant nucleoside. In some embodiments, the terms “double-stranded oligomeric compound” and “modified oligonucleotide” are used interchangeably. In other embodiments, the terms “oligomeric duplex” and “compound” are used interchangeably.

[0044] “Oligonucleotide” means a polymer of linked nucleosides, each of which may be modified or unmodified independently of each other.

[0045] “Parenteral administration” means administration by injection or infusion. Parenteral administration includes subcutaneous, intravenous, intramuscular, intra-arterial, intraperitoneal, or intracranial administration, such as intrathecal or intraventricular administration.

[0046] “Pharmaceutically acceptable carrier or diluent” means any substance suitable for administration to an individual. In some embodiments, a pharmaceutically acceptable carrier or diluent facilitates administration of the compound to and absorption by the individual, and may...The pharmaceutically acceptable excipients are included in the compositions disclosed herein without causing significant adverse toxic effects on patients. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, physiological saline solutions, etc. For example, a pharmaceutically acceptable carrier may be a sterile aqueous solution, such as PBS or water for injection. Those skilled in the art will recognize that other pharmaceutical excipients may be used in this disclosure.

[0047] “Pharmaceutically acceptable salt” means or refers to a physiologically and pharmaceutically acceptable salt of a compound (such as an oligomeric compound or oligonucleotide), i.e., a salt that retains the desired biological activity of the parent compound without conferring undesirable toxic effects on the parent compound.

[0048] As may be used interchangeably herein, “tropomyosin receptor kinase B” or “TrkB” means the receptor for the brain-derived neurotrophic factor (BDNF) protein encoded by the NTRK2 gene. TrkB is also known as tyrosine receptor kinase B, BDNF / NT-3 growth factor receptor, and neurotrophic tyrosine kinase type 2.

[0049] “Type 1 cannabinoid receptor” or “CB1” refers to the G protein-coupled receptor for cannabinoids. In humans, CB1 is encoded by the CNR1 gene. CB1 is also known as cannabinoid receptor 1.

[0050] “α4β1 / 7 integrin receptor” refers to a heterodimeric integrin receptor formed by the association of integrin α4 and integrin β1 (i.e., α4β1 integrin receptor) and integrin α4 and integrin β7 (i.e., α4β7 integrin receptor). In some embodiments, the α4β1 / 7 integrin receptor ligand has a higher binding affinity for the α4β1 integrin receptor than for the α4β7 integrin receptor. In some embodiments, the α4β1 / 7 integrin receptor ligand has a higher binding affinity for the α4β7 integrin receptor than for the α4β1 integrin receptor.

[0051] “N-methyl-D-aspartate receptor” or “NMDA receptor” refers to a glutamate receptor and ion channel found in neurons (e.g., neurons in humans). Many ligands of NMDA receptors are known in the art, including, for example, Neuropharmacology 2007, 53(6), 699-723; J. Med. Chem. 1990, 33(2), 789-808; Neuroscience 2001, 105(3), 663-669; J. Med. Chem. 2022, 65(13), 9063-9075; Drugs Fut. 2004, 29(10), 992; Drugs Fut. 2004, 29(10), 993; and British Journal ofThose disclosed in Pharmacology 2022, 179(6), 1146-1187, each of which is incorporated herein by reference.

[0052] As used herein, a pharmaceutically acceptable salt is any salt of the compounds provided herein that retains its biological properties and is non-toxic or not otherwise undesirable for pharmaceutical use. Pharmaceutically acceptable salts of the therapeutic agents disclosed herein include salts prepared using relatively non-toxic acids or bases (depending on the specific substituents found on the compounds or modified oligonucleotides described herein).

[0053] When the compounds of this disclosure contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base in a solvent-free manner or in a suitable inert solvent.

[0054] When the compounds of this disclosure contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid in a solvent-free manner or in a suitable inert solvent.

[0055] Therefore, the compounds of this disclosure can exist as salts, such as salts formed with pharmaceutically acceptable acids. Such salts can be derived from a variety of organic and inorganic counterions well known in the art. Such salts include, but are not limited to: (1) acid addition salts formed with organic or inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, aminosulfonic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, hexanoic acid, cyclopentylpropionic acid, glycolic acid, glutaric acid, pyruvic acid, lactic acid, malonic acid, succinic acid, sorbic acid, ascorbic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, picric acid, cinnamic acid, mandelic acid, phthalic acid, lauric acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-Hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphoric acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-en-1-carboxylic acid, glucoheponic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfide. Specification 6 / 151 pages 16 CN 121335980 A Acids, gluconic acid, benzoic acid, glutamic acid, hydroxynaphthylcarboxylic acid, salicylic acid, stearic acid, cyclohexylsulfamic acid, quinic acid, mucoconic acid and similar acids; or (2) when the acidic proton present in the parent compound is (a) replaced by a metal ion (e.g., alkali metal ion, alkaline earth metal ion or aluminum ion) or an alkali metal or alkaline earth metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, aluminum hydroxide, lithium hydroxide, zinc hydroxide and barium hydroxide), ammonia, or (b) replaced by an organic base (e.g., aliphatic, alicyclic or aromatic organic amines, such as ammonia, methylamine, dimethylamine, diethylamine, methylpyridine, ethanol).Salts formed when amines, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N-methylglucosamine piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, etc. are coordinated (see, for example, Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 1977, 66, 1-19).

[0056] Pharmaceutically acceptable salts further include, by way of example only and not limitation, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc., and salts of non-toxic organic or inorganic acids when the compound contains a basic functional group, such as hydrohalides, such as hydrochlorides and hydrobroms, sulfates, phosphates, aminosulfonates, nitrates, acetates, trifluoroacetates, trichloroacetates, propionates, hexanoates, cyclopentylpropionates, glycolates, glutarates, pyruvates, lactates, malonates, succinates, sorbates, ascorbic acid salts, malates, maleates, fumarates, tartrates, citrates, benzoates, 3-(4-hydroxybenzoyl)benzoates, picrates, cinnamates, mandelates, phthalates, laurates, methanesulfonates, ethanesulfonates, 1,2-ethane-disulfonates, 2- Hydroxyethanesulfonate, benzenesulfonate, 4-chlorobenzenesulfonate, 2-naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphor sulfonate, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylate, glucono-p-gluconate, 3-phenylpropionate, trimethylacetate, tert-butylacetate, lauryl sulfate, gluconate, benzoate, glutamate, hydroxynaphthylcarboxylate, salicylate, stearate, cyclohexylaminosulfonate, quinic acid salt, mucoconate, etc. In some embodiments, pharmaceutically acceptable salts of the compounds disclosed herein and the modified oligonucleotides are sodium or potassium salts. In some embodiments, pharmaceutically acceptable salts of the compounds disclosed herein and the modified oligonucleotides are sodium salts.

[0057] The neutral form of the compound is preferably regenerated by contacting the salt with a base or acid and separating the parent compound in a conventional manner. The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents. In embodiments, the compounds of this disclosure contain a content that allows the compound to be converted into a base addition salt or an acid addition salt.Both basic and acidic functional groups that form salts. The neutral form of the compound can be regenerated by contacting the salt with a base or acid and separating the parent compound in a conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties (such as solubility in polar solvents), but unless explicitly indicated, for the purposes of this disclosure, the salts disclosed herein are equivalent to the parent form of the compound.

[0058] “Pharmaceutical” means a compound that provides a therapeutic benefit when administered to an individual.

[0059] “Thiophosphate link” means a modified phosphate link in which a non-bridging oxygen atom is replaced by a sulfur atom.

[0060] “Part” means a defined number of adjacent (i.e., linked) nucleobases in a nucleic acid. In some embodiments, the part is a defined number of adjacent nucleobases in a target nucleic acid. In some embodiments, the part is a defined number of adjacent nucleobases in an oligonucleotide.

[0061] “Prevention” means delaying or preventing the onset, development, or progression of a disease, symptom, or illness for a period of time.

[0062] "RNA interference compound" or "RNAi compound" means a compound that regulates a target nucleic acid and / or a protein encoded by the target nucleic acid by at least partly through the RNA-induced silencing complex (RISC) pathway or Ago2, without RNase H. RNAi compounds include, but are not limited to, double-stranded siRNA, single-stranded siRNA, and microRNA, including microRNA mimics. Specification 7 / 151 pages 17 CN 121335980 A

[0063] "Sense oligonucleotide" or "sense strand" means the strand of a double-stranded compound containing a region substantially complementary to the antisense strand region of the compound.

[0064] "Specific inhibition" of a target nucleic acid or protein is intended to reduce or block the expression or activity of the target nucleic acid or protein while minimizing or eliminating the effect on non-target nucleic acids or proteins.

[0065] "Subunit" of an oligonucleotide means a nucleotide, nucleoside, nucleotide base, or sugar as provided herein, or a modified nucleotide, nucleoside, nucleotide base, or sugar.

[0066] “Target nucleic acid,” “target RNA,” and “nucleic acid target” all mean a nucleic acid that can be targeted by the compounds described herein.

[0067] “Target region” means a portion of the target nucleic acid that is targeted by one or more compounds.

[0068] “Target part” means, for example, a conjugate group that provides enhanced affinity to a selected target (e.g., a molecule, cell or cell type, compartment (e.g., a cell or organ compartment), tissue, organ, or body region) compared to a compound that does not have such a part.

[0069] “Terminal group” means a chemical group or group of atoms covalently attached to the end of an oligonucleotide.

[0070] “Therapeutic effective amount” or “effective amount” means a compound, agent, or composition that provides therapeutic benefit to an individual.Amount. A “therapeutic effective amount” or “effective amount” is an amount sufficient to enable a compound to achieve its stated purpose (e.g., to achieve the effect of administering the compound, to treat, prevent, or improve a disease, or to alleviate one or more symptoms of a disease or condition) relative to the absence of the compound. Examples of a “therapeutic effective amount” or “effective amount” are amounts sufficient to help treat, prevent, improve, or alleviate one or more symptoms of a disease. “Amelioration” (and its grammatical equivalent) of one or more symptoms means a reduction in the severity or frequency of the one or more symptoms, or the elimination of the one or more symptoms. A “preventive effective amount” of a drug is an amount of drug that, when administered to a subject, will have an expected preventive effect, such as preventing or delaying the onset (or recurrence) of an injury, disease, condition, or condition, or reducing the likelihood of the onset (or recurrence) of an injury, disease, condition, or condition or their symptoms. As used herein, the term “therapeutic effective amount” refers to an amount of therapeutic agent sufficient to provide a therapeutic benefit to an individual (such as the treatment, prevention, or improvement of a disease or condition or its symptoms as described above). For example, for a given parameter, the effective therapeutic dose will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy may also be expressed as an increase or decrease of "times". For example, the effective therapeutic dose may have an effect of at least 1.2 times, 1.5 times, 2 times, 5 times, or more than that of the control.

[0071] The term "treating" means any indication of success in the treatment or improvement of an injury, disease, symptom, or condition, including any objective or subjective parameter such as relief; mitigation; reduction of symptoms or making the injury, symptom, or condition more tolerable to the patient; slowing the rate of degeneration or decline; reducing the debilitating nature of the degenerative endpoint; or improving the patient's physical or mental health. Treatment or improvement of symptoms may be based on objective or subjective parameters, including physical examination results. The term "treatment" and its variations may include prevention of injury, symptom, condition, or disease. In an embodiment, treatment is prevention. In an embodiment, treatment does not include prevention.

[0072] As used herein (and as well understood in the art), “treating” or “treatment” also broadly includes any means of obtaining a beneficial or desired outcome (including clinical outcome) for a subject’s disease. Beneficial or desired clinical outcomes may include, but are not limited to, reduction or improvement of one or more symptoms of the disease, reduction of disease severity, stable (i.e., non-deteriorating) disease state, prevention of disease transmission or spread, delay or slowing of disease progression, improvement or mitigation of disease state, reduction of disease relapse, and remission, whether such clinical outcome is partial or complete and whether it is detectable or undetectable. In other words, “treatment” as used herein includes any cure, improvement, orDisease prevention. Treatment can prevent the occurrence of disease; inhibit the spread of disease; alleviate the symptoms of disease, completely or partially eliminate the underlying cause of the disease, shorten the duration of the disease, or a combination of these. Specification 8 / 151 pages 18 CN 121335980 A

[0073] As used herein, “treating” and “treatment” include preventive treatment. Treatment methods include administering a therapeutically effective amount of the compound described herein to a subject. The administration steps may consist of a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the disease, the age of the patient, the concentration of the compound, the activity of the composition used for treatment, or a combination thereof. It should also be understood that the effective dose of the active agent used for treatment or prevention may be increased or decreased during a particular treatment or prevention regimen. In some cases, long-term administration may be required. For example, administering the composition to a subject in an amount and duration sufficient to treat the patient. “Treatment” refers to administering a compound or pharmaceutical composition to an animal to achieve a change or improvement in the animal’s disease, symptom, or condition.

[0074] Certain compounds of this disclosure have asymmetric carbon atoms (optical or chiral centers) or double bonds; enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomers that can be defined by absolute stereochemistry as (R)- or (S)- or (D)- or (L)- for amino acids, and all such isomers are covered within the scope of this disclosure. The compounds of this disclosure do not include those known in the art that are too unstable to be synthesized and / or isolated. This invention is intended to include compounds in racemic and optically pure forms. Optically active (R)- and (S)- isomers or (D)- and (L)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other geometrically asymmetric centers, unless otherwise specified, the compounds are expected to include both E and Z geometric isomers.

[0075] As used herein, the term "isomer" refers to a compound having the same number and type of atoms and therefore the same molecular weight, but differing in the structural arrangement and configuration of the atoms.

[0076] As used herein, the term "tautomer" refers to one of two or more structural isomers that exist in equilibrium form and are readily convertible from one isomer to another.

[0077] It will be apparent to those skilled in the art that certain compounds of this disclosure may exist in tautomeric forms, and all such tautomeric forms of these compounds are within the scope of this disclosure.

[0078] Unless otherwise stated, the structures described herein are also intended to include all stereochemical forms of the structure.(i.e., the R and S configurations of each asymmetric center). Therefore, single stereochemical isomers of the compounds of the present invention, as well as mixtures of enantiomers and diastereomers, are within the scope of this disclosure.

[0079] As used herein, a “chiral enrichment cluster” means a plurality of molecules having the same molecular formula, wherein the number or percentage of molecules within the cluster containing a particular stereochemical configuration at a particular chiral center is greater than the number or percentage of molecules within the cluster expected to contain the same particular stereochemical configuration at the same particular chiral center when that particular chiral center is stereorandom. A chiral enrichment cluster of molecules having multiple chiral centers in each molecule may contain one or more stereorandom chiral centers. In some embodiments, the molecule is a modified oligonucleotide. In some embodiments, the molecule is a compound comprising a modified oligonucleotide.

[0080] Unless otherwise stated, the structures described herein are also intended to include compounds differing only in the presence of one or more isotopically enriched atoms. For example, compounds having the structure of the present invention, except for replacing hydrogen with deuterium or tritium or replacing carbon with carbon enriched in 13C- or 14C-, are within the scope of this disclosure.

[0081] As used herein, “stereorandom chiral center” means, in the context of a molecular population having the same molecular formula, a chiral center having a random stereochemical configuration. For example, in a molecular population containing stereorandom chiral centers, the number of molecules having a stereorandom chiral center (S) configuration may be the same as, but not necessarily the same as, the number of molecules having a stereorandom chiral center (R) configuration. The stereochemical configuration of a chiral center may be considered random when it is the result of a synthetic method not designed to control the stereochemical configuration. In some embodiments, the stereorandom chiral center is a stereorandom phosphate thioester nucleoside linker. Specification 9 / 151 pages 19 CN 121335980 A

[0082] In some aspects, this disclosure relates to methods, compounds, and compositions for inhibiting SOD1. In some embodiments, SOD1 is specifically inhibited. In some embodiments, SOD1 is specifically degraded. In some embodiments, SOD1 expression is inhibited. In some embodiments, SOD1 translation is inhibited. In some embodiments, SOD1 activity is inhibited. In some embodiments, SOD1 expression, translation, or activity is reduced by at least 10% relative to the expression, translation, or activity in an untreated sample or control sample. For example, in some embodiments, SOD1 expression, translation, or activity is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, 10-50%, 25-50%, or 25-75% relative to the expression, translation, or activity in an untreated sample or control sample.50-75%, 50-99%, or 75-99%. In some embodiments, SOD1 expression, translation, or activity is reduced, as measured by any suitable assay, including but not limited to immunoassays, hybridization-based assays, or sequencing-based assays (e.g., RNA-Seq).

[0083] In some aspects, this disclosure relates to compounds targeting SOD1 nucleic acids. In some embodiments, the SOD1 nucleic acid has the sequence shown in nucleotides 5001 to 14310 of GenBank accession number NM_000454.5 (incorporated herein as SEQ ID NO:1) and NG_008689.1 (incorporated herein as SEQ ID NO:2).

[0084] In some embodiments, the compound is an oligomeric compound. In some embodiments, the compound is single-stranded. In some embodiments, the compound is double-stranded.

[0085] Some embodiments provide compounds comprising modified oligonucleotides (e.g., of length 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases of any nucleobase sequence in the nucleobase sequence of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223.

[0086] Some embodiments provide compounds comprising modified oligonucleotides (e.g., of length 14 to 30, such as 14 to 23 linked nucleosides), the modified oligonucleotides having a nucleotide sequence comprising any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223.

[0087] Some embodiments provide compounds comprising modified oligonucleotides having a nucleotide sequence selected from the group consisting of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223.

[0088] In some embodiments, the modified oligonucleotide is at least 80%, at least 85%, at least 90%, or at least 95% complementary to SEQ ID NO: 1 or 2. In some embodiments, the modified oligonucleotide comprises at least one modification selected from modified nucleoside linkages, modified sugars, and modified nucleobases. In some embodiments, the compound is double-stranded.

[0089] Some embodiments provide a compound comprising: a first modified oligonucleotide (e.g., 14 nucleotides in length).The first modified oligonucleotide has a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases of any nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., 14 to 30, such as 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide.

[0090] In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence provided in Tables 2 and 3; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide.

[0091] Some embodiments provide a compound comprising: a first modified oligonucleotide (e.g., of 14 to 30, for example 14 to 23 linked nucleosides), the first modified oligonucleotide having a nucleobase sequence comprising any one of SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, for example 14 to 23 linked nucleosides), the second modified oligonucleotide having a region complementary to the first modified oligonucleotide.

[0092] Some embodiments provide a compound comprising: a first modified oligonucleotide having a nucleobase sequence selected from the group consisting of any one of SEQ ID NO: 11-223; and a second modified oligonucleotide of 19 to 23 linked nucleosides, the second modified oligonucleotide having a region complementary to the first modified oligonucleotide.

[0093] Some embodiments provide a compound comprising: a first modified oligonucleotide comprising a 5'-phosphonate modification, wherein the first modified oligonucleotide is at least 80% complementary to the region of SEQ ID NO: 1 or 2; and a second modified oligonucleotide comprising one or more of the compounds described herein.The described ligands (e.g., one or more tropomyosin receptor B (TrkB) ligands, one or more type 1 cannabinoid receptor (CB1) ligands, one or more α4β1 / 7 integrin ligands, or one or more N-methyl-D-aspartate receptor (NMDA) ligands). In some embodiments, the first modified oligonucleotide comprises a 5'-terminal nucleoside containing a 5'-phosphonate modification. In some embodiments, the 5'-phosphonate modification is a 5'-vinylphosphonate modification or a 5'-ethylidenephosphonate modification.

[0094] In some embodiments, the compound comprises a modified oligonucleotide (e.g., of length 14 to 30, such as 14 to 23 linked nucleosides) having a nucleonucleotide sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases from any of the nucleobase sequences of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of nucleobase sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of nucleotide sequences of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223; and a second modified oligonucleotide having a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213.

[0095] In some embodiments, the modified oligonucleotide or the first modified oligonucleotide of any of the foregoing compounds has at least 80%, at least 85%, at least 90%, or at least 95% complementarity or identity in length with SEQ ID NO: 1 or 2. In some embodiments, the modified oligonucleotide or the first modified oligonucleotide has at least one, at least two, or at least three mismatches with the region of SEQ ID NO: 1 or 2. In some embodiments, the length of the complementary region between the first modified oligonucleotide or the first chain and the second modified oligonucleotide or the second chain is 14 to 30 linked nucleosides. In some embodiments, the length of the complementary region between the first modified oligonucleotide or the first chain and the second modified oligonucleotide or the second chain is 14 to 23 linked nucleosides. In some embodiments, the length of the complementary region between the first modified oligonucleotide or the first chain and the second modified oligonucleotide or the second chain is 19 to 23 linked nucleosides. In some embodiments, the length of the complementary region between the first modified oligonucleotide or first strand and the second modified oligonucleotide or second strand is 21 to 23 linked nucleosides. In some embodiments, the first modified oligonucleotide and the second modified oligonucleotide are completely complementary.

[0096] In some embodiments, the modified oligonucleotide or first modified oligonucleotide of any of the foregoing compounds comprises at least one modification selected from modified nucleoside linkages, modified sugars, and modified nucleobases. In some embodiments, the second modified oligonucleotide of any of the foregoing compounds comprises at least one modification selected from the group consisting of modified nucleoside linkages, modified sugars, and modified nucleobases. In some embodiments, the modified nucleoside linkage is a phosphate thioate nucleoside linkage or a methylphosphonate nucleoside linkage. In some embodiments, the phosphate thioate nucleoside linkage or the methylphosphonate nucleoside linkage is located at the 3' end of the first or second modified oligonucleotide or at the 5' end of the first modified oligonucleotide. In some embodiments, the modified sugar comprises a modification selected from the group consisting of halogens, alkoxy groups, and bicyclic sugars. In some embodiments, the modified sugar comprises a 2'-F modification. In some embodiments, the modified sugar comprises a 2'-OMe modification. In some embodiments, each nucleoside of the first modified oligonucleotide comprises a modified sugar. In some embodiments, each nucleoside of the second modified oligonucleotide comprises a modified sugar. In some embodiments, the modified sugar comprises a modification selected from the group consisting of halogens, alkoxy groups, and bicyclic sugars, or combinations thereof.The modification. In some embodiments, the modified sugar comprises a modification selected from the group consisting of 2'-MOE, 2'-F, and 2'-OMe, or combinations thereof. In some embodiments, the first modified oligonucleotide comprises no more than ten 2'-F sugar modifications. In some embodiments, the second modified oligonucleotide comprises no more than five 2'-F sugar modifications.

[0097] In some embodiments, any of the compounds of the foregoing embodiments comprises a conjugation group. In some embodiments, the conjugation group is attached to the 5' end of the modified oligonucleotide. In some embodiments, the conjugation group is a targeting moiety. In some embodiments, the targeting moiety comprises one or more TrkB ligands. In some embodiments, the targeting moiety comprises one or more CB1 ligands. In some embodiments, the targeting moiety comprises one or more α4β1 / 7 integrin ligands. In some embodiments, the targeting moiety comprises one or more NMDA ligands. In some embodiments, the modified oligonucleotide is a second modified oligonucleotide or a positive oligonucleotide. In some embodiments, the one or more TrkB ligands are attached to the 5' end or 3' end of the oligonucleotide, or both the 5' end and 3' end of the oligonucleotide. In some embodiments, the one or more CB1 ligands are attached to the 5' end or 3' end of the oligonucleotide, or both the 5' end and 3' end of the oligonucleotide. In some embodiments, the one or more α4β1 / 7 integrin ligands are attached to the 5' end or 3' end of the oligonucleotide, or both the 5' end and 3' end of the oligonucleotide. In some embodiments, the one or more NMDA ligands are attached to the 5' end or 3' end of the oligonucleotide, or both the 5' end and 3' end of the oligonucleotide.

[0098] In some embodiments, the TrkB ligand of the modified oligonucleotide is of formula (I) or a salt, solvate or hydrate thereof: Specification 12 / 151 pages 22 CN 121335980 A

[0099] Formula (I), wherein: R1 is the modified oligonucleotide; L1, L2, L3 and L4 are as described herein; R2 is hydrogen, -OR7, -SR8 or -NR9R10; R3 is hydrogen, -OR11, -SR12 or -NR13R14; R4 is hydrogen, -OR15, -SR16 or -NR17R18; R5 is hydrogen, -OR19, -SR20 or -NR21R22; R6 is hydrogen, -OH, optionally substituted -O-alkyl, optionally substituted -OAc, -NH2, optionally substituted -NHAc, -SH or =O; R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, and R22 are each independently hydrogen, anyThe substituted alkyl group, the optionally substituted heteroalkyl group, the optionally substituted cycloalkyl group, the optionally substituted heterocycloalkyl group, the optionally substituted aryl group, the optionally substituted heteroaryl group; Y is CH2, NH, S or O; and Z is an optionally substituted aryl group or an optionally substituted heteroaryl group.

[0100] In some embodiments, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are each independently an optionally substituted unsaturated or partially unsaturated alkyl group. In some embodiments, R7, R8, R9 and R10 are each independently alkenyl. In some embodiments, R7, R8, R9 and R10 are each independently alkynyl.

[0101] In some embodiments, R2 is OR7. In some embodiments, R3 is OR11. In some embodiments, R7 and R11 are each independently hydrogen, optionally substituted alkyl, or optionally substituted alkenyl; in some embodiments, one or both of R7 and R11 are each independently hydrogen. In some embodiments, one or both of R7 and R11 are each independently optionally substituted alkyl. In some embodiments, one or both of R7 and R11 are each independently optionally substituted unsaturated or partially unsaturated alkyl. In some embodiments, one or both of R7 and R11 are each independently alkenyl. In some embodiments, R7 is optionally substituted alkyl and R11 is hydrogen. In some embodiments, R7 is hydrogen and R11 is optionally substituted alkyl. In some embodiments, R7 is alkenyl and R11 is hydrogen. In some embodiments, R7 is hydrogen and R11 is optionally substituted alkenyl.

[0102] In some embodiments, the TrkB ligand of the modified oligonucleotide is selected from the following formulas or their salts, solvates or hydrates:

[0103] Formula (II-A), Specification 13 / 151 pages 23 CN 121335980 A

[0104] Formula (II-B),

[0105] Formula (II-C), wherein: R1 is the modified oligonucleotide; L1, L2, L3 and L4 are as described herein.

[0106] In some embodiments, the TrkB ligand of the modified oligonucleotide is of formula (XXX) or a salt, solvate or hydrate thereof:

[0107] Formula (XXX), wherein: L1, L2, L3, L4 and R1 are as described herein; R11 and R13 are each independently absent, hydrogen or optionally substituted alkyl; R12, R14 and R15 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;R16 is hydrogen, halogen, –CN, –N3, –SOn16R 1A, –SOv16NR 16BR16C, –NHNR16BR16C, –ONR16BR16C, –NHC(O) NHNR16BR16C, –NHC(O)NR16BR16C, –N(O)m16, –NR 16BR16C, –C(O)R16D, –C(O)OR16D, –C(O)NR16BR16C, –OR16A, –NR16BSO2R 16A, –NR16BC(O)R16D, –NR16BC(O)OR16D, –NR16BOR16D, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl. Each of the following is independently a single or double bond, wherein if it is a single bond, it is a double bond and R13 is absent; and further wherein if it is a single bond, it is a double bond and R11 is absent; R16A, R16B, R16C, and R16D are each independently hydrogen, halogen, –CF3, –CCl3, –CBr3, –CI3, –COOH, –CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or substituents R16B and R16C bonded to the same nitrogen atom may optionally be linked to form substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; z3 is 0, 1, 2, 3, 4, or 5; n16 is 0, 1, 2, 3 or 4; and v16 and m16 are each independently 1 or 2.

[0108] In some embodiments, the α4β1 / 7 integrin ligand of the modified oligonucleotide is of formula (XXXI) or its salt, solvate or hydrate: .

[0109] Formula (XXXI) wherein L1, L2, L3, L4 and R1 are as described herein; R2, R3, R4 and R5 are each independently H, halogen, optionally substituted alkyl, optionally substituted -O-alkyl, cycloalkyl or absent; R8 is optionally substituted C1-C5 alkyl, optionally substituted C1-C5 alkylene-(C3-C6)-cycloalkyl or optionally substituted (C1-C4)-alkylene-(C1-C4)-alkoxy; and R6 and R7 are each independently H, halogen, alkyl, or optionally substituted alkyl, optionally substituted heteroalkyl, , , , , or.

[0110] In some embodiments, the α4β1 / 7 integrin ligand of the modified oligonucleotide is of formula (XXXII) or thereof.Salt, solvate, or hydrate:

[0111] Formula (XXXII) wherein L1, L2, L3, L4, and R1 are as described herein; R2 is H, polyethylene glycol (PEG), optionally substituted heteroalkyl, or optionally substituted heteroaryl; and R3 and R4 are each independently H, halogen, optionally substituted alkyl, or optionally substituted -O-alkyl.

[0112] In some embodiments, L1, L2, L3, and L4 are each independently absent, bonded, optionally substituted alkyl linker, optionally substituted polyethylene glycol (PEG) linker, optionally substituted heteroalkyl linker, or optionally substituted heteroaryl linker. Specification 15 / 151 pages 25 CN 121335980 A

[0113] In some embodiments, L1 is an optionally substituted heteroaryl linker.

[0114] In some embodiments, L1 is an optionally substituted unsaturated heteroaryl, optionally substituted heteroaryl, or optionally substituted saturated or partially unsaturated heterocyclic alkyl linker.

[0115] In some embodiments, L1 comprises the structure: .

[0116] In some embodiments, L1 is an optionally substituted heteroalkyl linker. In some embodiments, the optionally substituted heteroalkyl linker is an optionally substituted heteroalkyl or optionally substituted C1-10 alkyl chain, wherein one or more carbon atoms are substituted with O, N, or S.

[0117] In some embodiments, L1 comprises the structure: or .

[0118] In some embodiments, L1 comprises the structure: or –N(CH3)–.

[0119] In some embodiments, L2 is an optionally substituted PEG linker.

[0120] In some embodiments, the length of the PEG linker is five PEG units. In some embodiments, the length of the PEG linker is four PEG units. In some embodiments, the length of the PEG linker is three PEG units.

[0121] In some embodiments, L2 is an optionally substituted alkyl connector. In some embodiments, L2 is an optionally substituted C1-20 alkyl connector. In some embodiments, L2 is an optionally substituted C8 alkyl connector. In some embodiments, L3 is an optionally substituted heteroaryl connector.

[0122] In some embodiments, L3 is an optionally substituted partially unsaturated heteroaryl connector, an optionally substituted heteroaryl connector, or an optionally substituted saturated or partially unsaturated heterocyclic alkyl connector.

[0123] In some embodiments, L3 comprises the structure: .

[0124] In some embodiments, L4 is an optionally substituted heteroalkyl connector. In some embodiments, the heteroalkyl connector is substituted by one or more =O substituents.

[0125] In some embodiments, the heteroalkyl connector comprises two carbon rings linked together to form an optionally substituted carbon ring.Substituents of the base ring.

[0126] In some embodiments, L4 comprises the structure: or a salt thereof, wherein X is O or S. Specification 16 / 151 pages 26 CN 121335980 A

[0127] In some embodiments, L4 comprises the structure: or a salt thereof, wherein X is O or S.

[0128] In some embodiments, L1–L2–L3–L4 comprises the structures: , , , , , , , Specification 17 / 151 pages 27 CN 121335980 A , , , , , , Specification 18 / 151 pages 28 CN 121335980 A , , , , , Specification 19 / 151 pages 29 CN 121335980 A , or a salt thereof, wherein X is O or S.

[0129] In some embodiments, the TrkB ligand of the modified oligonucleotide is selected from the following formulas or their salts, solvates or hydrates:

[0130] Formula (III),

[0131] Formula (IV),

[0132] Formula (V), Specification 20 / 151 pages 30 CN 121335980 A

[0133] Formula (VI),

[0134] Formula (VII),

[0135] Formula (VIII),

[0136] Formula (IX), Specification 21 / 151 pages 31 CN 121335980 A

[0137] Formula (X),

[0138] Formula (XI),

[0139] Formula (XII), Specification 22 / 151 pages 32 CN 121335980 A

[0140] Formula (XIII),

[0141] Formula (XIV),

[0142] Formula (XV),

[0143] Formula (XVI),

[0144] Formula (XVII), Specification 23 / 151 page 33 CN 121335980 A

[0145] Formula (XVIII),

[0146] Formula (XIX),

[0147] Formula (XX),

[0148] Formula (XXV) Wherein: R is a modified oligonucleotide; X is S or O.

[0149] In some embodiments, the CB1 ligand of the modified oligonucleotide is selected from the following formula or its salt, solvate or hydrate:

[0150] Formula (XXVI) Wherein: R is a modified oligonucleotide; X is S or O.

[0151] In some embodiments, the α4β1 / 7 integrin ligand of the modified oligonucleotide is selected from the following formulas or their salts, solvates or hydrates:

[0152] Formula (XXVII)

[0153] Formula (XXVIII) Wherein: ExplanationPage 35 of 25 / 151 CN 121335980 AR is a modified oligonucleotide; X is S or O.

[0154] In some embodiments, the NMDA ligand of the modified oligonucleotide is selected from the following formula or its salt, solvate or hydrate:

[0155] Formula (XXIX) Wherein: R is a modified oligonucleotide; X is S or O.

[0156] In some embodiments, any of the compounds in the foregoing embodiments comprises a lipid. In some embodiments, the lipid is attached to the nucleoside internucleotide of the modified oligonucleotide. In some embodiments, the modified oligonucleotide comprises one or more lipids. In some embodiments, the one or more lipids are attached to one or more nucleoside internucleotides of the modified oligonucleotide. In some embodiments, the modified oligonucleotide is a second modified oligonucleotide or a positive oligonucleotide.

[0157] In some embodiments, any of the compounds in the foregoing embodiments comprises one or more substituted or unsubstituted alkyl or alkenyl groups. In some embodiments, the substituted or unsubstituted alkyl or alkenyl group is attached to the nucleoside internucleotide of the modified oligonucleotide. In some embodiments, the modified oligonucleotide comprises one or more substituted or unsubstituted alkyl or alkenyl groups. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups are attached to one or more nucleoside internucleotides of the modified oligonucleotide. In some embodiments, the modified oligonucleotide is a second modified oligonucleotide or a positive oligonucleotide.

[0158] In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C4-C30 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C5-C20 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C14-C20 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C16 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise a saturated or unsaturated C17 hydrocarbon chain. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise a saturated or unsaturated C18 hydrocarbon chain. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise a saturated or unsaturated C22 hydrocarbon chain.

[0159] In some embodiments, the substituted or unsubstituted alkyl or alkenyl group is attached to a nucleoside linker of a modified oligonucleotide (e.g., a second modified oligonucleotide or a positive oligonucleotide). In some embodiments, the nucleoside linker is located within 10 positions (e.g., 8 positions) starting from the end (e.g., the 5' end and / or the 3' end) of the modified oligonucleotide.The nucleoside linkages are located between nucleosides within 5 positions (within 6, 5, 4, 3, or 2 positions). In some embodiments, the nucleoside linkages are located between nucleosides within 5 positions starting from the 5' end of the modified oligonucleotide. In some embodiments, as described on page 26 / 151 of CN 121335980 A, the nucleoside linkages are located between nucleosides within 5 positions starting from the 3' end of the modified oligonucleotide.

[0160] In some embodiments, the nucleoside linkages are located between positions 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11, 11 and 12, 12 and 13, or 13 and 14, starting from the 5' end of the modified oligonucleotide. In some embodiments, the internucleotide link is located between positions 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, or 7 and 8, starting from the 5' end of the modified oligonucleotide. In some embodiments, the internucleotide link is located between positions 2 and 3, starting from the 5' end of the modified oligonucleotide. In some embodiments, the internucleotide link is located between positions 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11, 11 and 12, 12 and 13, or 13 and 14, starting from the 3' end of the modified oligonucleotide. In some embodiments, the internucleotide link is located between position 1 and position 2, position 2 and position 3, position 3 and position 4, position 4 and position 5, position 5 and position 6, position 6 and position 7, or position 7 and position 8, starting from the 3' end of the modified oligonucleotide. In some embodiments, the internucleotide link is located between position 2 and position 3, starting from the 3' end of the modified oligonucleotide.

[0161] In some embodiments, the internucleotide link of the modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV.

[0162] In some embodiments, the internucleotide link of the modified oligonucleotide comprises formula (XXI), or a salt, solvate, or hydrate thereof:

[0163] Formula (XXI), wherein: Y is –C(=O)N(RC)–, or –N(RC)C(=O)–;Q1 and Q3 are each independently –H, –OR4, ligand, linker, or lipid; Q2 and Q4 are each independently a bond, ligand, linker, or lipid; RC is independently –H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; each R2 is independently –H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, –OR6, –N(R6), or –SR6; Specification 27 / 151 Page 37 CN 121335980 A Each R3 is independently –H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, –OR7, –N(R7), or –SR7; R4 and R5 are independently oligonucleotides, or R4 and R5 linked together to form a single oligonucleotide; each R6 is independently hydrogen, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted heteroalkyl group; each R7 is independently hydrogen, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted heteroalkyl group; each R8 is independently substituted or unsubstituted heteroaryl; each R9 is independently substituted or unsubstituted heteroaryl; each instance of Z1 or Z2 is independently a bond, a C1-C6 alkylene group, or a C2-C6 alkenyl group; and each X is independently O or S; or a salt thereof.

[0164] In some embodiments, the nucleoside-internucleotide linking of the modified oligonucleotide includes formula (XXII), or a salt, solvate, or hydrate thereof:

[0165] Formula (XXII), wherein: RC is –H, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted heteroalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; each R2 is independently –H, a halogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, –OR6, –N(R6), or –SR6; each R3 is independently –H, a halogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, –OR7, –N(R7), or –SR7; R4 and R5 are independently oligonucleotides, or R4 and R5 are linked together to form a single oligonucleotide; Each R6 is independently hydrogen, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted heteroalkyl group; each R7 is independently hydrogen, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted heteroalkyl group; each R8 is independently a substituted or unsubstituted heteroaryl ring; each R9 is independently a substituted or unsubstituted heteroaryl ring; and each X is independently O or S; Specification 28 / 151Page 38 CN 121335980 A or its salt or prodrug.

[0166] In some embodiments, the nucleoside-internucleotide linking of the modified oligonucleotide comprises formula (XXIII), or a salt, solvate, or hydrate thereof:

[0167] Formula (XXIII), wherein: each R2 is independently –H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, –OR6, –N(R6), or –SR6; each R3 is independently –H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, –OR7, –N(R7), or –SR7; R4 and R5 are independently oligonucleotides, or R4 and R5 are linked together to form a single oligonucleotide; each R6 is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; each R7 is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl. Each R8 is independently a substituted or unsubstituted heteroaryl ring; each R9 is independently a substituted or unsubstituted heteroaryl ring; and each X is independently O or S; or a salt or prodrug thereof.

[0168] In some embodiments, the nucleoside-internucleotide linking of the modified oligonucleotide includes formula (XXIV), or a salt, solvate or hydrate thereof:

[0169] Formula (XXIV).

[0170] Wherein: R4 and R5 are independently oligonucleotides, or R4 and R5 are linked together to form a single oligonucleotide; and each X is independently O or S.

[0171] In some embodiments, the nucleoside-to-nucleotide linkage of the modified oligonucleotide includes formula (XXXIII), or a salt, solvate, or hydrate thereof:

[0172] Formula (XXXIII) wherein: R4 and R5 are independently oligonucleotides, or R4 and R5 are linked together to form a single oligonucleotide; and each X is independently O or S.

[0173] In some embodiments, the nucleoside-to-nucleotide linkage of the modified oligonucleotide includes formula (XXXIV), or a salt, solvate, or hydrate thereof:

[0174] Formula (XXXIV) wherein: R4 and R5 are independently oligonucleotides, or R4 and R5 are linked together to form a single oligonucleotide; and each X is independently O or S.

[0175] In some embodiments, the nucleoside-to-nucleotide linkage of the modified oligonucleotide includes formula (XXXV), or a salt, solvate, or hydrate thereof: Specification 30 / 151 page 40 CN 121335980 A

[0176] Formula (XXXV) Wherein: R4 and R5 are oligonucleotides independently, or R4 and R5 are linked together to form a single oligonucleotide; andEach X is independently O or S.

[0177] In some embodiments, any of the compounds of the foregoing embodiments comprises a 5'-phosphonate modification. For example, in some embodiments, the modified oligonucleotide comprises one or more sugars having a phosphonate modification at the 5' position. In some embodiments, the modified oligonucleotide comprises a 5'-phosphonate modification. In some embodiments, the modified oligonucleotide comprises a 5'-terminal nucleoside containing a 5'-phosphonate modification (e.g., a 5'-terminus). In some embodiments, the 5'-phosphonate modification is a 5'-vinylphosphonate modification or a 5'-ethylidenephosphonate modification. In some embodiments, the 5'-phosphonate modification is a 5'-vinylphosphonate modification. In some embodiments, the 5'-phosphonate modification is a 5'-ethylidenephosphonate modification. In some embodiments, the modified oligonucleotide is a first modified oligonucleotide or an antisense oligonucleotide.

[0178] Certain embodiments provide a compound comprising: a first modified oligonucleotide comprising a 5'-phosphonate modification, wherein the first modified oligonucleotide is at least 80% complementary to the region of SEQ ID NO: 1 or 2; and a second modified oligonucleotide comprising one or more ligands.

[0179] In some embodiments, the first modified oligonucleotide comprises a 5'-terminal nucleoside containing a 5'-phosphonate modification. In some embodiments, the 5'-phosphonate modification is a 5'-vinylphosphonate modification or a 5'-ethylidenephosphonate modification. In some embodiments, the 5'-phosphonate modification is a 5'-vinylphosphonate modification. In some embodiments, the 5'-phosphonate modification is a 5'-ethylidenephosphonate modification.

[0180] In some embodiments, the second modified oligonucleotide comprises one or more ligands selected from one or more TrkB ligands, one or more CB1 ligands, one or more α4β1 / 7 integrin ligands, and one or more NMDA ligands. In some embodiments, the one or more TrkB ligands, the one or more CB1 ligands, the one or more α4β1 / 7 integrin ligands, or the one or more NMDA ligands are attached to the 5' end of the second modified oligonucleotide. In some embodiments, the one or more TrkB ligands, the one or more CB1 ligands, the one or more α4β1 / 7 integrin ligands, or the one or more NMDA ligands are attached to the 3' end of the second modified oligonucleotide. In some embodiments, the one or more TrkB ligands, the one or more CB1 ligands, the one or more α4β1 / 7 integrin ligands, or the one or more NMDA ligands are attached to both the 5' and 3' ends of the second modified oligonucleotide. In some embodiments, the one or more TrkB ligands, the one or more CB1 ligands, the one or more α4β1 / 7 integrin ligands, or the one or more NMDA ligands are attached to both the 5' and 3' ends of the second modified oligonucleotide.The TrkB ligands are selected from any of formulas I-XX, XXV, and XXX; the one or more CB1 ligands are of formula XXVI; the one or more α4β1 / 7 integrin ligands are selected from any of formulas XXVII, XXVIII, XXXI, and XXXII, and the one or more NMDA ligands are of formula XXIX.

[0181] In some embodiments, the second modified oligonucleotide comprises one or more TrkB ligands. In some embodiments, the one or more TrkB ligands are selected from any of formulas I-XX, XXV, and XXX. In some embodiments, the second modified oligonucleotide comprises one TrkB ligand. In some embodiments, the second modified oligonucleotide comprises two TrkB ligands. In some embodiments, the second modified oligonucleotide comprises at least two TrkB ligands. In some embodiments, the at least two TrkB ligands are the same. In some embodiments, the at least two TrkB ligands are different.

[0182] In some embodiments, the second modified oligonucleotide comprises one or more CB1 ligands. In some embodiments, the one or more CB1 ligands are of formula XXVI. In some embodiments, the second modified oligonucleotide comprises one CB1 ligand. In some embodiments, the second modified oligonucleotide comprises two CB1 ligands. In some embodiments, the second modified oligonucleotide comprises at least two CB1 ligands. In some embodiments, the at least two CB1 ligands are the same. In some embodiments, the at least two CB1 ligands are different.

[0183] In some embodiments, the second modified oligonucleotide comprises one or more α4β1 / 7 integrin ligands. In some embodiments, the one or more α4β1 / 7 integrin ligands are selected from any one of formulas XXVII, XXVIII, XXXI, and XXXII. In some embodiments, the second modified oligonucleotide comprises one α4β1 / 7 integrin ligand. In some embodiments, the second modified oligonucleotide comprises two α4β1 / 7 integrin ligands. In some embodiments, the second modified oligonucleotide comprises at least two α4β1 / 7 integrin ligands. In some embodiments, the at least two α4β1 / 7 integrin ligands are the same. In some embodiments, the at least two α4β1 / 7 integrin ligands are different.

[0184] In some embodiments, the second modified oligonucleotide comprises one or more NMDA ligands. In some embodiments, the one or more NMDA ligands are of formula XXIX. In some embodiments, the second modified oligonucleotide contains...Contains one NMDA ligand. In some embodiments, the second modified oligonucleotide contains two NMDA ligands. In some embodiments, the second modified oligonucleotide contains at least two NMDA ligands. In some embodiments, the at least two NMDA ligands are the same. In some embodiments, the at least two NMDA ligands are different.

[0185] In some embodiments, the second modified oligonucleotide contains one or more lipids. In some embodiments, the second modified oligonucleotide contains one or more substituted or unsubstituted alkyl or alkenyl groups. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups contain saturated or unsaturated C4-C30 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups contain saturated or unsaturated C5-C20 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups contain saturated or unsaturated C14-C20 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C16 hydrocarbon chains, saturated or unsaturated C17 hydrocarbon chains, saturated or unsaturated C18 hydrocarbon chains, or saturated or unsaturated C22 hydrocarbon chains.

[0186] In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups are attached to a nucleoside internucleotide link of a second modified oligonucleotide. In some embodiments, the nucleoside internucleotide link is located between nucleosides within 10 positions (e.g., within 8 positions, within 6 positions, within 5 positions, within 4 positions, within 3 positions, within 2 positions) starting from the end (e.g., the 5' end and / or the 3' end) of the second modified oligonucleotide. In some embodiments, the nucleoside internucleotide link is located between nucleosides within 5 positions starting from the 5' end of the second modified oligonucleotide. In some embodiments, the nucleoside internucleotide link is located between nucleosides within 5 positions starting from the 3' end of the second modified oligonucleotide.

[0187] In some embodiments, the nucleotide-to-nucleotide link is located between position 1 and position 2, position 2 and position 3, position 3 and position 4, position 4 and position 5, position 5 and position 6, position 6 and position 7, position 7 and position 8, position 8 and position 9, position 9 and position 10, position 10 and position 11, position 11 and position 12, position 12 and position 13, or position 13 and position 14, starting from the 5' end of the second modified oligonucleotide. In some embodiments, the nucleotide-to-nucleotide link is located between position 1 and position 2, position 2 and position 3, position 3 and position 4, position 4 and position 5, position 5 and position 6, starting from the 5' end of the second modified oligonucleotide.Between position 6 and position 7 or between position 7 and position 8. In some embodiments, the internucleotide link is located between position 2 and position 3, starting from the 5' end of the second modified oligonucleotide. In some embodiments, the internucleotide link is located between position 1 and position 2, position 2 and position 3, position 3 and position 4, position 4 and position 5, position 5 and position 6, position 6 and position 7, position 7 and position 8, position 8 and position 9, position 9 and position 10, position 10 and position 11, position 11 and position 12, position 12 and position 13, or position 13 and position 14, starting from the 3' end of the second modified oligonucleotide. In some embodiments, the internucleotide link is located between position 1 and position 2, position 2 and position 3, position 3 and position 4, position 4 and position 5, position 5 and position 6, position 6 and position 7, or position 7 and position 8, starting from the 3' end of the second modified oligonucleotide. In some embodiments, the internucleotide link is located between position 2 and position 3, starting from the 3' end of the second modified oligonucleotide.

[0188] In some embodiments, the internucleotide link of the second modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV.

[0189] In some embodiments, the length of the first modified oligonucleotide is 14 to 30 linked nucleosides. In some embodiments, the length of the second modified oligonucleotide is 14 to 30 linked nucleosides, having a region complementary to the first modified oligonucleotide. In some embodiments, the first modified oligonucleotide has a nucleobase sequence comprising at least 14 adjacent nucleosides of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the second modified oligonucleotide has a nucleobase sequence comprising at least 14 adjacent nucleosides of any one of SEQ ID NOs: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the first modified oligonucleotide is selected from any one of 1A Ref ID NOs in Table 3. In some embodiments, the second modified oligonucleotide is selected from any one of 1S Ref ID NOs in Table 3.

[0190] Some embodiments provide a compound comprising: a first modified oligonucleotide selected from the group consisting of any one of the Ref ID NOs listed in Table 3; and a second modified oligonucleotide having a length of 14 to 21 linked nucleosides, the second modified oligonucleotide being completely complementary to the first modified oligonucleotide.

[0191] Some embodiments provide compounds comprising: a first modified oligonucleotide selected from the group consisting of any one of the IA Ref ID NOs listed in Table 3; and a second modified oligonucleotide selected from the group consisting of any one of the IS Ref ID NOs listed in Table 3.

[0192] In some embodiments, the pharmaceutically acceptable salt of the modified oligonucleotides provided herein is a sodium or potassium salt. In some embodiments, the pharmaceutically acceptable salt of the compounds provided herein is a sodium or potassium salt.

[0193] In some embodiments, a group of modified oligonucleotides is provided herein, wherein all thiophosphate nucleoside linkages of the modified oligonucleotides are stereorandom. In some embodiments, a group of compounds is provided herein, wherein all thiophosphate nucleoside linkages of the modified oligonucleotides are stereorandom.

[0194] In some embodiments, any of the compounds of the foregoing embodiments are in the form of a pharmaceutically acceptable salt. In some embodiments, the pharmaceutically acceptable salt is a sodium salt. In some embodiments, the pharmaceutically acceptable salt is a potassium salt.

[0195] Some embodiments provide a composition comprising the compound of any of the foregoing embodiments (page 33 / 151, CN 121335980 A) and a pharmaceutically acceptable carrier.

[0196] Some embodiments provide a composition comprising any of the compounds of the foregoing embodiments for use in a therapy.

[0197] Some embodiments provide a method of treating, preventing, or improving an individual’s SOD1-related disease, condition, or disorder, the method comprising administering to the individual a compound targeting SOD1, thereby treating, preventing, or improving the disease.

[0198] In some embodiments, any of the compounds or compositions of the foregoing embodiments are administered to an individual. In some embodiments, the disease, condition, or disorder is a CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death.

[0199] In some embodiments, administration of the compound can inhibit or alleviate or improve CNS-related diseases, conditions, or disorders or their symptoms, or neurodegenerative diseases or their symptoms, including ALS or its symptoms such as loss of motor function or neuronal death.

[0200] In some embodiments, the compound or a composition comprising any of the compounds of the foregoing embodiments is administered to an individual in a therapeutically effective amount. In some embodiments, the compound or a composition comprising any of the compounds of the foregoing embodiments is administered to an individual at a dose level sufficient to deliver about 1 to 100 mg / kg of individual body weight. In some embodiments, the compound is administered to an individual in a dose level sufficient to deliver about 1 to 100 mg / kg of individual body weight.The compound or a composition comprising any of the compounds described in the foregoing embodiments is administered to an individual at a fixed dose of about 25 mg to about 1,000 mg. In some embodiments, the compound or composition is administered to the individual one or more times a day until the dose level or fixed dose is reached.

[0201] In some embodiments, the compound or a composition comprising any of the compounds described in the foregoing embodiments is administered to the individual daily, weekly, monthly, quarterly, or annually. In some embodiments, the compound or a composition comprising any of the compounds described in the foregoing embodiments is administered to the individual about once per quarter (i.e., every three months) to about once per year. In some embodiments, the compound or a composition comprising any of the compounds described in the foregoing embodiments is administered to the individual about once per quarter, about once every six months, or about once per year.

[0202] Some embodiments provide a method for inhibiting SOD1 expression in cells, the method comprising contacting the cells with a compound targeting SOD1, thereby inhibiting SOD1 expression in the cells. In some embodiments, the cells are in the liver of an individual. In some embodiments, an individual suffers from or is at risk of suffering from: a CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death.

[0203] Some embodiments provide a method for alleviating or suppressing an individual's CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms (including ALS or its symptoms such as loss of motor function or neuronal death), the method comprising administering to the individual a compound targeting SOD1, thereby alleviating or suppressing the individual's CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the individual suffers from or is at risk of suffering from: a CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the compound is a compound targeting SOD1. In some embodiments, the compound is any of the aforementioned compounds. In some embodiments, the compound or composition is administered parenterally. In some embodiments, the compound or composition is administered via intrathecal (IT) administration.

[0204] Some embodiments provide the use of compounds targeting SOD1 for the treatment, prevention, or improvement of diseases, conditions, or disorders associated with SOD1. In some embodiments, the disease, condition, or disorder is a CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. (Instructions for Use 34 / 151, Page 44, CN 121335980)Symptoms of A. In some embodiments, the compound is a compound targeting SOD1. In some embodiments, the compound is any of the aforementioned compounds.

[0205] Some embodiments provide the use of a compound targeting SOD1 in the manufacture of a medicament for treating, preventing, or improving a disease, condition, or disorder related to SOD1. In some embodiments, the disease, condition, or disorder is a CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the compound is a compound targeting SOD1. In some embodiments, the compound is any of the aforementioned compounds.

[0206] Certain indications In some aspects, this disclosure relates to a method of inhibiting SOD1 expression by administering a compound targeting SOD1, which may be used to treat, prevent, or improve an individual's SOD1-related disease. In some embodiments, the compound may be an SOD1-specific inhibitor. In some embodiments, the compound may be an antisense oligonucleotide, oligomer, or oligonucleotide targeting SOD1.

[0207] In some aspects, this disclosure relates to treating, preventing, or improving SOD1-related diseases, conditions, or disorders. In some embodiments, SOD1-related diseases, conditions, or disorders that are treatable, preventable, and / or improveable using the methods provided herein include CNS-related diseases, conditions, or disorders or their symptoms, or neurodegenerative diseases or their symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. Certain compounds provided herein relate to compounds and compositions that alleviate CNS-related diseases, conditions, or disorders or their symptoms, or neurodegenerative diseases or their symptoms (including ALS or its symptoms such as loss of motor function or neuronal death) in animals.

[0208] In some embodiments, a method of treating, preventing, or improving an individual's SOD1-related disease includes administering to the individual a compound comprising an SOD1-specific inhibitor, thereby treating, preventing, or improving the disease. In some embodiments, the individual is identified as having an SOD1-related disease or at risk of having an SOD1-related disease. In some embodiments, the disease is a CNS-related disease. In some embodiments, the compound comprises an antisense oligonucleotide targeting SOD1. In some embodiments, the compound comprises an oligonucleotide targeting SOD1. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having nucleobases comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223.The sequence comprises a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), and the modified oligonucleotide has a nucleobase sequence comprising any one of the nucleobase sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleobase sequences of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleonucleotide sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases from any of the nucleobase sequences of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of nucleobase sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleotide sequences of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from SEQ ID NO:The compound comprises a nucleotide sequence consisting of the group consisting of nucleotide sequences selected from SEQ ID NO: 19-27, 107-183, 188-195, and 203-213; and a second modified oligonucleotide having a nucleotide sequence consisting of the group consisting of nucleotide sequences selected from SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In any of the foregoing embodiments, the compound may be single-stranded or double-stranded. In some embodiments, the single-stranded compound may be 14 to 30, 14 to 23, 14 to 20, 16 to 20, or 14 to 16 linked nucleosides. In some embodiments, the single-stranded compound may be 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 linked nucleosides. In some embodiments, as described elsewhere herein, the double-stranded compound may comprise two oligonucleotides of the same or different lengths. In any of the foregoing embodiments, the compound may be an antisense oligonucleotide or an oligomeric compound. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the first modified oligonucleotide having a nucleobase sequence comprising any of the nucleobase sequences in SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the group consisting of any of SEQ ID NO: 11-223; and a second modified oligonucleotide of 19 to 23 linked nucleosides, the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound will...The compound is administered parenterally to an individual. In some embodiments, the compound is administered to an individual via intrathecal (IT) administration. In some embodiments, administration of the compound can improve, maintain, or prevent CNS-related diseases, conditions, or disorders or their symptoms, or neurodegenerative diseases or their symptoms, including ALS or its symptoms such as loss of motor function or neuronal death.

[0209] In some embodiments, methods of treating, preventing, or improving CNS-related diseases, conditions, or disorders or their symptoms, or neurodegenerative diseases or their symptoms (including ALS or its symptoms such as loss of motor function or neuronal death) in an animal include administering a compound containing an SOD1-specific inhibitor to an individual, thereby treating, preventing, or improving CNS-related diseases, conditions, or disorders or their symptoms, or neurodegenerative diseases or their symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the compound contains an antisense oligonucleotide targeting SOD1. In some embodiments, the compound contains an oligonucleotide targeting SOD1. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleonucleotide sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) as specified on page 36 / 151 of CN 121335980 A, and the modified oligonucleotide has a nucleobase sequence comprising any one of the nucleobase sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleobase sequences of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having at least 14, at least 15, or at least 16 nucleosides of any of the nucleobase sequences comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223.A nucleobase sequence of at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases from any nucleobase sequence comprising SEQ ID NO: 19-27, 107-183, 188-195, or 203-213. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleotide sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleotide sequences of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223; and a second modified oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In any of the foregoing embodiments, the compound may be single-stranded or double-stranded. In any of the foregoing embodiments, the compound may be an antisense oligonucleotide or an oligomeric compound. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the first modified oligonucleotide having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises the first modified oligonucleotide.The compound comprises an oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising any one of the nucleobase sequences in SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NO: 11-223; and a second modified oligonucleotide of 19 to 23 linked nucleosides having a region complementary to the first modified oligonucleotide. In some embodiments, administration of the compound can improve, maintain, or prevent CNS-related diseases, conditions, or disorders or their symptoms, or neurodegenerative diseases or their symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the individual is identified as having or at risk of having an SOD1-related disease.

[0210] In some embodiments, a method of inhibiting SOD1 expression in an individual having or at risk of having an SOD1-related disease comprises administering to the individual a compound containing an SOD1-specific inhibitor, thereby inhibiting SOD1 expression in the individual. In some embodiments, administration of the compound can inhibit SOD1 expression in the liver. In some embodiments, the disease is a CNS-related disease. In some embodiments, the individual has or is at risk of having: a CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the compound comprises an antisense oligonucleotide targeting SOD1. In some embodiments, the compound comprises an oligonucleotide targeting SOD1. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223.In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), and the modified oligonucleotide has a nucleobase sequence comprising any one of the nucleobase sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleobase sequences of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleonucleotide sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases comprising any nucleobase sequence of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of nucleobase sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223; and a second modified oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213.The nucleotide sequence of the group consisting of nucleotide sequences 107-183, 188-195, and 203-213. In any of the foregoing embodiments, the compound may be single-stranded or double-stranded. In any of the foregoing embodiments, the compound may be an antisense oligonucleotide or an oligomeric compound. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., 14 to 30, for example 14 to 23 linked nucleosides) having a nucleobase sequence comprising any one of SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., 14 to 30, for example 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the group consisting of any one of SEQ ID NO: 11-223; and a second modified oligonucleotide of 19 to 23 linked nucleosides having a region complementary to the first modified oligonucleotide. In some embodiments, the compound is administered parenterally to an individual. In some embodiments, the compound is administered to an individual via intrathecal (IT) administration. In some embodiments, administration of the compound can improve, maintain, or prevent CNS-related diseases, conditions, or disorders or their symptoms, neurodegenerative diseases or their symptoms, including ALS or its symptoms such as loss of motor function or neuronal death.

[0211] In some embodiments, a method of inhibiting SOD1 expression in cells includes contacting the cells with a compound containing an SOD1-specific inhibitor, thereby inhibiting SOD1 expression in the cells. In some embodiments, the cells are hepatocytes. In some embodiments, the cells are in the liver. In some embodiments, the cells are in patients with the following or...In the liver of individuals at risk of: CNS-related disease, condition, or disorder or its symptoms, or neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the compound comprises an antisense oligonucleotide targeting SOD1. In some embodiments, the compound comprises an oligonucleotide targeting SOD1. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30 linked nucleosides, such as 14 to 23), and the modified oligonucleotide has a nucleobase sequence comprising any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleobase sequences of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides from any of the nucleobase sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides comprising any nucleobase sequence of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound contains...The compound contains a modified oligonucleotide selected from the group consisting of the nucleotide sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleotide sequences of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223; and a second modified oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In any of the foregoing embodiments, the compound may be single-stranded or double-stranded. In any of the foregoing embodiments, the compound may be an antisense oligonucleotide or an oligomeric compound. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of length 14 to 30, such as 14 to 23 linked nucleosides), the first modified oligonucleotide having a nucleobase sequence comprising any of the nucleobase sequences in SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of length 14 to 30, such as 14 to 23 linked nucleosides), the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the group consisting of any of SEQ ID NO: 11-223; and a nucleobase sequence comprising any of the nucleobase sequences in ...A second modified oligonucleotide consisting of 19 to 23 linked nucleosides, the second modified oligonucleotide having a region complementary to the first modified oligonucleotide.

[0212] In some embodiments, a method of alleviating or suppressing a CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms (including ALS or its symptoms such as loss of motor function or neuronal death) in an individual suffering from or at risk of suffering from a SOD1-related disease includes administering a compound comprising an SOD1-specific inhibitor to the individual, thereby alleviating or suppressing the individual's CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the individual suffers from or is at risk of suffering from a CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the compound comprises an antisense oligonucleotide targeting SOD1. In some embodiments, the compound comprises an oligonucleotide targeting SOD1. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), and the modified oligonucleotide has a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleobase sequences of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the modified oligonucleotide having a SEQ ID NO: 11-18, 28-106, 184-187, 196-202 or 214-The nucleobase sequence of SEQ ID NO: 19-27, 107-183, 188-195, 203-213 includes at least 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 adjacent nucleobases. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of length 14 to 30, such as 14 to 23 linked nucleosides) having at least 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 adjacent nucleobases. In some embodiments, as described on pages 40 / 151 of CN 121335980 A, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleotide sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleotide sequences of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223; and a second modified oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In any of the foregoing embodiments, the compound may be single-stranded or double-stranded. In any of the foregoing embodiments, the compound may be an antisense oligonucleotide or an oligomeric compound. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the first modified oligonucleotide having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30).In some embodiments, the compound comprises a first modified oligonucleotide (e.g., 14 to 30 linked nucleosides, for example, 14 to 23), the first modified oligonucleotide having a nucleobase sequence comprising any one of SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., 14 to 30 linked nucleosides, for example, 14 to 23), the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the group consisting of any one of SEQ ID NO: 11-223; and a second modified oligonucleotide of 19 to 23 linked nucleosides, the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound is administered parenterally to an individual. In some embodiments, the compound is administered to an individual via intrathecal (IT) administration. In some embodiments, the individual is identified as having an SOD1-related disease or at risk of having an SOD1-related disease.

[0213] Some embodiments involve compounds comprising an SOD1-specific inhibitor for treating SOD1-related diseases, conditions, or disorders. In some embodiments, the disease, condition, or disorder is a CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the compound comprises an antisense oligonucleotide targeting SOD1. In some embodiments, the compound comprises an oligonucleotide targeting SOD1. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), and the modified oligonucleotide has at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising SEQ ID NO:The nucleobase sequence of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleobase sequences of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising any nucleobase sequence of SEQ ID NO: 11-18, 28-106, 184-187, 196-202 or page 41 / 151 of specification 51 CN 121335980 A 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases of any nucleobase sequence comprising SEQ ID NO: 19-27, 107-183, 188-195, or 203-213. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of nucleobase sequences comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of nucleotide sequences of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223; and a second modified oligonucleotide having a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In any of the foregoing embodiments, the compound may be single-stranded or double-stranded.In any of the embodiments described above, the compound may be an antisense oligonucleotide or an oligomeric compound. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the first modified oligonucleotide having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the first modified oligonucleotide having a nucleobase sequence comprising any of the nucleobase sequences in SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the group consisting of any of SEQ ID NO: 11-223; and a second modified oligonucleotide of 19 to 23 linked nucleosides, the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound is administered parenterally to an individual. In some embodiments, the compound is administered to an individual via intrathecal (IT) administration.

[0214] Some embodiments relate to a compound comprising an SOD1-specific inhibitor for alleviating or inhibiting CNS-related diseases, conditions, or disorders or their symptoms, or neurodegenerative diseases or their symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the compound comprises an antisense oligonucleotide targeting SOD1. In some embodiments, the compound comprises an oligonucleotide targeting SOD1. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 15 nucleosides of any of the nucleobase sequences comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223.The nucleotide sequence has at least 20, 21, 22, or 23 adjacent nucleotides. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), and the modified oligonucleotide has a nucleotide sequence comprising the nucleotide sequence of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleotide sequences of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising any of the nucleobase sequences in SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the group consisting of any of SEQ ID NO: 11-223; and a second modified oligonucleotide of 19 to 23 linked nucleosides having a region complementary to the first modified oligonucleotide.

[0215] Some embodiments relate to the use of compounds comprising SOD1-specific inhibitors for the manufacture or preparation of medicaments for treating SOD1-related diseases. Some implementations involve compounds containing SOD1-specific inhibitors for use in the manufacture of...Use of an agent for treating a disease, condition, or disorder related to SOD1. In some embodiments, the disease, condition, or disorder is a CNS-related disease, condition, or disorder or a symptom thereof. In some embodiments, the disease, condition, or disorder is a neurodegenerative disease or a symptom thereof, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the compound comprises an antisense oligonucleotide targeting SOD1. In some embodiments, the compound comprises an oligonucleotide targeting SOD1. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleonucleotide sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30 linked nucleosides, such as 14 to 23), and the modified oligonucleotide has a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleobase sequences of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleonucleotide sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having at least 14, at least 15, at least 16, at least 17, at least 18, or at least 19 nucleosides of any of the nucleobase sequences comprising SEQ ID NO: 19-27, 107-183, 188-195, or 203-213.A nucleobase sequence of at least 1, 20, 21, 22, or 23 adjacent nucleobases. In some embodiments, as described on page 43 / 151 of CN 121335980 A, the compound comprises a modified oligonucleotide selected from the group consisting of nucleobase sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of nucleobase sequences of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223; and a second modified oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In any of the foregoing embodiments, the compound may be single-stranded or double-stranded. In any of the foregoing embodiments, the compound may be an antisense oligonucleotide or an oligomeric compound. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of length 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides; and a second modified oligonucleotide (e.g., of length 14 to 30, such as 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the first modified oligonucleotide having a nucleobase sequence comprising any one of the nucleobase sequences in SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide having a region selected from SEQ ID NO:The nucleobase sequence of any one of 11-223; and a second modified oligonucleotide of 19 to 23 linked nucleosides having a region complementary to the first modified oligonucleotide.

[0216] Some embodiments relate to the use of compounds comprising SOD1-specific inhibitors for the manufacture or preparation of an agent for alleviating or inhibiting CNS-related diseases, conditions, or disorders or symptoms thereof in individuals at risk of having, or suffering from, SOD1-related CNS-related diseases, conditions, or disorders or symptoms thereof. In some embodiments, the CNS-related disease, condition, or disorder is a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. Some embodiments relate to the use of compounds comprising SOD1-specific inhibitors for the preparation of an agent for treating SOD1-related diseases, conditions, or disorders. In some embodiments, the disease, condition, or disorder is a CNS-related disease, condition, or disorder or its symptoms, or a neurodegenerative disease or its symptoms, including ALS or its symptoms such as loss of motor function or neuronal death. In some embodiments, the compound comprises an antisense oligonucleotide targeting SOD1. In some embodiments, the compound comprises an oligonucleotide targeting SOD1. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30 linked nucleosides, such as 14 to 23), and the modified oligonucleotide has a nucleobase sequence comprising any one of the nucleobase sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of the nucleobase sequences of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments...The compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleonucleotide sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides of any nucleobase sequence comprising SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises a modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleobases comprising any nucleobase sequence of SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of nucleobase sequences of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223. In some embodiments, the compound comprises a modified oligonucleotide selected from the group consisting of nucleotide sequences selected from SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleotide sequence selected from the group consisting of nucleotide sequences selected from SEQ ID NO: 11-18, 28-106, 184-187, 196-202, and 214-223; and a second modified oligonucleotide having a nucleotide sequence selected from the group consisting of nucleotide sequences selected from SEQ ID NO: 19-27, 107-183, 188-195, and 203-213. In any of the foregoing embodiments, the compound may be single-stranded or double-stranded. In any of the foregoing embodiments, the compound may be an antisense oligonucleotide or an oligomeric compound. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the first modified oligonucleotide having at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or at least [number missing] nucleosides comprising any nucleobase sequence comprising SEQ ID NO: 11-223.The compound comprises a nucleobase sequence of 22 or at least 23 adjacent nucleosides; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides) having a nucleobase sequence comprising any one of the nucleobase sequences in SEQ ID NO: 11-223; and a second modified oligonucleotide (e.g., of 14 to 30, such as 14 to 23 linked nucleosides), the second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the group consisting of any of SEQ ID NO: 11-223; and a second modified oligonucleotide having a length of 19 to 23 linked nucleosides having a region complementary to the first modified oligonucleotide.

[0217] In any of the foregoing methods or uses, the compound may be an oligomeric compound. In any of the foregoing methods or uses, the compound may be single-stranded or double-stranded. In any of the foregoing methods or uses, the compound may target SOD1. In some embodiments, the compound comprises or is composed of a modified oligonucleotide. In some embodiments, the compound comprises one or more modified oligonucleotides. In some embodiments, the compound comprises a first modified oligonucleotide and a second modified oligonucleotide. In some embodiments, the modified oligonucleotide has a length of 8 to 80 linked nucleosides, 10 to 30 linked nucleosides, 14 to 30 linked nucleosides, 14 to 23 linked nucleosides, or 19 to 23 linked nucleosides. In some embodiments, the modified oligonucleotide is at least 80%, 85%, 90%, 95%, or 100% complementary in length to the nucleobase sequence listed in SEQ ID NO: 1. In some embodiments, the modified oligonucleotide comprises at least one modified nucleoside link, at least one modified sugar, and / or at least one modified nucleobase. In some embodiments, the modified nucleoside link is a phosphate thioester nucleoside link. In some embodiments, the modified sugar is a bicyclic sugar, 2'-MOE, 2'-F, or 2'-OMe. In some embodiments, the modified nucleobase is 5-methylcytosine.In any of the foregoing embodiments, the length of each modified oligonucleotide is independently 12 to 30, 14 to 30, 14 to 25, 14 to 24, 14 to 23, 16 to 23, 17 to 23, 18 to 23, 19 to 23, 19 to 22, or 19 to 20 linked nucleosides. In some embodiments, the modified oligonucleotide has at least one, at least two, or at least three mismatches with the region of SEQ ID NO: 1 or 2.

[0218] In any of the foregoing methods or uses, the compound comprises first and second modified oligonucleotides, wherein there is a complementary region between the first and second modified oligonucleotides. In some embodiments, the length of the complementary region between the first and second oligonucleotides is 14 to 23, 19 to 23, or 21 to 23 linked nucleosides. In some embodiments, the first modified oligonucleotide and the second modified oligonucleotide are completely complementary. In some embodiments, the first modified oligonucleotide comprises at least one modification selected from modified nucleoside linkages, modified sugars, and modified nucleobases. In some embodiments, the second modified oligonucleotide comprises at least one modification selected from the group consisting of modified nucleoside linkages, modified sugars, and modified nucleobases. In some embodiments, the modified nucleoside linkage is a phosphate thioate nucleoside linkage or a methylphosphonate nucleoside linkage. In some embodiments, the modified nucleoside linkage is located at the 3' end or the 5' end of the first or second modified oligonucleotide. In some embodiments, the first or second modified oligonucleotide comprises one or more modified sugars. In some embodiments, each nucleoside of the first or second modified oligonucleotide comprises a modified sugar. In some embodiments, the modified sugar comprises a modification selected from the group consisting of halogens, alkoxy groups, and bicyclic sugars. In some embodiments, the modified sugar comprises a modification selected from the group consisting of 2'-MOE, 2'-F, and 2'-OMe, or combinations thereof. In some embodiments, the first or second modified oligonucleotide contains no more than ten 2'-F sugar modifications. In some embodiments, the first or second modified oligonucleotide contains no more than five 2'-F sugar modifications.

[0219] In any of the foregoing methods or uses, the compound contains a conjugation group. In some embodiments, the conjugation group is attached to the 5' end of the modified oligonucleotide. In some embodiments, the conjugation group is a targeting moiety. In some embodiments, the targeting moiety contains one or more TrkB ligands. In some embodiments, the one or more TrkB ligands are attached to the 5' end or 3' end of the oligonucleotide, or both the 5' end and 3' end of the oligonucleotide.In some embodiments, the TrkB ligand is selected from formulas I-XX, XXV, and XXX, or their salts, solvates, or hydrates, wherein R is a modified oligonucleotide. In some embodiments, the modified oligonucleotide is attached to the TrkB ligand via a phosphodiester group. In some embodiments, the modified oligonucleotide is attached to the TrkB ligand via a thiophosphate group. In some embodiments, the targeting portion comprises one or more CB1 ligands. In some embodiments, the one or more CB1 ligands are attached to the 5' end or 3' end of the oligonucleotide, or both the 5' end and 3' end of the oligonucleotide. In some embodiments, the CB1 ligand is of formula XXVI, or its salts, solvates, or hydrates, wherein R is a modified oligonucleotide. In some embodiments, the modified oligonucleotide is attached to the CB1 ligand via a phosphodiester group. In some embodiments, the modified oligonucleotide is attached to the CB1 ligand via a thiophosphate group. In some embodiments, the targeting portion comprises one or more α4β1 / 7 integrin ligands. In some embodiments, the one or more α4β1 / 7 integrin ligands are attached to the 5' end or 3' end of the oligonucleotide, or both the 5' end and 3' end of the oligonucleotide. In some embodiments, the α4β1 / 7 integrin ligand is selected from formulas XXVII, XXVIII, XXXI, and XXXII, or their salts, solvates, or hydrates, wherein R is a modified oligonucleotide. In some embodiments, the modified oligonucleotide is attached to the α4β1 / 7 integrin ligand via a phosphodiester group. In some embodiments, the modified oligonucleotide is attached to the α4β1 / 7 integrin ligand via a thiophosphate group. In some embodiments, the targeting portion comprises one or more NMDA ligands. In some embodiments, the one or more NMDA ligands are attached to the 5' end or 3' end of the oligonucleotide, or both the 5' end and 3' end of the oligonucleotide. In some embodiments, the NMDA ligand is of formula XXIX, or a salt, solvate, or hydrate thereof, wherein R is a modified oligonucleotide. In some embodiments, the modified oligonucleotide is attached to the NMDA ligand via a phosphodiester group. In some embodiments, the modified oligonucleotide is attached to the NMDA ligand via a thiophosphate group. In some embodiments, the conjugating group comprises one or more lipids. In some embodiments, the modified oligonucleotide is a second modified oligonucleotide. In some embodiments, the one or more lipids are attached to the nucleoside-to-nucleotide link of the modified oligonucleotide. In some embodiments, the nucleoside-to-nucleotide link of the modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV, or a salt, solvate, or hydrate thereof.The oligonucleotide is a modified oligonucleotide. In some embodiments, the modified oligonucleotide comprises one or more TrkB ligands and one or more lipids. In some embodiments, the modified oligonucleotide comprises one or more CB1 ligands and one or more lipids. In some embodiments, the modified oligonucleotide comprises one or more α4β1 / 7 integrin ligands and one or more lipids. In some embodiments, the modified oligonucleotide comprises one or more NMDA ligands and one or more lipids. In some embodiments, the modified oligonucleotide is a second modified oligonucleotide. In some embodiments, the one or more TrkB ligands are attached to the 5' end of the modified oligonucleotide. In some embodiments, the one or more TrkB ligands are attached to the 3' end of the modified oligonucleotide. In some embodiments, the one or more TrkB ligands are attached to both the 5' and 3' ends of the modified oligonucleotide. In some embodiments, the one or more lipids are attached to the nucleoside internucleotide linker of the modified oligonucleotide. In some embodiments, the one or more TrkB ligands are selected from any of formulas I-XX, XXV, and XXX, or their salts, solvates, or hydrates, wherein R is a modified oligonucleotide, and the nucleoside-to-nucleotide linkage of the modified oligonucleotide is selected from any of formulas XXI-XXIV and XXXIII-XXXV, or their salts, solvates, or hydrates, wherein R is a modified oligonucleotide. In some embodiments, the one or more CB1 ligands are attached to the 5' end of the modified oligonucleotide. In some embodiments, the one or more CB1 ligands are attached to the 3' end of the modified oligonucleotide. In some embodiments, the one or more CB1 ligands are attached to both the 5' and 3' ends of the modified oligonucleotide. In some embodiments, the one or more lipids are attached to the nucleoside-to-nucleotide linkage of the modified oligonucleotide. In some embodiments, the one or more CB1 ligands are of formula XXVI, or a salt, solvate, or hydrate thereof, wherein R is a modified oligonucleotide, and the nucleoside-to-nucleotide linkage of the modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV, or a salt, solvate, or hydrate thereof, wherein R is a modified oligonucleotide. In some embodiments, the one or more α4β1 / 7 integrin ligands are attached to the 5' end of the modified oligonucleotide. In some embodiments, the one or more α4β1 / 7 integrin ligands are attached to the 3' end of the modified oligonucleotide. In some embodiments, the one or more α4β1 / 7 integrin ligands are attached to both the 5' and 3' ends of the modified oligonucleotide. In some embodiments, the one or more lipids are attached to the nucleoside-to-nucleotide linkage of the modified oligonucleotide. In some embodiments...In this embodiment, the one or more α4β1 / 7 integrin ligands are selected from any one of formulas XXVII, XXVIII, XXXI, and XXXII, or their salts, solvates, or hydrates, wherein R is a modified oligonucleotide, and the nucleoside-to-nucleotide linkage of the modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV, or their salts, solvates, or hydrates, wherein R is a modified oligonucleotide. In some embodiments, the one or more NMDA ligands are attached to the 5' end of the modified oligonucleotide. In some embodiments, the one or more NMDA ligands are attached to the 3' end of the modified oligonucleotide. In some embodiments, the one or more NMDA ligands are attached to both the 5' and 3' ends of the modified oligonucleotide. In some embodiments, the one or more lipids are attached to the nucleoside-to-nucleotide linkage of the modified oligonucleotide. In some embodiments, the one or more NMDA ligands described in this specification (page 47 / 151, CN 121335980 A) are of formula XXIX, or a salt, solvate, or hydrate thereof, wherein R is a modified oligonucleotide, and the nucleoside-to-nucleotide linkage of the modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV, or a salt, solvate, or hydrate thereof, wherein R is a modified oligonucleotide.

[0220] In any of the foregoing methods or uses, in some embodiments, the compound comprises one or more substituted or unsubstituted alkyl or alkenyl groups. In some embodiments, the substituted or unsubstituted alkyl or alkenyl group is attached to the nucleoside-to-nucleotide linkage of the modified oligonucleotide. In some embodiments, the modified oligonucleotide comprises one or more substituted or unsubstituted alkyl or alkenyl groups. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups are attached to one or more nucleoside-to-nucleotide linkages of the modified oligonucleotide. In some embodiments, the modified oligonucleotide is a second modified oligonucleotide or a positive oligonucleotide. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C4-C30 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C5-C20 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C14-C20 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C16 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C17 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C17 hydrocarbon chains.Or an unsaturated C18 hydrocarbon chain. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise a saturated or unsaturated C22 hydrocarbon chain.

[0221] In some embodiments, the substituted or unsubstituted alkyl or alkenyl group is attached to an internucleotide link of a modified oligonucleotide (e.g., a second modified oligonucleotide or a positive oligonucleotide). In some embodiments, the substituted or unsubstituted alkyl or alkenyl group is attached to an internucleotide link of a modified oligonucleotide (e.g., a second modified oligonucleotide or a positive oligonucleotide). In some embodiments, the internucleotide link is located between nucleosides within 10 positions (e.g., within 8 positions, within 6 positions, within 5 positions, within 4 positions, within 3 positions, within 2 positions) starting from the end (e.g., the 5' end and / or the 3' end) of the modified oligonucleotide. In some embodiments, the internucleotide link is located between nucleosides within 5 positions starting from the 5' end of the modified oligonucleotide. In some embodiments, the nucleoside-to-nucleotide linkages are located between nucleosides at five positions starting from the 3' end of the modified oligonucleotide.

[0222] In some embodiments, the nucleoside-to-nucleotide linkages are located between positions 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11, 11 and 12, 12 and 13, or 13 and 14, starting from the 5' end of the modified oligonucleotide. In some embodiments, the nucleoside-to-nucleotide linkages are located between positions 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, or 7 and 8, starting from the 5' end of the modified oligonucleotide. In some embodiments, the nucleoside-to-nucleotide link is located between position 2 and position 3, starting from the 5' end of the modified oligonucleotide. In some embodiments, the nucleoside-to-nucleotide link is located between position 1 and position 2, position 2 and position 3, position 3 and position 4, position 4 and position 5, position 5 and position 6, position 6 and position 7, position 7 and position 8, position 8 and position 9, position 9 and position 10, position 10 and position 11, position 11 and position 12, position 12 and position 13, or position 13 and position 14, starting from the 3' end of the modified oligonucleotide. In some embodiments, the nucleoside-to-nucleotide link is located between position 1 and position 2, position 2 and position 3, position 3 and position 4, position 4 and position 5, position 5 and position 6, starting from the 3' end of the modified oligonucleotide.Between positions 6, between positions 6 and 7, or between positions 7 and 8. In some embodiments, the internucleotide link is located between positions 2 and 3, starting from the 3' end of the oligonucleotide modified as per page 48 / 151 of CN 121335980 A.

[0223] In some embodiments, the internucleotide link of the modified oligonucleotide is selected from any of the formulas XXI-XXIV and XXXIII-XXXV.

[0224] In any of the foregoing methods or uses, in some embodiments, the compound comprises a 5'-phosphonate modification. For example, in some embodiments, the modified oligonucleotide comprises one or more sugars having a phosphonate modification at the 5' position. In some embodiments, the modified oligonucleotide comprises a 5'-phosphonate modification. In some embodiments, the modified oligonucleotide comprises a 5'-terminal nucleoside containing a 5'-phosphonate modification (e.g., a 5' end). In some embodiments, the 5'-phosphonate modification is a 5'-vinylphosphonate modification or a 5'-ethylenephosphonate modification. In some embodiments, the 5'-phosphonate modification is a 5'-vinylphosphonate modification. In some embodiments, the 5'-phosphonate modification is a 5'-ethylidenephosphonate modification. In some embodiments, the modified oligonucleotide is a first modified oligonucleotide or an antisense oligonucleotide.

[0225] In any of the methods or uses described above, the compound comprises a first modified oligonucleotide selected from any of the IA Ref ID NOs in Table 3 and a second modified oligonucleotide of 14 to 23 linked nucleosides that is completely complementary to the first modified oligonucleotide. In some embodiments, the compound comprises a first modified oligonucleotide selected from any of the IA Ref ID NOs in Table 3 and a second modified oligonucleotide selected from any of the IS Ref ID NOs in Table 3. In some embodiments, the compound is in the form of a pharmaceutically acceptable salt. In some embodiments, the pharmaceutically acceptable salt is a sodium salt. In some embodiments, the pharmaceutically acceptable salt is a potassium salt. In some embodiments, the composition comprises a compound of any of the embodiments described above and a pharmaceutically acceptable carrier.

[0226] In any of the foregoing methods or uses, the compound or a composition comprising any of the compounds of the foregoing embodiments is administered to an individual in a therapeutically effective amount. In some embodiments, the compound or a composition comprising any of the compounds of the foregoing embodiments is administered to an individual at a dose level sufficient to deliver about 1 to 100 mg / kg of individual body weight. In some embodiments, the compound or a composition comprising any of the compounds of the foregoing embodiments is administered at a dose of about 25 mg to about 1,000 mg / kg of individual body weight.A fixed dose of mg is administered to an individual. In some embodiments, the composition is administered to the individual one or more times a day until the dose level or fixed dose is reached.

[0227] In any of the methods or uses described above, the compound or a composition containing the compound of any of the aforementioned embodiments is administered to the individual daily, weekly, monthly, quarterly, or annually. In some embodiments, the compound or a composition containing the compound of any of the aforementioned embodiments is administered to the individual about once per quarter (i.e., every three months) to about once per year. In some embodiments, the compound or a composition containing the compound of any of the aforementioned embodiments is administered to the individual about once per quarter, about once every six months, or about once per year.

[0228] Certain compounds In some aspects, this disclosure relates to compounds comprising or composed of oligomeric compounds. In some embodiments, the oligomeric compound comprises a nucleobase sequence complementary to the nucleobase sequence of the target nucleic acid.

[0229] In some aspects, this disclosure relates to compounds comprising or composed of modified oligonucleotides. In some embodiments, the modified oligonucleotide has a nucleobase sequence complementary to the nucleobase sequence of the target nucleic acid.

[0230] In some aspects, this disclosure relates to compounds comprising or composed of antisense oligonucleotides. In some embodiments, the antisense oligonucleotide has a nucleobase sequence complementary to the nucleobase sequence of a target nucleic acid.

[0231] In some aspects, this disclosure relates to compounds as single-stranded compounds. In some embodiments, single-stranded compounds comprise or are composed of oligomeric compounds. In some embodiments, such oligomeric compounds comprise or are composed of oligonucleotides and optionally conjugated groups. In some embodiments, the oligonucleotide is a modified oligonucleotide. In some embodiments, the oligonucleotide is an antisense oligonucleotide. In some embodiments, the oligonucleotide of the single-stranded compound or the modified oligonucleotide comprises a self-complementary nucleobase sequence.

[0232] In some aspects, this disclosure relates to compounds as double-stranded compounds. In some embodiments, the double-stranded compound comprises or is composed of oligomeric compounds. In some embodiments, the double-stranded compound comprises a first oligonucleotide and a second oligonucleotide. In some embodiments, the first oligonucleotide has a region complementary to the target nucleic acid, and the second oligonucleotide has a region complementary to the first modified oligonucleotide. In some embodiments, the double-stranded compound comprises a modified oligonucleotide. In some embodiments, the modified oligonucleotide has a region complementary to the target nucleic acid. In some embodiments, the double-stranded compound comprises a first modified oligonucleotide and a second modified oligonucleotide.Modified oligonucleotides. In some embodiments, the first modified oligonucleotide has a region complementary to the target nucleic acid, and the second modified oligonucleotide has a region complementary to the first modified oligonucleotide. In some embodiments, the oligonucleotide or modified oligonucleotide of the double-stranded compound is an RNA oligonucleotide. In these embodiments, the thymine nucleobase in the modified oligonucleotide is replaced by a uracil nucleobase.

[0233] In some embodiments, the compound described herein contains a conjugation group. In some embodiments, the first oligonucleotide or first modified oligonucleotide of the double-stranded compound contains a conjugation group. In some embodiments, the second oligonucleotide or second modified oligonucleotide of the double-stranded compound contains a conjugation group. In some embodiments, the first oligonucleotide or first modified oligonucleotide and the second oligonucleotide or second modified oligonucleotide of the double-stranded compound each contain a conjugation group.

[0234] In some embodiments, the length of the compound is 14-30 linked nucleosides. In some embodiments, the length of the first oligonucleotide or first modified oligonucleotide of the double-stranded compound is 14-30 linked nucleosides. In some embodiments, the second oligonucleotide or the second modified oligonucleotide has a length of 14-30 linked nucleosides. In some embodiments, the oligonucleotide or the modified oligonucleotide of the double-stranded compound is blunt-ended at one or both ends of the compound. In some embodiments, the oligonucleotide or the modified oligonucleotide of the double-stranded compound contains non-complementary pendant nucleosides at one or both ends of the compound.

[0235] In some embodiments, the compound has a nucleobase sequence comprising at least 14 adjacent nucleosides of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202 or 214-223. In some embodiments, one of the oligonucleotides of the double-stranded compound or the modified oligonucleotide has a nucleobase sequence comprising at least 14 adjacent nucleosides of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202 or 214-223.

[0236] Examples of single-stranded and double-stranded compounds include, but are not limited to, oligonucleotides, antisense oligonucleotides, siRNAs, oligonucleotides targeting microRNAs, site-based compounds (e.g., mRNA processing or translation blocking compounds and splicing compounds), and single-stranded RNAi compounds (e.g., small hairpin RNA (shRNA), single-stranded siRNA (ssRNA), and microRNA mimics).

[0237] In some embodiments, the compounds described herein have a nucleobase sequence that, when written in the 5' to 3' orientation, contains the reverse complementary sequence of the target region of the target nucleic acid to which the sequence is targeted.

[0238] In some embodiments, the compounds described herein comprise oligonucleotides with 12 to 30 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 12 to 23 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 14 to 30 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 14 to 23 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 15 to 30 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 15 to 23 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 16 to 30 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 16 to 23 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 17 to 30 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 17 to 23 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 18 to 30 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 18 to 23 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 19 to 30 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides with 19 to 23 linked subunits in length. In other words, such oligonucleotides are of 12 to 30 linked subunits, 12 to 23 linked subunits, 14 to 30 linked subunits, 14 to 23 linked subunits, 15 to 30 linked subunits, 15 to 23 linked subunits, 16 to 30 linked subunits, 16 to 23 linked subunits, 17 to 30 linked subunits, 17 to 23 linked subunits, 18 to 30 linked subunits, 18 to 23 linked subunits, 19 to 30 linked subunits, or 19 to 23 linked subunits. In some embodiments, the compounds described herein comprise oligonucleotides of 14 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides of 16 linked subunits in length. In some embodiments, the compounds described herein comprise oligonucleotides of 17 linked subunits in length. In some...In some embodiments, the compounds described herein comprise oligonucleotides with 18 linked subunits. In some embodiments, the compounds described herein comprise oligonucleotides with 19 linked subunits. In some embodiments, the compounds described herein comprise oligonucleotides with 20 linked subunits. In some embodiments, the compounds described herein comprise oligonucleotides with 21 linked subunits. In some embodiments, the compounds described herein comprise oligonucleotides with 22 linked subunits. In some embodiments, the compounds described herein comprise oligonucleotides with 23 linked subunits. In other embodiments, the compounds described herein comprise 8 to 80, 12 to 50, 13 to 30, 13 to 50, 14 to 30, 14 to 50, 15 to 30, 15 to 50, 16 to 30, 16 to 50, 17 to 30, 17 to 50, 18 to 23, 18 to 24, 18 to 25, 18 to 50, 19 to 23, 19 to 30, 19 to 50, 20 to 23, or 20 to 30 linked subunits of oligonucleotides. In some such embodiments, the compounds described herein comprise oligonucleotides of lengths of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 linked subunits or ranges defined by any two of the above values.

[0239] In some embodiments, the compounds may further comprise additional portions, such as conjugation groups or delivery portions. In some embodiments, such compounds are oligomeric compounds, and the additional portions are attached to the oligonucleotides. In some embodiments, the conjugation groups are attached to the nucleoside of the oligonucleotide.

[0240] In some embodiments, the compounds may be shortened or truncated. For example, one or more subunits may be deleted from the 5' end of the oligonucleotide (5' truncation), or alternatively deleted from the 3' end of the oligonucleotide (3' truncation).

[0241] In some embodiments, the compounds may be lengthened. For example, one or more subunits may be attached to the 3' or 5' end of the oligonucleotide. In some embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more subunits) is attached to the 5' end of the oligonucleotide.In some embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more subunits) is attached to the 3' end of the oligonucleotide. In some embodiments, at least one or more subunits may be attached to the 3' or 5' end of the oligonucleotide of the double-stranded compound, thereby creating a 3' and / or 5' overhang. In some embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more subunits) is attached to the 5' end of two oligonucleotides of the double-stranded compound. In some embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more subunits) is attached to the 3' end of two oligonucleotides of the double-stranded compound. In some embodiments, the subunit is attached to the same end of the two oligonucleotides of the double-stranded compound (e.g., the subunit is attached to the 3' end of one oligonucleotide and the subunit is attached to the 5' end of the other oligonucleotide). In some embodiments, when a subunit is attached to the same end of two oligonucleotides of a double-stranded compound, the number of subunits attached to each oligonucleotide may be the same or different. In some embodiments, when a subunit is attached to the same end of two oligonucleotides of a double-stranded compound, the number of subunits attached to each oligonucleotide is the same. In some embodiments, when a subunit is attached to the same end of two oligonucleotides of a double-stranded compound, the number of subunits attached to each oligonucleotide is different. This situation of subunits attaching to the same end of two oligonucleotides of a double-stranded compound can occur at one end or both ends of the double-stranded compound. In some embodiments, the subunits attached to the 3' end and / or the 5' end are modified.

[0242] In some embodiments, the compounds described herein are oligonucleotides. In some embodiments, the compounds described herein are modified oligonucleotides. In some embodiments, the compounds described herein are antisense oligonucleotides. In some embodiments, the compounds described herein are oligomeric compounds. In some embodiments, the compounds described herein are RNAi compounds. In some embodiments, the compounds described herein are siRNA compounds.

[0243] In some embodiments, the compounds described herein may comprise any of the SOD1-targeting oligonucleotide sequences described herein. In some embodiments, the compounds may be double-stranded.

[0244] In some embodiments, the compounds comprise oligonucleotides comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 adjacent nucleobase moieties of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223. In some embodiments, the compound comprises an oligonucleotide comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 adjacent nucleobase moieties of any one of SEQ ID NOs: 11-18, 28-106, 184-187, 196-202, 214-223. In some embodiments, the compound comprises a second oligonucleotide. In some embodiments, the compound comprises an oligonucleotide comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 adjacent nucleobase moieties of any one of SEQ ID NOs: 19-27, 107-183, 188-195, 203-213.

[0245] In some embodiments, the compound comprises a ribonucleotide, wherein, for any sequence provided herein, the oligonucleotide in the ribonucleotide is replaced by uracil (U) instead of thymine (T). In some embodiments, the compound comprises a deoxyribonucleotide, wherein, for any sequence provided herein, the oligonucleotide in the deoxyribonucleotide is replaced by thymine (T) instead of uracil (U).

[0246] Certain mechanisms In some embodiments, the compound described herein comprises or consists of a modified oligonucleotide. In some embodiments, the compound described herein comprises or consists of an antisense oligonucleotide. In some embodiments, the compound described herein comprises an antisense oligonucleotide or consists of an antisense oligonucleotide. In some embodiments, the compound comprises or consists of an oligomeric compound. In some embodimentsIn this document, the compounds described herein are capable of hybridizing with target nucleic acids. In some embodiments, the compounds described herein selectively affect one or more target nucleic acids. Such compounds comprise a nucleobase sequence that hybridizes with one or more target nucleic acids to produce one or more desired activities, and does not hybridize with one or more non-target nucleic acids or does not hybridize with one or more non-target nucleic acids in a manner that would produce significantly undesirable activities.

[0247] In some embodiments, hybridization of the compounds described herein with target nucleic acids results in the recruitment of one or more proteins that cleave the target nucleic acid. For example, certain compounds described herein, or portions thereof, are loaded into an RNA-induced silencing complex (RISC) that ultimately results in the cleavage of the target nucleic acid. For example, certain compounds described herein cause the target nucleic acid to be cleaved by Argonaute proteins. The compounds loaded into the RISC are RNAi compounds. RNAi compounds may be double-stranded (siRNA) or single-stranded (ssRNA).

[0248] In some embodiments, hybridization of the compounds described herein with target nucleic acids does not result in the recruitment of proteins that cleave the target nucleic acid. In some such embodiments, hybridization of the compounds with target nucleic acids results in changes in the splicing of the target nucleic acid. In some embodiments, hybridization of the compound with the target nucleic acid results in inhibition of the binding interaction between the target nucleic acid and a protein or other nucleic acid. In some such embodiments, hybridization of the compound with the target nucleic acid results in alterations in RNA processing. In some such embodiments, hybridization of the compound with the target nucleic acid results in alterations in the translation of the target nucleic acid.

[0249] The activity resulting from hybridization of the compound with the target nucleic acid can be observed directly or indirectly. In some embodiments, observing or detecting activity involves observing or detecting changes in the amount of the target nucleic acid or the protein encoded by such target nucleic acid, changes in the ratio of splice variants of the nucleic acid or protein, and / or phenotypic changes in cells or animals.

[0250] Certain modifications In some aspects, this disclosure relates to compounds comprising or composed of oligonucleotides. Oligonucleotides consist of linked nucleosides. In some embodiments, the oligonucleotide may be unmodified RNA or DNA, or may be modified. In some embodiments, the oligonucleotide is a modified oligonucleotide. In some embodiments, the modified oligonucleotide, relative to unmodified RNA or DNA, comprises at least one modified sugar, a modified nucleobase, or a modified nucleoside linker. In some embodiments, the oligonucleotide has a modified nucleoside. The modified nucleoside may comprise a modified sugar, a modified nucleobase, or both a modified sugar and a modified nucleobase. The modified oligonucleotide may also include terminal modifications, such as 5' and 3' modifications.

[0251] Sugar Modification and Motif In some embodiments, the modified sugar is a substituted furanyl sugar or a non-bicyclic modified sugar.In some embodiments, the modified sugar is a bicyclic or tricyclic modified sugar. In some embodiments, the modified sugar is a sugar substitute. The sugar substitute may contain one or more substitutions described herein.

[0252] In some embodiments, the modified sugar is a substituted furanyl sugar or a non-bicyclic modified sugar. In some embodiments, the furanyl sugar is a ribosyl sugar. In some embodiments, the furanyl sugar contains one or more substituents, including but not limited to substituents at the 2', 3', 4', and 5' positions.

[0253] In some embodiments, the substituent at the 2' position includes, but is not limited to, F and OCH3 (“OMe”, “O-methyl”, or “methoxy”). In some embodiments, substituents suitable for the 2' position of the non-bicyclic modified sugar include, but are not limited to, halogen, allyl, amino, azide, SH, CN, OCN, CF3, OCF3, F, Cl, Br, SCH3, SOCH3, SO2CH3, ON02, ON2, N3, and NH2. In some embodiments, substituents at the 2' position include, but are not limited to, O-(C1-C10)alkoxy, alkoxyalkyl, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, O-ynyl, S-ynyl, N-ynyl, O-alkyl-O-alkyl, and ynyl, wherein the alkyl, alkenyl, and ynyl groups can be substituted or unsubstituted C1 to C10 alkyl or C2 to C10 alkenyl and ynyl groups. In some embodiments, the substituents at the 2' position include, but are not limited to, alkylaryl, aralkyl, O-alkylaryl, and O-aralkyl. In some embodiments, these 2' substituents may be further substituted by one or more substituents independently selected from: hydroxyl, alkoxy, carboxyl, benzyl, phenyl, nitro(NO2), thiol, thioalkoxy, thioalkyl, halogen, alkyl, aryl, alkenyl, and alkynyl. In some embodiments, the substituents at the 2' position include, but are not limited to, O[(CH2)nO]mCH3, O(CH2)nOCH3, O(CH2)nCH3, O(CH2)nONH2, O(CH2)nNH2, O(CH2)nSCH3, and O(CH2)nON[(CH2)nCH3)]2, wherein n and m are independently 1 to about 10. In some embodiments, the substituents at the 2' position include, but are not limited to, OCH2CH2OCH3 (“MOE”), O(CH2)2ON(CH3)2 (“DMAOE”), O(CH2)2O(CH2)2N(CH3)2 (“DMAEOE”), and OCH2C(=O)-N(H)CH3 (“NMA”).

[0254] In some embodiments, the substituents applicable to the 4' position of the non-bicyclic modified sugar include, but are not limited to, alkoxy (e.g., methoxy), alkyl, and those described in Manoharan et al., WO 2015 / 106128. In some embodiments, the substituents applicable to the 5' position of the non-bicyclic modified sugar include, but are not limited to, methyl (“Me” or “CH3”) (R or S), vinyl, and methoxy. In some embodiments, the 5' is modified as 5'-monophosphate ((HO)2(O)P-O-5'); 5'-diphosphate ((HO)2(O)P-O-P(HO)(O)-O-5'); 5'-triphosphate ((HO)2(O)P-O-(HO)(O)P-O-P(HO)(O)-O-5'); 5'-guanosine cap (7-methylated or unmethylated) (7m-G-O-5'-(HO)(O)P-O-(HO)(O)P-O-P(HO)(O)-O-5'); 5'-adenosine cap (Appp); and any modified or unmodified nucleotide cap structure (N-O-5'(HO)(O)P-O-(HO)(O)P-O-P(HO)(O)-O-5'); 5'-monothiophosphate (thiophosphate; (HO)2(S)P-O- 5'); 5'-mono-dithiophosphate (dithiophosphate; (HO)(HS)(S)P-O-5'), 5'-thiophosphate ((HO)2(O)P-S-5'); any additional combination of oxygen / sulfur-substituted monophosphates, diphosphates, and triphosphates (e.g., 5'-α-thiotriphosphate, 5'-γ-thiotriphosphate, etc.), 5'-aminophosphate ((HO)2(O)P-NH-5', (HO)(NH2)(O)P-O-5'), 5'-alkylphosphonates (R = alkyl = methyl, ethyl, isopropyl, propyl, etc., e.g., RP(OH)(O)-O-5'-), 5'-alkenylphosphonates (i.e., vinyl, substituted vinyl, (OH)2(O)P-5'-CH2-), 5'-alkyl ether phosphonates (R = alkyl ether = methoxymethyl (MeOCH2-), ethoxymethyl, etc., e.g., RP(OH)(O)-O-5'-). In some embodiments, one or more sugars contain a 5'-phosphonate modification. In some embodiments, the 5'-phosphonate modification is a 5'-vinylphosphonate modification or a 5'-ethylidenephosphonate modification. In some embodiments, one or more sugars contain a 5'-vinylphosphonate modification. In some embodiments, one or more sugars contain a 5'-ethylidenephosphonate modification. In some embodiments, the 5' modification is located at the end of the oligonucleotide. In some embodiments, the 5' modification is located at the end of the antisense oligonucleotide. In some embodiments, the substituents described herein with respect to the 2', 4', and 5' positions can be added to other specific positions on the sugar. In some embodiments, such...Substituents can be added to the 3' position of the sugar on the 3' terminal nucleotide or the 5' position of the 5' terminal nucleotide. In some embodiments, the non-bicyclic modified sugar may contain more than one non-bridging sugar substituent. In some such embodiments, the non-bicyclic modified sugar substituents include, but are not limited to, 5'-Me-2'-F, 5'-Me-2'-OMe (including both R and S isomers). In some embodiments, the modified sugar substituents include those described in Migawa et al., WO 2008 / 101157 and Rajeev et al., US2013 / 0203836.

[0255] In some embodiments, the modified sugar is a bicyclic sugar. A bicyclic sugar is a modified sugar comprising two rings, wherein the second ring is formed via a bridge connecting two atoms in the first ring, thereby forming a bicyclic structure. In some embodiments, the bicyclic sugar contains a bridging substituent that bridges two atoms of the furanyl ring to form the second ring. In some embodiments, the bicyclic sugar does not contain a furanyl moiety. A “bicyclic nucleoside” (“BNA”) is a nucleoside having a bicyclic sugar. In some embodiments, the bicyclic sugar contains a bridge between the 4' and 2' furanyl ring atoms. In some embodiments, the bicyclic sugar contains a bridge between the 5' and 3' furanyl ring atoms. In some such embodiments, the furanyl ring is a ribose ring. In some embodiments, the 4' to 2' bridging substituents include, but are not limited to, 4'-CH2-2', 4'-(CH2)2-2', 4'-(CH2)3-2', 4'-CH2-O-2' (“LNA”), 4'-CH2-S-2', 4'-(CH2)2-O-2' (“ENA”), 4'-CH(CH3)-O-2' (“restricted ethyl” or “cEt” when in the S configuration), 4'-CH2-O-CH2-2', 4'-CH2-N(R)-2', 4'-CH(CH2OCH3)-O-2' (“constrained MOE” or “cMOE”) and its analogues (e.g., U.S. Patent No. 7,399,845), 4'-C(CH3)(CH3)-O-2' and its analogues (e.g., U.S. Patent No. 8,278,283), 4'-CH2-N(OCH3)-2' and its analogues (e.g., U.S. Patent No. 8,278,425), 4'-CH2-O-N(CH3)-2' (e.g., U.S. Patent Publication No. 2004 / 0171570), 4'-CH2-N(R)-O-2', wherein R is H, C1-C12 alkyl or protecting group (e.g., U.S. Patent No. 7,427,672), 4'-CH2-C(H)(CH3)-2' (e.g., Chattopadhyaya et al., J. Org. Chem.,2009, 74, 118–134), and 4'-CH2-C(=CH2)-2' and the like (e.g., U.S. Patent No. 8,278,426). The entire contents of each of the foregoing documents are hereby incorporated herein by reference. Other representative U.S. patents and U.S. patent disclosures teaching the preparation of bicyclic nucleic acid nucleotides include, but are not limited to, the following: U.S. Patent Nos. 6,268,490, 6,525,191, 6,670,461, 6,770,748, 6,794,499, 6,998,484, 7,053,207, 7,034,133, 7,084,125, 7,399,845, 7,427,672, 7,569,686, 7,741,457, 8,022,193, 8,030,467, 8,278,425, 8,278,426, 8,278,283; US 2008 / 0039618; and US 2009 / 0012281, US U.S. Patent Nos. 2013 / 0190383; and WO 2013 / 036868, the entire contents of each of these U.S. Patent Publications are hereby incorporated herein by reference. Any of the aforementioned bicyclic nucleotides may be prepared to have one or more stereochemical sugar configurations, including, for example, α-L-ribofuranosaccharide and β-D-ribofuranosaccharide (e.g., see WO 99 / 14226). Unless otherwise specified, the bicyclic nucleotides specified herein are of the β-D configuration.

[0256] In some embodiments, the modified sugar is a sugar substitute. In some embodiments, the oxygen atom of the sugar substitute is replaced by, for example, a sulfur, carbon, or nitrogen atom. In some such embodiments, the sugar substitute may also contain bridging and / or non-bridging substituents as described herein. In some embodiments, the sugar substitute comprises a ring having more than 5 atoms. In some such embodiments, the sugar substitute comprises a cyclobutyl moiety replacing the furanopentose sugar. In some embodiments, the sugar substitute comprises a six-membered ring replacing the furanopentose sugar. In some embodiments, the sugar substitute comprises tetrahydropyran (“THP”) instead of furanylpentose sugar. In some embodiments, the sugar substitute comprises morphine instead of furanylpentose sugar. Representative U.S. patents teaching the preparation of such modified sugar structures include, but are not limited to, U.S. patent numbers 4,981,957, 5,118,800, 5,166,315, 5,185,444, 5,319,080, 5,359,044, 5,393,878, 5,446,137, 5,466,786, 5,514,785, 5,519,134, 5,567,811, 5,576,427, 5,591,722, 5,597,909, 5,610,300, and 5,627.The entire contents of each of the aforementioned patents, namely, 5,639,873, 5,646,265, 5,658,873, 5,670,633, 5,700,920, 7,875,733, 7,939,677, 8,088,904, 8,440,803, and 9,005,906, are hereby incorporated herein by reference.

[0257] In some embodiments, the sugar substitute comprises an acyclic moiety. In some embodiments, the sugar substitute is an unlocking nucleic acid (“UNA”). UNA is an unlocking acyclic nucleic acid in which any bond in the sugar bond has been removed, thereby forming an unlocking “sugar” residue. In one instance, UNA also encompasses monomers in which the bond between C1' and C4' (i.e., the covalent carbon-oxygen-carbon bond between C1' and C4' carbons) has been removed. In another example, the C2'-C3' bond of the sugar (i.e., the covalent carbon-carbon bond between the C2' and C3' carbons) has been removed. Representative U.S. publications teaching the preparation of UNA include, but are not limited to, U.S. Patent No. 8,314,227; and U.S. Patent Publications Nos. 2013 / 0096289, 2013 / 0011922, and 2011 / 0313020, the entire contents of which are hereby incorporated herein by reference. In some embodiments, sugar substitutes include peptide nucleic acids (“PNA”), acyclic butyl nucleic acids (see, for example, Kumar et al., Org. Biomol. Chem., 2013, 11, 5853-5865), and nucleosides and oligonucleotides described in Manoharan et al., US2013 / 130378, the entire contents of which are hereby incorporated herein by reference. Many other bicyclic and tricyclic sugar and sugar substitute ring systems are known in the art and can be used in modified nucleosides. Specification 55 / 151 pages 65 CN 121335980 A

[0258] In some aspects, this disclosure relates to compounds comprising at least one oligonucleotide, wherein the nucleoside of such oligonucleotide comprises one or more types of modified sugars and / or unmodified sugars arranged in a defined pattern or “glycomolecular motif” along the oligonucleotide or a region thereof. In some cases, such glycomolecular motifs include, but are not limited to, any of the sugar modification patterns described herein.

[0259] In some embodiments, the oligonucleotide comprises a gapmer glycomolecular motif. The gapmer oligonucleotide comprises, or is composed of, a region having two outer “wing” regions and a central or inner “gap” region. The gap region and the wing regions form adjacent sequences of the nucleoside, wherein the majority of the nucleotide sugar in each wing differs from the majority of the nucleotide sugar in the gap. In some embodiments, the wing regions comprise the majority of modified sugars, and the gap comprises the majority of unmodified sugars. In some embodimentsIn this case, the interstitial nucleoside is a deoxynucleoside. Compounds having interstitial glycosyl motifs are described, for example, in U.S. Patent 8,790,919, the entire contents of which are incorporated herein by reference.

[0260] In some embodiments, one or both oligonucleotides of the double-stranded compound contain a triplet glycosyl motif. The oligonucleotide having a triplet glycosyl motif contains three identical sugar modifications on three consecutive nucleosides. In some embodiments, the triplet is located at or near the cleavage site of the oligonucleotide. In some embodiments, the oligonucleotide of the double-stranded compound may contain more than one triplet glycosyl motif. In some embodiments, the identical sugar modification of the triplet glycosyl motif is a 2'-F modification. Compounds having triplet glycosyl motifs are disclosed, for example, in U.S. Patent 10,668,170, the entire contents of which are incorporated herein by reference.

[0261] In some embodiments, one or both oligonucleotides of the double-stranded compound contain a tetrat glycosyl motif. Oligonucleotides with tetrad glycosidic motifs contain four identical sugar modifications on four consecutive nucleotides. In some embodiments, the tetrad is located at or near the cleavage site. In some embodiments, the oligonucleotide of the double-stranded compound may contain more than one tetrad glycosidic motif. In some embodiments, the identical sugar modification of the tetrad glycosidic motif is a 2'-F modification. For double-stranded compounds having a double-stranded region of 19-23 nucleotides in length, the cleavage site of the antisense oligonucleotide is typically located near positions 10, 11, and 12 starting from the 5' end. In some embodiments, counting begins from the first nucleotide at the 5' end of the positive oligonucleotide, or from the first paired nucleotide within the double-stranded region at the 5' end of the positive oligonucleotide, with the tetrad glycosyl motif located at positions 8, 9, 10, 11; 9, 10, 11, 12; 10, 11, 12, 13; 11, 12, 13, 14; or 12, 13, 14, 15 of the positive oligonucleotide. In some embodiments, counting begins from the first nucleotide at the 5' end of the antisense oligonucleotide, or from the first paired nucleotide within the 5' end duplex region of the antisense oligonucleotide, with the tetrad glycosidic motif located at positions 8, 9, 10, 11; 9, 10, 11, 12; 10, 11, 12, 13; 11, 12, 13, 14; or 12, 13, 14, 15 of the antisense oligonucleotide. The cleavage site may vary depending on the length of the duplex region of the double-stranded compound, and the position of the tetrad may be altered accordingly.

[0262] In some embodiments, the oligonucleotide comprises alternating glycosidic motifs. In some embodiments, one or both oligonucleotides of the double-stranded compound comprise alternating glycosidic motifs. Oligonucleotides having alternating glycosidic motifs comprise at least two different nucleotides.The alternating glycomotif may contain alternating sequences of one or more consecutive nucleotides with a first sugar modification, one or more consecutive nucleotides with a second sugar modification, and one or more consecutive nucleotides with a third sugar modification. For example, if A, B, and C each represent a type of nucleotide modification, the alternating motif may be “ABABABABABAB…”, “AABBAABBAABB…”, “AABAABAABAAB…”, “AAABAAABAAAB…”, “AAABBBAAABBB…”, or “ABCABCABCABC…”, etc. In some embodiments, the alternating glycomotif repeats along the oligonucleotide with at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 adjacent nucleobases. In some embodiments, the alternating glycomotif contains two different sugar modifications. In some embodiments, the alternating glycomotif contains 2'-OMe and 2'-F sugar modifications. Specification 56 / 151 pages 66 CN 121335980 A

[0263] In some embodiments, each nucleoside of the oligonucleotide is independently modified by one or more sugar modifications provided herein. In some embodiments, each oligonucleotide of the double-stranded compound independently has one or more glycomole motifs provided herein. In some embodiments, the oligonucleotide containing the glycomole motif is completely modified because each nucleoside other than the nucleoside containing the glycomole motif contains a sugar modification.

[0264] Nucleobase Modification and Motif In some embodiments, the compounds described herein comprise modified oligonucleotides. In some embodiments, the modified oligonucleotide comprises one or more nucleosides containing modified nucleosides. In some embodiments, the modified oligonucleotide comprises one or more nucleosides that do not contain nucleosides, referred to as base-free nucleosides.

[0265] In some embodiments, the modified nucleosides are selected from: 5-substituted pyrimidines, 6-azapyrimidines, alkyl or alkynyl-substituted pyrimidines, alkyl-substituted purines, and N-2, N-6, and O-6-substituted purines. In some embodiments, the modified nucleobases are selected from: 2-aminopropyladenine, 5-hydroxymethylcytosine, 5-methylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-N-methylguanine, 6-N-methyladenine, 2-propyladenine, 2-thiouracil, 2-thiothymidine and 2-thiocytosine, 5-propynyl(C≡C-CH3)uracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymidine, 5-ribosyluracil (pseudouracil), 4-thiouracil, 8-halogen, 8-amino, 8-thiol, 8-Thioalkyl, 8-hydroxy, 8-aza and other 8-substituted purines, 5-halogens (especially 5-bromine), 5-trifluoromethyl, 5-haloururacil and 5-halocytosine, 7-methylguanine, 7-methyladenine, 2-F-adenine, 2-aminoadenine, 7-deadenine, 7-deadenine, 3-deadenine, 3-deadenine, 6-N-benzoyladenine, 2-N-isobutyrylguanine, 4-N-benzoylcytosine, 4-N-benzoyluracil, 5-methyl4-N-benzoylcytosine, 5-methyl4-N-benzoyluracil, universal bases, hydrophobic bases, hybrid bases, size-enlarged bases and fluorinated bases. Further modified nucleobases include tricyclic pyrimidines, such as 1,3-diazaphenoxazin-2-one, 1,3-diazaphenthiazin-2-one, and 9-(2-aminoethoxy)-1,3-diazaphenoxazin-2-one (G-clamp). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced by other heterocycles such as 7-deadenine, 7-deadenine, 2-aminopyridine, and 2-pyridone.

[0266] Other nucleobases include those disclosed in the following literature: U.S. Patent 3,687,808; Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P (ed.), Wiley-VCH, 2008; The Concise Encyclopedia Of Polymer Science and Engineering, pp. 858-859; Kroschwitz, JL (ed.), John Wiley & Sons, 1990, pp. 858-859; Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613; Sanghvi, YS, Chapter 15, dsRNA Research and Applications, pp. 289-302; Antisense Research and Applications, Crooke, S.T. and Lebleu, B (ed.), CRC Press, 1993. 273–288; Antisense Drug Technology, Crooke ST (ed.), CRC Press, 2008, 163–166 and 442–443 (Chapters 6 and 15), each of which is incorporated herein by reference.

[0267] The disclosures teaching the preparation of certain modified nucleobases mentioned above, as well as other modified nucleobases, include, but are not limited to, U.S. Patent Publications 2003 / 0158403 and 2003 / 0175906, U.S. Patents 4,845,205, 5,130,302, 5,134,066, 5,175,273, 5,367,066, 5,432,272, 5,434,257, 5,457,187, 5,459,255, 5,484,908, 5,502,177, 5,525,711, 5,552,540, 5,587,469, 5,594,121, 5,596,091, and 5,614. 617, 5,645,985, 5,681,941, 5,811,534, 5,750,692, 5,948,903, 5,587,470, 5,457,191, 5,763,588, 5,830,653, 5,808,027, 6,005,096, 6,015,886, 6,147,200, 6,166,197, 6,166,199, 6,222,025, 6,235,887, 6,380,368, 6,528,640, 6,639,062, 6,617,438, 7,045,610, 7, The entire contents of each of these U.S. Application Publications and U.S. Patents, 427,672 and 7,495,088, are hereby incorporated herein by reference on page 57 / 151 of specification 67 CN 121335980 A.

[0268] In some embodiments, the compounds described herein comprise oligonucleotides. In some embodiments, the oligonucleotides comprise modified and / or unmodified nucleobases arranged in a defined pattern or motif along regions of the oligonucleotide or thereof. In some embodiments, each nucleobase is modified. In some embodiments, none of the nucleobases are modified. In some embodiments, each purine or each pyrimidine is modified. In some embodiments, each adenine is modified. In some embodiments, each guanine is modified. In some embodiments, each thymine is modified. In some embodiments, each uracil is modified. In some embodiments, each cytosine is modified. In some embodiments, some or all of the cytosine nucleobases in the modified oligonucleotide are 5-methylcytosine.

[0269] In some embodiments, the modified oligonucleotide comprises a block of modified nucleobases. In some such embodiments, the block is located at the 3' end of the oligonucleotide. In some embodiments, the block is located within three nucleosides at the 3' end of the oligonucleotide. In some embodiments, the block is located at the 5' end of the oligonucleotide. In some embodiments, the block...Located within the three nucleosides at the 5' end of the oligonucleotide.

[0270] Nucleoside interlinking modifications and motif 3' to 5' phosphodiester links are naturally occurring nucleoside interlinkings of RNA and DNA. In some embodiments, the compounds described herein have one or more modified (i.e., non-naturally occurring) nucleoside interlinkings. Certain non-naturally occurring nucleoside interlinkings can confer desired properties, such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases. Representative phosphorus-containing modified nucleoside interlinkings include, but are not limited to, phosphate triesters, alkyl phosphonates (e.g., methylphosphonates), amino phosphates and thiophosphates (“P=S”) and dithiophosphates (“HS-P=S”). Representative phosphorus-free internucleotide linking groups include, but are not limited to, methylene methyl imino (-CH2-N(CH3)-O-CH2), thiodiester, thiocarbamate (-O-C(=O)(NH)-S-); siloxane (-O-SiH2-O-); and N,N'-dimethylhydrazine (-CH2-N((CH3)-N((CH3)-). Methods for preparing phosphorus-containing and phosphorus-free internucleotide linkages are well known to those skilled in the art. Neutral internucleotide linkages include, but are not limited to, phosphate triesters, methylphosphonates, and MMI (3'-CH2-). N(CH3)-O-5'), amide-3 (3'-CH2-C(=O)-N(H)-5'), amide-4 (3'-CH2-N(H)-C(=O)-5'), methyl acetal (3'-O-CH2-O-5'), methoxypropyl and thiomethyl acetal (3'-S-CH2-O-5'). Other neutral nucleoside linkages include nonionic linkages comprising siloxanes (dialkylsiloxanes), carboxylic esters, carboxamides, sulfides, sulfonates, and amides (see, for example: Carbohydrate Modifications in Antisense Research; edited by YS Sanghvi and PD Cook, ACS Symposium Series 580; Chapters 3 and 4, 40-65). Other neutral nucleoside linkages include nonionic linkages comprising a mixture of N, O, S, and CH2 components.

[0271] In some embodiments, the compounds provided herein comprise at least one modified internucleotide link. The modified internucleotide link may be located at any position on the oligonucleotide. For double-stranded compounds, the modified internucleotide link may be located within the sense oligonucleotide, the antisense oligonucleotide, or both of the oligonucleotides.

[0272] In some embodiments, the internucleotide link modification may occur on each nucleoside of the oligonucleotide. In some embodiments, the internucleotide link modification may occur along the oligonucleotide in an alternating pattern. In some embodiments, substantially eachAll internucleotide linking groups are phosphate ester internucleotide links (P=O). In some embodiments, each internucleotide linking group of the modified oligonucleotide is a phosphate thioester (P=S). In some embodiments, each internucleotide linking group of the modified oligonucleotide is independently selected from phosphate thioester and phosphate ester internucleotide links. In some embodiments, the internucleotide linking modification pattern on each oligonucleotide of the double-stranded compound is the same. In some embodiments, the internucleotide linking modification pattern on each oligonucleotide of the double-stranded compound is different. In some embodiments, the double-stranded compound contains 6-8 modified internucleotide links. In some embodiments, the 6-8 modified internucleotide links are phosphate thioester internucleotide links or alkylphosphonate internucleotide links. In some embodiments, the positive oligonucleotide contains at least two modified internucleotide links at either the 5' end or the 3' end, or at both ends. In some such embodiments, the modified internucleotide links are phosphate thioester internucleotide links or alkylphosphonate internucleotide links. In some embodiments, the antisense oligonucleotide contains at least two modified internucleotide links at either the 5' end or the 3' end, or at both ends. In some such embodiments, the modified internucleotide links are phosphate thioester internucleotide links or alkylphosphonate internucleotide links.

[0273] In some embodiments, the double-stranded compound contains a dangling region. In some embodiments, the double-stranded compound contains phosphate thioester or alkylphosphonate internucleotide link modifications in the dangling region. In some embodiments, the double-stranded compound contains phosphate thioester or alkylphosphonate internucleotide links linking the dangling nucleotide to a pairing nucleotide adjacent to the dangling nucleotide. For example, at least two phosphate thioester internucleotide links may be present between the three terminal nucleotides, wherein two of the three nucleotides are dangling nucleotides, and the third is a pairing nucleotide adjacent to the dangling nucleotide. The three terminal nucleotides may be located at the 3' end of the antisense oligonucleotide, the 3' end of the sense oligonucleotide, the 5' end of the antisense oligonucleotide, or the 5' end of the antisense oligonucleotide.

[0274] In some embodiments, the modified oligonucleotide comprises one or more internucleotide links having a chiral center. Representative chiral internucleotide links include, but are not limited to, alkylphosphonates and thiophosphates. Modified oligonucleotides comprising internucleotide links having a chiral center can be prepared into a modified oligonucleotide population comprising stereorandom internucleotide links, or into a modified oligonucleotide population comprising thiophosphate links having a specific stereochemical configuration. In some embodiments, the modified oligonucleotide population comprises thiophosphate internucleotide links, wherein all of these thiophosphate internucleotide links are stereorandom. Such modified oligonucleotides may be used to cause each thiophosphateThe linked stereochemical configuration can be generated by a randomly selected synthetic method. As will be well understood by those skilled in the art, each individual thiophosphate ester of each individual oligonucleotide molecule has a defined stereochemical configuration. In some embodiments, a modified oligonucleotide population is enriched with modified oligonucleotides comprising one or more thiophosphate ester nucleoside-linked modified oligonucleotides exhibiting a specific, independently selected stereochemical configuration. In some embodiments, the specific thiophosphate ester-linked specific configuration is present in at least 65% of the molecules in the population. In some embodiments, the specific thiophosphate ester-linked specific configuration is present in at least 70% of the molecules in the population. In some embodiments, the specific thiophosphate ester-linked specific configuration is present in at least 80% of the molecules in the population. In some embodiments, the specific thiophosphate ester-linked specific configuration is present in at least 90% of the molecules in the population. In some embodiments, the specific thiophosphate ester-linked specific configuration is present in at least 99% of the molecules in the population. Such enriched modified oligonucleotide populations can be produced using synthetic methods known in the art, such as those described in the following literature: Oka et al., JACS 125, 8307 (2003), Wan et al., Nuc. Acid. Res. 42, 13456 (2014), and WO 2017 / 015555. In some embodiments, the modified oligonucleotide population is enriched with a modified oligonucleotide having at least one indicated thiophosphate in the (Sp) configuration. In some embodiments, the modified oligonucleotide population is enriched with a modified oligonucleotide having at least one indicated thiophosphate in the (Rp) configuration.

[0275] Conjugation Groups In some embodiments, the compounds described herein comprise one or more oligonucleotides and optionally one or more conjugation groups, or consist of one or more oligonucleotides and optionally one or more conjugation groups. Conjugation groups may be attached to either end or both ends of the oligonucleotide and / or attached to any internal location. In some embodiments, the conjugation group is attached to the 3' end of the oligonucleotide. In some embodiments, the conjugation group is attached to the 5' end of the oligonucleotide. In some embodiments, the oligonucleotide is covalently attached to one or more conjugation groups.

[0276] In some embodiments, the conjugation group is a terminal group attached to either or both ends of the oligonucleotide. In some such embodiments, the terminal group is attached to the 3' end of the oligonucleotide. In some such embodiments, the terminal group is attached to the 5' end of the oligonucleotide. In some embodiments, the terminal group includes, but is not limited to, capping groups, phosphate moieties, protecting groups, modified or unmodified nucleosides, and two or more independently modified or unmodified nucleosides.Glycosides, such as suspensions.

[0277] In some embodiments, the conjugation group alters one or more properties of the attached oligonucleotide, including but not limited to pharmacodynamics, pharmacokinetics, stability, activity, half-life, binding, absorption, tissue distribution, cellular distribution, cellular uptake, charge, and clearance. In some embodiments, such a conjugation group enhances the affinity of the compound for selected targets (e.g., molecules, cells or cell types, compartments (e.g., cell or organ compartments), tissues, organs, or body regions) compared to compounds without the conjugation group. In some embodiments, the conjugation group imparts new properties to the attached oligonucleotide, such as enabling the detection of a fluorophore or reporter group of the oligonucleotide.

[0278] In some embodiments, the conjugation groups include, but are not limited to, intercalating agents, reporter molecules, polyamines, polyamides, peptides, carbohydrates, vitamin portions, polyethylene glycols, thioethers, polyethers, cholesterol, thiocholesterol, bile acid portions, folic acid, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluorescein, rhodamine, coumarin, fluorophores, and dyes.

[0279] In some embodiments, the conjugation group comprises an active drug substance, such as aspirin, warfarin, phenylbutazone, ibuprofen, suprafen, fen-bufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, fingolimod, flufenamic acid, folinic acid, benzothiazide, chlorothiazide, diazoxide, indomethacin, barbiturate, cephalosporin, sulfonamides, antidiabetic agents, antibacterial agents, or antibiotics.

[0280] In some embodiments, the conjugation group is a targeting moiety. In some embodiments, the targeting moiety includes, but is not limited to, lectins, glycoproteins, lipids, proteins, peptides, peptide mimics, receptor ligands, antibodies, thyroid-stimulating hormone, melanocyte-stimulating hormone, surfactant protein A, carbohydrates, carbohydrate derivatives, modified carbohydrates, carbohydrate clusters, polysaccharides, modified polysaccharides or polysaccharide derivatives, mucinous carbohydrates, polyvalent lactose, polyvalent galactose, N-acetyl-galactamine sugar (GalNAc), N-acetylglucosamine polymannose, polyvalent fucose, glycosylated polyamino acids, and polyvalent galactose.Sugars, transferrin, bisphosphonates, polyglutamate, polyaspartate, lipids, cholesterol, steroids, bile acids, folate, vitamin B12, vitamin A, biotin or RGD peptides or RGD peptide mimics.

[0281] In some embodiments, the conjugating group may include, but is not limited to, the conjugating groups described in the following references, such as cholesterol (e.g., Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86: 6553-6556), bile acids (e.g., Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), thioethers, such as hexyl-S-triphenylmethylthiol (e.g., Manoharan et al., Ann. NY. Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem. Let., 1993, 3:2765-2770), thiocholesterol (e.g., Oberhauser et al., Nucl. Acids Res., 1992, 20:533-538), aliphatic chains, such as dodecyl diol or undecyl residues (e.g., Saison-Behmoaras et al., EMBO J, 1991, 10: 1111-1118; Kabanov et al., FEBS Lett., 1990, 259:327-330; Svinarchuk et al., Biochimie, 1993, 75:49-54), phospholipids, such as di-hexadecyl-racemic-glycerol or 1,2-di-O-hexadecyl-racemic-glycerol-3-H-phosphonate triethylammonium (e.g., Manoharan et al., Tetrahedron Lett., 1995, specification 60 / 151 pages 70 CN 121335980 A 36:3651-3654; Shea et al., Nucl. Acids Res., 1990, 18:3777-3783), polyamine or polyethylene glycol chains (e.g., Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969-973), adamantane acetate (e.g., Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654), palmityl (e.g., Mishra et al., Biochim. Biophys. Acta, 1995,1264:229-237), octadecylamine or hexanocarbonyloxycholesterol moieties (e.g., Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923-937), tocopherols (e.g., Nishina et al., Molecular Therapy Nucleic Acids, 2015, 4, e220 and Nishina et al., Molecular Therapy, 2008, 16:734-740), GalNAc and other carbohydrates (e.g., Maier et al., Bioconjugate Chemistry, 2003, 14, 18-29; Rensen et al., J. Med. Chem. 2004, 47, 5798-5808; WO2009 / 073809 and U.S. Patent 8,106,022; 8,450,467 and 8,828,957; and WO2014 / 179445; WO2014 / 179620 and U.S. Patents 9,127,276; 9,181,549 and 10,844,379), each of which is incorporated herein by reference in its entirety.

[0282] The conjugating group can be attached to the oligonucleotide via a conjugating linker. In some embodiments, the conjugating linker comprises a chain structure, such as a hydrocarbon chain, or an oligomer of repeating units or a combination of such repeating units. In some embodiments, the conjugating linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxyamino. In some embodiments, the conjugating linker comprises at least one phosphorus group. In some embodiments, the conjugating linker comprises at least one phosphate ester group. In some embodiments, the conjugating linker comprises at least one neutral linking group. In some embodiments, the conjugation linkers include, but are not limited to, pyrrolidine, 8-amino-3,6-dioxanoic acid (ADO), 4-(N-maleimidemethyl)cyclohexane-1-carboxylic acid succinimide (SMCC), and 6-aminohexanoic acid (AHEX or AHA). Other conjugation linkers include, but are not limited to, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C2-C10 alkenyl, or substituted or unsubstituted C2-C10 alkynyl, wherein a non-limiting list of preferred substituents includes hydroxyl, amino, alkoxy, carboxyl, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl, and alkynyl. In some embodiments, the conjugation linker comprises 1-10 linker-nucleosides. In some embodiments, such linker-nucleosides may be modified or unmodified nucleosides. It is generally desirable for the linker-nucleosides to cleave from the compound upon arrival at the target tissue. Therefore, this document...The linker-nucleosides can be linked to each other and to the rest of the compound via cleavable bonds. In this document, linker-nucleosides are not considered part of the oligonucleotide. Therefore, in embodiments where the compound comprises an oligonucleotide consisting of a specified number or range of linked nucleosides and / or having a specified percentage of complementarity to a reference nucleic acid, and the compound also comprises a conjugate group containing a linker (which comprises a linker-nucleoside), those linker-nucleosides are not counted in the length of the oligonucleotide and are not used to determine the percentage of complementarity of the oligonucleotide to the reference nucleic acid.

[0283] In some embodiments, the conjugating groups and conjugating links, as well as other modifications, include, but are not limited to, those described in the following references: US 5,994,517; US 6,300,319; US 6,660,720; US 6,906,182; US 7,262,177; US 7,491,805; US 8,106,022; US 7,723,509; US 9,127,276; US 2006 / 0148740; US 2011 / 0123520; WO2013 / 033230; WO2012 / 037254, Biessen et al., J. Med. Chem. 1995, 38, 1846-1852; Lee et al., Bioorganic & Medicinal Chemistry 2011, 19, 2494–2500; Rensen et al., J. Biol. Chem. 2001, 276, 37577–37584; Rensen et al., J. Med. Chem. 2004, 47, 5798–5808; Sliedregt et al., J. Med. Chem. 1999, 42, 609–618; Valentijn et al., Tetrahedron, 1997, 53, 759–770; Lee, Carhohydr Res, 1978, 67, 509–514; Connolly et al., J Biol Chem. 1982, 257, 939–945; Pavia et al., Int J Pep Protein Res. 1983, 22, 539-548; Lee et al., Biochem, 1984, 23, 4255-4261; Lee et al., Glycoconjugate J, 1987, 4, 317-328; Toyokuni et al., Tetrahedron Lett, 1990, 31, manual 61 / 151 pages 71 CN121335980 A 2673-2676; Biessen et al., J Med Chem, 1995, 38, 1538-1546; Valentijn et al., Tetrahedron, 1997, 53, 759-770; Kim et al., Tetrahedron Lett, 1997, 38, 3487-3490; Lee et al., Bioconjug Chem, 1997, 8, 762-765; Kato et al., Glycohiol, 2001, 11, 821-829; Rensen et al., J Biol Chem, 2001, 276, 37577-37584; Lee et al., Methods Enzymol, 2003, 362, 38-43; Westerlind et al., Glycoconj J, 2004, 21, 227-241; Lee et al., Bioorg Med Chem Lett, 2006, 16(19), 5132-5135; Maierhofer et al., Bioorg Med Chem, 2007, 15, 7661-7676; Khorev et al., Bioorg Med Chem, 2008, 16, 5216-5231; Lee et al., Bioorg Med Chem, 2011, 19, 2494-2500; Kornilova et al., Analyt Biochem, 2012, 425, 43-46; Pujol et al., Angew Chemie Int Ed Engl, 2012, 51, 7445–7448; Biessen et al., J Med Chem, 1995, 38, 1846–1852; Sliedregt et al., J Med Chem, 1999, 42, 609–618; Rensen et al., J Med Chem, 2004, 47, 5798–5808; Rensen et al., Arterioscler Thromh Vase Biol, 2006, 26, 169–175; van Rossenberg et al., Gene Ther, 2004, 11, 457–464; Sato et al., J Am Chem Soc, 2004, 126, 14013–14022; Lee et al., J Org Chem,2012, 77, 7564-7571; Biessen et al., FASEB J, 2000, 14, 1784-1792; Rajur et al., Bioconjug Chem, 1997, 8, 935-940; Duff et al., Methods Enzymol, 2000, 313, 297-321; Maier et al., Bioconjug Chem, 2003, 14, 18-29; Jayaprakash et al., Org Lett, 2010, 12, 5410-5413; Manoharan, Antisense Nucleic Acid Drug Dev, 2002, 12, 103-128; Merwin et al., Bioconjug Chem, 1994, 5 612-620; Tomiya et al., Bioorg Med Chem, 2013, 21, 5275-5281; International applications WO1998 / 013381; WO2011 / 038356; WO1997 / 046098; WO2008 / 098788; WO2004 / 101619; WO2012 / 037254; WO2011 / 120053; WO2011 / 100131; WO2011 / 163121; WO2012 / 177947; WO2013 / 033230; WO2013 / 075035; WO2012 / 083185; WO2012 / 083046; W02009 / 082607; WO2009 / 134487; W02010 / 144740; W02010 / 148013; WO1997 / 020563; W02010 / 088537; W02002 / 043771; W02010 / 129709; WO2012 / 068187; WO2009 / 126933; W02004 / 024757; WO2010 / 054406; WO2012 / 089352; WO2012 / 089602; WO2013 / 166121; WO2013 / 165816; US Patents 4,751,219; 7,582,744; 8,552,163; 8,137,695; 6,908,903; 6,383,812; 7,262,177; 6,525,031; 5,994,517; 6,660,720; 6,300,319; 7,723,509; 8,106,022; 7,491,805; 7,491,805; 8,541,548; 8,344,125; 8,313,772; 8,349,308; 8,450,467; 8,501,930; 8,158,601; 7,262,177; 6,906,182; 6,620,916; 8,435,491; 8,404,862; 7,851,615; Published U.S. patent applications: US2011 / 0097264; US2011 / 0097265; US2013 / 0004427; US2003 / 0119724; US2011 / 0207799; US2012 / 0035115; US2012 / 0230938; US2005 / 0164235; US2006 / 0183886; US2012 / 0136042; US2012 / 0095075; US2013 / 0109817; US2006 / 0148740; US2008 / 0206869; US2012 / 0165393; US2012 / 0101148; US2013 / 0121954; US2011 / 0123520; US2003 / 0077829; Each of the following documents, US2008 / 0108801 and US2009 / 0203132, is incorporated herein by reference in its entirety.

[0284] Certain conjugation groups In some embodiments, the compounds provided herein contain conjugation groups. In some embodiments, the oligonucleotides provided herein contain conjugation groups. In some embodiments, the conjugation group is a targeting moiety. In some embodiments, the targeting moiety contains one or more TrkB ligands. In some embodiments, the targeting moiety contains one or more CB1 ligands. In some embodiments, the targeting moiety contains one or more α4β1 / 7 integrin ligands. In some embodiments, the targeting moiety contains one or more NMDA ligands. Specification 62 / 151 pages 72 CN 121335980 A

[0285] In some embodiments, the TrkB ligand of the modified oligonucleotide is of formula (I) or a salt, solvate or hydrate thereof:

[0286] Formula (I), wherein: R1 is the modified oligonucleotide; L1, L2, L3 and L4 are as described herein; R2 is hydrogen, -OR7, -SR8 or -NR9R10; R3 is hydrogen, -OR11, -SR12 or -NR13R14; R4 is hydrogen, -OR15, -SR16 or -NR17R18; R5 is hydrogen, -OR19, -SR20 or -NR21R22; R6 is hydrogen, -OH, optionally substituted -O-alkyl, optionally substituted -OAc, -NH2, optionally substituted-NHAc, -SH, or =O; R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, and R22 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; Y is CH2, NH, S, or O; and Z is optionally substituted aryl or optionally substituted heteroaryl.

[0287] In some embodiments, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, and R22 are each independently optionally substituted unsaturated or partially unsaturated alkyl. In some embodiments, R7, R8, R9, and R10 are each independently alkenyl. In some embodiments, R7, R8, R9, and R10 are each independently alkynyl.

[0288] In some embodiments, R2 is OR7. In some embodiments, R3 is OR11. In some embodiments, R7 and R11 are each independently hydrogen, optionally substituted alkyl, or optionally substituted alkenyl; in some embodiments, one or both of R7 and R11 are each independently hydrogen. In some embodiments, one or both of R7 and R11 are each independently optionally substituted alkyl. In some embodiments, one or both of R7 and R11 are each independently optionally substituted unsaturated or partially unsaturated alkyl. In some embodiments, one or both of R7 and R11 are each independently alkenyl. In some embodiments, R7 is optionally substituted alkyl and R11 is hydrogen. In some embodiments, R7 is hydrogen and R11 is optionally substituted alkyl. In some embodiments, R7 is alkenyl and R11 is hydrogen. In some embodiments, R7 is hydrogen and R11 is optionally substituted alkenyl.

[0289] In some embodiments, the TrkB ligand of the modified oligonucleotide is selected from the following formulas or their salts, solvates or hydrates: Specification 63 / 151 pages 73 CN 121335980 A

[0290] Formula (II-A),

[0291] Formula (II-B),

[0292] Formula (II-C), wherein: R1 is a modified oligonucleotide; and L1, L2, L3 and L4 are as described herein.

[0293] In some embodiments, the TrkB ligand of the modified oligonucleotide is of formula (XXX) or a salt, solvate or hydrate thereof:

[0294] Formula (XXX), wherein: L1, L2, L3, L4 and R1 are as described herein; R11 and R13 are each independently absent, hydrogen or optionally substituted alkyl;R12, R14, and R15 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; R16 is hydrogen, halogen, –CN, –N3, –SOn16R 1A, –SOv16NR 16BR16C, –NHNR16BR16C, –ONR16BR16C, –NHC(O)NHNR16BR16C, –NHC(O)NR16BR16C, –N(O)m16, –NR 16BR16C, –C(O)R16D, –C(O)OR16D, –C(O)NR16BR16C, –OR16A, –NR16BSO2R 16A, -NR16BC(O)R16D, -NR16BC(O)OR16D, -NR16BOR16D, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and each independently is a single or double bond, wherein if it is a single bond, it is a double bond and R13 is not present; and further wherein if it is a single bond, it is a double bond and R11 is not present; R16A, R16B, R16C, R16D are each independently hydrogen, halogen, -CF3, -CCl3, -CBr3, -CI3, -COOH, -CONH2, Substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; or R16B and R16C substituents bonded to the same nitrogen atom may optionally be linked to form substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; z3 is 0, 1, 2, 3, 4 or 5; n16 is 0, 1, 2, 3 or 4; and v16 and m16 are each independently 1 or 2.

[0295] In some embodiments, the α4β1 / 7 integrin ligand of the modified oligonucleotide is of formula (XXXI) or a salt, solvate or hydrate thereof: .

[0296] Formula (XXXI) wherein L1, L2, L3, L4 and R1 are as described herein; R2, R3, R4 and R5 are each independently H, halogen, optionally substituted alkyl, optionally substituted -O-alkyl, cycloalkyl or absent; R8 is optionally substituted C1-C5 alkyl, optionally substituted C1-C5 alkylene-(C3-C6)-cycloalkyl or optionally substituted (C1-C4)-alkylene-(C1-C4)-alkoxy; andR6 and R7 are each independently H, halogen, alkyl, or optionally substituted alkyl, optionally substituted heteroalkyl, or.

[0297] In some embodiments, the α4β1 / 7 integrin ligand of the modified oligonucleotide is of formula (XXXII) or a salt, solvate or hydrate thereof:

[0298] Formula (XXXII) wherein L1, L2, L3, L4 and R1 are as described herein; R2 is H, polyethylene glycol (PEG), optionally substituted heteroalkyl or optionally substituted heteroaryl; and R3 and R4 are each independently H, halogen, optionally substituted alkyl or optionally substituted -O-alkyl. Specification 65 / 151 pages 75 CN 121335980 A

[0299] In some embodiments, L1, L2, L3 and L4 are each independently absent, bonded, optionally substituted alkyl connectors, optionally substituted polyethylene glycol (PEG) connectors, optionally substituted heteroalkyl connectors or optionally substituted heteroaryl connectors.

[0300] In some embodiments, L1 is an optionally substituted heteroaryl connector.

[0301] In some embodiments, L1 is an optionally substituted unsaturated heteroaryl, optionally substituted heteroaryl or optionally substituted saturated or partially unsaturated heterocyclic alkyl connector.

[0302] In some embodiments, L1 comprises the structure: .

[0303] In some embodiments, L1 is an optionally substituted heteroalkyl connector. In some embodiments, the optionally substituted heteroalkyl linker is an optionally substituted heteroalkyl or optionally substituted C1-C10 alkyl chain, wherein one or more carbon atoms are replaced by O, N, or S.

[0304] In some embodiments, L1 comprises the structure: or.

[0305] In some embodiments, L1 comprises the structure: or –N(CH3)–.

[0306] In some embodiments, L2 is an optionally substituted PEG linker.

[0307] In some embodiments, the length of the PEG linker is five PEG units. In some embodiments, the length of the PEG linker is four PEG units. In some embodiments, the length of the PEG linker is three PEG units.

[0308] In some embodiments, L2 is an optionally substituted alkyl linker. In some embodiments, L2 is an optionally substituted C1-20 alkyl linker. In some embodiments, L2 is an optionally substituted C8 alkyl linker. In some embodiments, L3 is an optionally substituted heteroaryl linker.

[0309] In some embodiments, L3 is an optionally substituted partially unsaturated heteroaryl linker, an optionally substituted heteroaryl linker, or an optionally substituted saturated or partially unsaturated heterocycloalkyl linker.

[0310] In some embodiments, L3 comprises the structure: .

[0311] In some embodiments, L4 is an optionally substituted heteroalkyl linker. In some embodiments, the heteroalkyl linker is substituted with one or more =O substituents.

[0312] In some embodiments, the heteroalkyl linker comprises two substituents linked together to form an optionally substituted carbocyclic ring.

[0313] In some embodiments, L4 comprises the structure: or a salt thereof, wherein X is O or S. Specification 66 / 151 pages 76 CN 121335980 A

[0314] In some embodiments, L4 comprises the structure: or a salt thereof, wherein X is O or S.

[0315] In some embodiments, L1–L2–L3–L4 comprises the structures: , , , , , , , Specification 67 / 151 page 77 CN 121335980 A, , , , , , Specification 68 / 151 page 78 CN 121335980 A, , , , Specification 69 / 151 page 79 CN 121335980 A, or salts thereof, wherein X is O or S.

[0316] In some embodiments, the TrkB ligand of the modified oligonucleotide is selected from the following formulas or their salts, solvates or hydrates:

[0317] Formula (III),

[0318] Formula (IV),

[0319] Formula (V), Specification 70 / 151 pages 80 CN 121335980 A

[0320] Formula (VI),

[0321] Formula (VII),

[0322] Formula (VIII),

[0323] Formula (IX), Specification 71 / 151 pages 81 CN 121335980 A

[0324] Formula (X),

[0325] Formula (XI),

[0326] Formula (XII), Specification 72 / 151 pages 82 CN 121335980 A

[0327] Formula (XIII),

[0328] Formula (XIV),

[0329] Formula (XV),

[0330] Formula (XVI),

[0331] Formula (XVII), Specification 73 / 151 pages 83 CN 121335980 A

[0332] Formula (XVIII),

[0333] Formula (XIX),

[0334] Formula (XX),

[0335] Formula (XXV) Wherein: R is a modified oligonucleotide; and X is S or O.

[0336] In some embodiments, the CB1 ligand of the modified oligonucleotide is selected from the following formula or its salt, solvate or hydrate: Specification 74 / 151 pages 84 CN 121335980 A:

[0337] Formula (XXVI) Wherein:R is a modified oligonucleotide; X is S or O.

[0338] In some embodiments, the α4β1 / 7 integrin ligand of the modified oligonucleotide is selected from the following formulas or their salts, solvates or hydrates:

[0339] Formula (XXVII)

[0340] Formula (XXVIII) Wherein: AR is a modified oligonucleotide; X is S or O.

[0341] In some embodiments, the NMDA ligand of the modified oligonucleotide is selected from the following formulas or their salts, solvates or hydrates:

[0342] Formula (XXIX) Wherein: R is a modified oligonucleotide; X is S or O.

[0343] In some embodiments, the compounds provided herein contain a conjugation group. In some embodiments, the oligonucleotides provided herein contain a conjugation group. In some embodiments, the conjugation group is a lipid. In some embodiments, the nucleoside interlinking of the modified oligonucleotides provided herein contains one or more lipids.

[0344] In some embodiments, the nucleoside-internucleotide link of the modified oligonucleotide includes formula (XXI), or a salt, solvate, or hydrate thereof:

[0345] Formula (XXI), wherein: Y is –C(=O)N(RC)–, or –N(RC)C(=O)–; Q1 and Q3 are each independently –H, –OR4, ligand, linker, or lipid; Q2 and Q4 are each independently a linker, ligand, linker, or lipid; RC is independently –H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; each R2 is independently –H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, specification 76 / 151 pages 86 CN 121335980 A Substituted or unsubstituted alkynyl, –OR6, –N(R6) or –SR6; Each R3 is independently –H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, –OR7, –N(R7) or –SR7; R4 and R5 are independently oligonucleotides, or R4 and R5 linked together to form a single oligonucleotide; Each R6 is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; Each R7 is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; Each R8 is independently substituted or unsubstituted heteroaryl; Each R9 is independently substituted or unsubstituted heteroaryl; Each instance of Z1 or Z2 is independently a bond, C1-C6 alkylene or C2-C6 alkenyl; and each X is independently O or S; or a salt thereof.

[0346] In some embodiments, the nucleoside-internucleotide linking of the modified oligonucleotide includes formula (XXII), or a salt, solvate, or hydrate thereof:

[0347] Formula (XXII), wherein: RC is –H, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted heteroalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; each R2 is independently –H, a halogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, –OR6, –N(R6), or –SR6; each R3 is independently –H, a halogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, –OR7, –N(R7), or –SR7; R4 and R5 are independently oligonucleotides, or R4 and R5 are linked together to form a single oligonucleotide; Each R6 is independently hydrogen, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted heteroalkyl group; each R7 is independently hydrogen, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted heteroalkyl group; each R8 is independently a substituted or unsubstituted heteroaryl ring; each R9 is independently a substituted or unsubstituted heteroaryl ring; and each X is independently O or S; or a salt or prodrug thereof.

[0348] In some embodiments, the nucleoside-internucleotide linking of the modified oligonucleotide includes formula (XXIII), or a salt, solvate, or hydrate thereof:

[0349] Formula (XXIII), wherein: each R2 is independently –H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, –OR6, –N(R6), or –SR6; each R3 is independently –H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, –OR7, –N(R7), or –SR7; R4 and R5 are independently oligonucleotides, or R4 and R5 are linked together to form a single oligonucleotide; each R6 is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; each R7 is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl. Each R8 is independently a substituted or unsubstituted heteroaryl ring; each R9 is independently a substituted or unsubstituted heteroaryl ring; and each X is independently O or S; or a salt or prodrug thereof.

[0350] In some embodiments, the nucleoside-internucleotide linker of the modified oligonucleotide includes formula (XXIV), or a salt, solvate or hydrate thereof:

[0351] Formula (XXIV).

[0352] Wherein: (See page 78 / 151 of the specification)88 CN 121335980 A R4 and R5 are independently oligonucleotides, or R4 and R5 are linked together to form a single oligonucleotide; and each X is independently O or S.

[0353] In some embodiments, the nucleoside-to-nucleotide linkage of the modified oligonucleotide includes formula (XXXIII), or a salt, solvate, or hydrate thereof:

[0354] Formula (XXXIII) Wherein: R4 and R5 are independently oligonucleotides, or R4 and R5 are linked together to form a single oligonucleotide; and each X is independently O or S.

[0355] In some embodiments, the nucleoside-to-nucleotide linkage of the modified oligonucleotide includes formula (XXXIV), or a salt, solvate, or hydrate thereof:

[0356] Formula (XXXIV) Wherein: R4 and R5 are independently oligonucleotides, or R4 and R5 are linked together to form a single oligonucleotide; and each X is independently O or S.

[0357] In some embodiments, the nucleoside-to-nucleotide linkage of the modified oligonucleotide comprises formula (XXXV), or a salt, solvate, or hydrate thereof: Specification 79 / 151 page 89 CN 121335980 A

[0358] Formula (XXXV) Wherein: R4 and R5 are independently oligonucleotides, or R4 and R5 are linked together to form a single oligonucleotide; and each X is independently O or S.

[0359] In some embodiments, the compound of any of the foregoing embodiments comprises one or more lipid conjugate groups. In some embodiments, the one or more lipid conjugate groups are attached to one or more nucleoside-to-nucleotide linkages of the modified oligonucleotide. In some embodiments, the one or more lipid conjugate groups are attached to the 5' or 3' end of the modified oligonucleotide. In some embodiments, the one or more lipid conjugate groups are attached to both the nucleoside-to-nucleotide linkage and the 5' or 3' end of the modified oligonucleotide. In some embodiments, the one or more lipid conjugates are attached to both the nucleotide interlink and the 5' and 3' ends of the modified oligonucleotide. In some embodiments, the one or more TrkB ligands are attached to either the 5' or 3' end of the modified oligonucleotide, or both the 5' and 3' ends of the modified oligonucleotide. In some embodiments, the one or more conjugates comprise at least one TrkB ligand attached to either the 5' or 3' end of the modified oligonucleotide, or both the 5' and 3' ends of the modified oligonucleotide, and at least one lipid. In some embodiments, the one or more conjugates comprise at least one TrkB ligand attached to either the 5' or 3' end of the modified oligonucleotide, or both the 5' and 3' ends of the modified oligonucleotide, and one or more lipid conjugates attached to one or more nucleotide interlinks of the modified oligonucleotide. In some embodiments, the modified oligonucleotide comprises...TrkB ligands and lipids. In some embodiments, the modified oligonucleotide comprises one or more TrkB ligands and one or more lipids. In some embodiments, the modified oligonucleotide is a second modified oligonucleotide or a positive oligonucleotide.

[0360] In some embodiments, any of the compounds of the foregoing embodiments comprises one or more substituted or unsubstituted alkyl or alkenyl groups. In some embodiments, the substituted or unsubstituted alkyl or alkenyl group is attached to a nucleoside internucleotide of the modified oligonucleotide. In some embodiments, the modified oligonucleotide comprises one or more substituted or unsubstituted alkyl or alkenyl groups. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups are attached to one or more nucleoside internucleotides of the modified oligonucleotide. In some embodiments, the modified oligonucleotide is a second modified oligonucleotide or a positive oligonucleotide. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise a saturated or unsaturated C4-C30 hydrocarbon chain. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise a saturated or unsaturated C5-C20 hydrocarbon chain. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C14-C20 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C16 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C17 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C18 hydrocarbon chains. In some embodiments, the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C22 hydrocarbon chains.

[0361] In some embodiments, the substituted or unsubstituted alkyl or alkenyl groups are attached to a nucleoside linker of a modified oligonucleotide (e.g., a second modified oligonucleotide or a positive oligonucleotide). In some embodiments, a substituted or unsubstituted alkyl or alkenyl group is attached to an internucleotide link of a modified oligonucleotide (e.g., a second modified oligonucleotide or a sense oligonucleotide). In some embodiments, the internucleotide link is located between nucleosides at 10 positions (e.g., within 8 positions, 6 positions, 5 positions, 4 positions, 3 positions, or 2 positions) starting from the end (e.g., the 5' end and / or the 3' end) of the modified oligonucleotide. In some embodiments, the internucleotide link is located between nucleosides at 5 positions starting from the 5' end of the modified oligonucleotide. In some embodiments, the internucleotide link is located between nucleosides at 5 positions starting from the 3' end of the modified oligonucleotide.

[0362] In some embodiments, the internucleotide link is located between positions 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11, 11 and 12, 12 and 13, or 13 and 14, starting from the 5' end of the modified oligonucleotide. In some embodiments, the internucleotide link is located between positions 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, or 7 and 8, starting from the 5' end of the modified oligonucleotide. In some embodiments, the internucleotide link is located between positions 2 and 3, starting from the 5' end of the modified oligonucleotide. In some embodiments, the internucleotide link is located between positions 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11, 11 and 12, 12 and 13, or 13 and 14, starting from the 3' end of the modified oligonucleotide. In some embodiments, the internucleotide link is located between positions 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, 6 and 7, or 7 and 8, starting from the 3' end of the modified oligonucleotide. In some embodiments, the internucleotide link is located between positions 2 and 3, starting from the 3' end of the modified oligonucleotide.

[0363] In some embodiments, the internucleotide linkage of the modified oligonucleotide is selected from any of the formulas XXI-XXIV and XXXIII-XXXV.

[0364] Target Nucleic Acid and Target Region In some embodiments, the compound described herein comprises or is composed of an oligonucleotide containing a region complementary to the target nucleic acid. In some embodiments, the target nucleic acid is an endogenous RNA molecule. In some embodiments, the target nucleic acid encodes a protein. In some embodiments, the target nucleic acid is non-coding. In some such embodiments, the target nucleic acid is selected from mRNA and premRNA, including intron regions, exon regions, and untranslated regions. In some embodiments, the target RNA is mRNA. In some embodiments, the target nucleic acid is premRNA. In some such embodiments, the target region is entirely located within an exon. In some such embodiments, the target region is entirely located within an intron. In some embodiments, the target region spans...Intron / exon junctions. In some embodiments, at least 50% of the target region is located within an intron.

[0365] In some embodiments, the compounds disclosed herein hybridize with SOD1 nucleic acid. The most common hybridization mechanism involves hydrogen bonding between complementary nucleobases of nucleic acid molecules. Hybridization can occur under different conditions. Hybridization conditions are sequence-dependent and determined by the nature and composition of the nucleic acid molecule to be hybridized. Methods for determining whether a sequence specifically hybridizes with a target nucleic acid are well known in the art, as described on pages 81 / 151 of the specification, CN 121335980 A. In some embodiments, the compounds provided herein specifically hybridize with SOD1 nucleic acid.

[0366] Nucleotide sequences encoding SOD1 include, but are not limited to, those of GenBank accession number NM_000454.5 (incorporated herein as SEQ ID NO:1) and nucleotides 5001 to 14310 of NG_008689.1 (incorporated herein as SEQ ID NO:2).

[0367] Complementarity The oligonucleotides provided herein may have a defined percentage of complementarity with a specific nucleic acid, target region, oligonucleotide, or portion thereof. Non-complementary nucleobases are tolerable, provided that the oligonucleotide is still able to specifically hybridize with the nucleic acid, oligonucleotide, or portion thereof. In some embodiments, the oligonucleotides provided herein or a designated portion thereof are at least or at most 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to the target nucleic acid, target region, oligonucleotide, or designated portion thereof. In some embodiments, the oligonucleotides provided herein or a designated portion thereof are 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95%, 95% to 100%, or any value between these ranges, complementary to the target nucleic acid, target region, oligonucleotide, or designated portion thereof. The percentage of complementarity between an oligonucleotide and a target nucleic acid, target region, oligonucleotide, or designated portion thereof can be determined using conventional methods. For example, an oligonucleotide in which 18 of its 20 nucleotides are complementary to the target region and will therefore specifically hybridize will represent 90% complementarity. In this example, the remaining non-complementary nucleotides may cluster or intersperse with complementary nucleotides and do not need to be adjacent to each other or to complementary nucleotides. Therefore, an 18-nucleotide oligonucleotide with four non-complementary nucleotides (flanked by two regions that are fully complementary to the target nucleic acid) has a total complementarity of 77.8% with the target nucleic acid. The percentage of complementarity between an oligonucleotide and a region of the target nucleic acid, target region, oligonucleotide, or designated portion thereof can be conventionally determined using BLAST (Basic Local Alignment Search) procedures known in the art. In some embodiments, the oligonucleotides described herein...A nucleotide or a designated portion thereof is completely complementary (i.e., 100% complementary) to a target nucleic acid, target region, oligonucleotide, or a designated portion thereof. For example, an oligonucleotide may be completely complementary to a target nucleic acid, target region, oligonucleotide, or a designated portion thereof. As used herein, “completely complementary” means that each nucleobase of the oligonucleotide is complementary to the corresponding nucleobase of the target nucleic acid, target region, oligonucleotide, or a designated portion thereof. For example, a 20-nucleobase oligonucleotide is completely complementary to a 400-nucleobase target sequence, provided that the corresponding 20-nucleobase portion of the target nucleic acid is completely complementary to the compound. “Completely complementary” can also be used for designated portions of a first and / or second nucleic acid. For example, a 20-nucleobase portion of a 30-nucleobase oligonucleotide may be “completely complementary” to a 20-nucleobase region of a 400-nucleobase target sequence. The 20 nucleobase portions of the 30-nucleobase compound are completely complementary to the target sequence if the target sequence has a corresponding 20 nucleobase portion, wherein each nucleobase is complementary to the 20 nucleobase portions of the compound. Meanwhile, the entire 30-nucleobase compound may be completely or partially complementary to the target sequence, depending on whether the remaining 10 nucleobases of the compound are also complementary to the target sequence.

[0368] In some embodiments, the oligonucleotides described herein contain one or more mismatched nucleobases relative to the target nucleic acid, target region, oligonucleotide, or designated portion thereof. In some embodiments, the oligonucleotides described herein with a length of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleobases contain no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobases relative to the target nucleic acid or designated portion thereof. In some embodiments, the oligonucleotides described herein, having a length of 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides, contain no more than 6, 5, 4, 3, 2, or 1 non-complementary nucleotides relative to the target nucleic acid, target region, oligonucleotide, or designated portion thereof. In some embodiments, mismatches are located at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14, starting from the 5' end of the oligonucleotide. In some embodiments, the mismatch is located at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14, starting from the 3' end of the oligonucleotide. In some embodiments, the mismatch forms a wobbling base with the corresponding nucleobase on the target nucleic acid.Yes. For example, in some embodiments, mismatches form a wobble base pair selected from inosine (a nucleobase of inosine) and uracil (I:U base pair); guanine and uracil (G:U base pair); inosine and adenine (I:A base pair); and inosine and cytosine (I:C base pair). Thus, in some embodiments, the mismatched nucleobases on the oligonucleotide include inosine, guanine, or uracil.

[0369] In some embodiments, the oligonucleotide described herein may be complementary to a portion of a nucleic acid. As used herein, “portion” refers to a defined number of adjacent nucleobases within a nucleic acid region. “Portion” may also refer to a defined number of adjacent nucleobases of an oligonucleotide. In some embodiments, the oligonucleotide is complementary to at least 8 nucleobase portions of a nucleic acid. In some embodiments, the oligonucleotide is complementary to at least 9 nucleobase portions of a nucleic acid. In some embodiments, the oligonucleotide is complementary to at least 10 nucleobase portions of a nucleic acid. In some embodiments, the oligonucleotide is complementary to at least 11 nucleotides of the nucleic acid. In some embodiments, the oligonucleotide is complementary to at least 12 nucleotides of the nucleic acid. In some embodiments, the oligonucleotide is complementary to at least 13 nucleotides of the nucleic acid. In some embodiments, the oligonucleotide is complementary to at least 14 nucleotides of the nucleic acid. In some embodiments, the oligonucleotide is complementary to at least 15 nucleotides of the nucleic acid. In some embodiments, the oligonucleotide is complementary to at least 16 nucleotides of the nucleic acid. Oligonucleotides complementary to at least 9, 10, 17, 18, 19, 20, 21, 22, or 23 or more nucleotides of the nucleic acid, or a range defined by any two of these values, are also considered. In some embodiments, the oligonucleotide is an antisense oligonucleotide. In some embodiments, a portion of the antisense oligonucleotide is compared to an equal-length portion of the target nucleic acid. In some embodiments, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotide moieties are compared to an equivalent length portion of the target nucleic acid. In some embodiments, the oligonucleotide is a sense oligonucleotide. In some embodiments, a portion of the sense oligonucleotide is compared to an equivalent length portion of the antisense oligonucleotide. In some embodiments, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotide moieties of the sense oligonucleotide are compared to an equivalent length portion of the antisense oligonucleotide.

[0370] Identity The oligonucleotides provided herein may also have a defined percentage of identity with a specific nucleic acid, target region, oligonucleotide, or designated portion thereof. As used herein, if an oligonucleotide has the same nucleobase pairing ability, then the oligonucleotide is considered to have the same nucleobase pairing ability.The sequence is identical to that disclosed herein. For example, DNA containing thymidine in place of uracil in a disclosed RNA sequence will be considered identical to that RNA sequence because both uracil and thymidine pair with adenine. Shortened and lengthened forms of the compounds described herein, as well as compounds having bases that are not identical to those provided herein, are also considered. These non-identical bases may be adjacent to each other or dispersed throughout the compound. The percentage of identity of an oligonucleotide is calculated based on the number of bases that have identical base pairs relative to the sequence to which the oligonucleotide is compared. In some embodiments, the oligonucleotide or portions thereof described herein are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to one or more of the nucleic acids, oligonucleotides, or portions thereof disclosed herein. In some embodiments, the oligonucleotides described herein are identical to a particular nucleic acid or oligonucleotide or a portion thereof in percentages of about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, or any percentage between such values.

[0371] In some embodiments, the oligonucleotide may have one or more mismatched nucleobases. In some such embodiments, the mismatch is located at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, or position 14, starting from the 5' end of the oligonucleotide. In some such embodiments, the mismatch is located at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, or position 12, position 13, or position 14, starting from the 3' end of the oligonucleotide. In some embodiments, a portion of the oligonucleotide is compared to an equivalent length portion of the target nucleic acid. In some embodiments, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotide portions are compared to an equivalent length portion of the target nucleic acid. In some embodiments, the oligonucleotide is a sense oligonucleotide. In some embodiments, a portion of the sense oligonucleotide is compared to an equivalent length portion of the target nucleic acid. In some embodiments, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotide portions are compared to an equivalent length portion of the target nucleic acid.

[0372] Pharmaceutical Compositions and Formulations The compounds described herein may be mixed with pharmaceutically acceptable active or inert substances to prepare pharmaceutical compositions.For use in formulations or preparations. The compositions and methods used to formulate pharmaceutical compositions depend on many criteria, including but not limited to route of administration, disease severity, or dose to be administered. Some embodiments provide a pharmaceutical composition comprising one or more compounds or salts thereof. In some embodiments, the compound is an antisense oligonucleotide. In some embodiments, the compound is an oligomeric compound. In some embodiments, the compound comprises or is composed of one or more modified oligonucleotides. In some such embodiments, the pharmaceutical composition comprises one or more compounds and a suitable pharmaceutically acceptable diluent or carrier. In some embodiments, the pharmaceutical composition comprises one or more compounds and a sterile aqueous saline solution. In some embodiments, this pharmaceutical composition consists of a compound and a sterile aqueous saline solution. In some embodiments, the sterile saline solution is pharmaceutical grade saline. In some embodiments, the pharmaceutical composition comprises one or more compounds and sterile water. In some embodiments, the pharmaceutical composition consists of a compound and sterile water. In some embodiments, the sterile water is pharmaceutical grade water. In some embodiments, the pharmaceutical composition comprises one or more compounds and phosphate-buffered saline (PBS). In some embodiments, the pharmaceutical composition consists of a compound and sterile PBS. In some embodiments, the sterile PBS is pharmaceutical grade PBS.

[0373] The compound can be used in a pharmaceutical composition by combining the SOD1-targeting compound described herein with a suitable pharmaceutically acceptable diluent or carrier. In some embodiments, the pharmaceutically acceptable diluent is water, such as sterile water suitable for injection. Thus, in one embodiment, the method described herein employs a pharmaceutical composition comprising a SOD1-targeting compound and a pharmaceutically acceptable diluent. In some embodiments, the pharmaceutically acceptable diluent is water. In some embodiments, the compound comprises or is composed of one or more modified oligonucleotides provided herein.

[0374] Pharmaceutical compositions comprising the compounds provided herein encompass any pharmaceutically acceptable salt, ester, or salt of such esters, or any other oligonucleotide capable of providing (directly or indirectly) its biologically active metabolites or residues after administration to animals (including humans). In some embodiments, the compound is an antisense oligonucleotide. In some embodiments, the compound is an oligomeric compound. In some embodiments, the compound comprises or is composed of one or more modified oligonucleotides. Therefore, for example, this disclosure also relates to pharmaceutically acceptable salts of compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts. Prodrugs may be incorporated at one or both ends of a compound into a portion of the compound that is cleaved by endogenous nucleases in the body to form the active compound.Exonucleotides. In some embodiments, the compound or composition further comprises a pharmaceutically acceptable carrier or diluent.

[0375] Examples The following examples describe the process of identifying lead compounds targeting SOD1. Some compounds have been identified as having high potency and tolerability.

[0376] The following examples are for illustrative purposes only and are not intended to limit the compounds described herein. The sequences in the following examples and the related sequence listings accompanying this application may be identified as “RNA” or “DNA”; however, as disclosed herein, these sequences can be modified with any combination of chemical modifications. Those skilled in the art will readily understand that, in some cases, designating a sequence as “RNA” or “DNA” is arbitrary. For example, an oligonucleotide containing a nucleoside with a 2'-OH sugar moiety and a thymine base may be described as DNA having a modified sugar (2'-OH replacing the native 2'-H of DNA) or as RNA having a modified base (methylated uracil replacing the native uracil of RNA). Therefore, the nucleic acid sequences provided herein (including, but not limited to, those in the sequence listing) are intended to cover nucleic acids containing any combination of natural or modified RNA and / or DNA, including, but not limited to, such nucleic acids having modified nucleobases.

[0377] Each of the references listed in this application is incorporated herein by reference in its entirety.

[0378] Table 1 Chemical Nomenclature Specification 85 / 151 pages 95 CN 121335980 A

[0379]

[0380] Table 2 Compound Sequence and Target Position on SEQ ID NO: 1 Specification 86 / 151 pages 96 CN 121335980 A Specification 87 / 151 pages 97 CN 121335980 A

[0381] Specification 88 / 151 pages 98 CN 121335980 A

[0382] Specification 89 / 151 pages 99 CN 121335980 A

[0383] Specification 90 / 151 pages 100 CN 121335980 A

[0384] Specification 91 / 151 pages 101 CN 121335980 A

[0385] Specification 92 / 151 pages 102 CN 121335980 A

[0386] Specification 93 / 151 pages 103 CN 121335980 A

[0387]

[0388] Table 3 Compound Chemical Specification 94 / 151 pages 104 CN 121335980 A Specification 95 / 151 pages 105 CN 121335980 A

[0389] Specification 96 / 151 pages 106 CN 121335980 A

[0390] Specification 97 / 151 pages 107 CN 121335980 A

[0391] Specification 98 / 151 pages 108 CN 121335980 A

[0392] Specification 99 / 151 pages 109 CN 121335980 A

[0393] Specification 100 / 151 pages 110 CN 121335980 A

[0394] Specification 101 / 151 pages 111 CN 121335980 A

[0395] Specification 102 / 151 pages 112 CN 121335980 A

[0396] Specification 103 / 151 pages 113 CN 121335980 A

[0397] Specification 104 / 151 pages 114 CN 121335980 A

[0398] Specification 105 / 151 pages 115 CN 121335980 A

[0399] Specification 106 / 151 pages 116 CN 121335980 A

[0400] Specification 107 / 151 pages 117 CN 121335980 A

[0401] Specification 108 / 151 pages 118 CN 121335980 A

[0402] Specification 109 / 151 pages 119 CN 121335980 A

[0403]

[0404] Example 1: Preparation of N-(17-azido-3,6,9,12,15-pentoxaheptadecyl)-4-(7,8-dihydroxy-4-oxochroman-2-yl)benzamide

[0405] A solution of 2,5-dioxopyrrolidine-1-yl ester of 4-(7,8-dihydroxy-4-oxochroman-2-yl)benzoic acid (144 mg, 0.365 mmol, 1 equivalent) and 17-azido-3,6,9,12,15-pentoxaheptadecyl-1-amine (223 mg, 0.73 mmol, 2 equivalent) in DMF (2 mL) was heated at 60 °C for 20 min. The mixture was then concentrated, and the crude product was purified by rapid column chromatography (ethyl acetate / methanol, 0-5% eluent) to give the title compound (160 mg, 75% yield) as a brown solid.

[0406] LCMS m / z 587 (M+1) 1H NMR (499 MHz, DMSO-d6) δ 8.71 (t, J = 5.6 Hz, 1H), 8.25 (d, J = 8.6 Hz,2H), 8.02 (d, J = 8.6 Hz, 2H), 7.41 (d, J = 8.6 Hz, 1H), 6.99 (s, 1H), 6.96 (d, J = 8.6 Hz, 1H), 3.60 – 3.48 (m, 20H), 3.45 (q, J = 5.8 Hz, 2H), 3.40 – 3.34 (m, 2H) Example 2: Preparation of N-(17-azido-3,6,9,12,15-pentaheptadecyl)-4-(7,8-dimethoxy-4-oxochroman-2-yl)benzamide Instructions 110 / 151 pages 120 CN 121335980 A

[0407] Iodimethane (0.043 mL, 0.683 mmol, 1 equivalent) was added to a stirred suspension of N-(17-azido-3,6,9,12,15-pentaheptadecyl)-4-(7,8-dihydroxy-4-oxochroman-2-yl)benzamide (400 mg, 0.683 mmol, 1 equivalent) and K₂CO₃ (188 mg, 1.365 mmol, 2 equivalent) in DMF (10 mL), and the mixture was stirred overnight at RT. LCMS showed a mixture of starting material, monomethylated compound, and dimethylated compound. The mixture was concentrated and purified by reversed-phase column chromatography using 0–60% water / MeCN (containing 0.1% formic acid) as eluent to give three products as yellow viscous solids: (100 mg, 24% yield) purity 100%. LCMS: m / z = 615 [M+1] 1H NMR (500 MHz, DMSO–d6) δ 8.71 (t, J = 5.6 Hz, 1H), 8.16 (d, J = 8.5 Hz, 2H), 8.04 (d, J = 8.5 Hz, 2H), 7.80 (d, J = 9.0 Hz, 1H), 7.30 (d, J = 9.0 Hz, 1H), 7.07 (s, 1H), 3.97 (s, 3H). 3.96 (s, 3H), 3.60 – 3.42 (m, 22H), 3.40 – 3.34 (m, 2H).

[0408] Example 3: Preparation of N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-4-(7,8-dihydroxy-4-oxochroman-2-yl)benzamide

[0409] 2,5-dioxopyrrolidine-1-yl ester of 4-(7,8-dihydroxy-4-oxochroman-2-yl)benzoic acid (665 mg, 1.684 mmol,A suspension of 1-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl-1-amine (440 mg, 2 mmol, 1.2 equivalent) and DIPEA (0.5 mL, 3.7 mmol, 2.2 equivalent) in THF (20 mL) was heated at 60 °C for 3 h. The mixture was concentrated, and the resulting solid was ground with methanol and filtered to give the title compound (595 mg, 71%) as a beige solid with a purity >95% according to HPLC. Instruction manual, pages 111 / 151, CN 121335980 A

[0410] LCMS m / z 521 (M+Na) 1H NMR (499 MHz, DMSO-d6) δ 8.71 (t, J = 5.6 Hz, 1H), 8.25 (d, 8.6 Hz, 2H), 8.02 (d, 8.6 Hz, 2H), 7.41 (d, J = 8.6 Hz, 1H), 6.99 (s, 1H), 6.96 (d, J = 8.7 Hz, 1H), 3.61 – 3.51 (m, 12H), 3.45 (q, J = 5.8 Hz, 2H), 3.39 – 3.35 (m, 2H) Example 4: Preparation of 8-(4-((17-azido-3,6,9,12,15-pentoxaheptadecyl)(methyl)amino)phenyl)-2-methylchromeno[7,8-d]imidazol-6(3H)-one

[0411] Step 1: 8-(4-((17-azido-3,6,9,12,15-pentoxaheptadecyl)(methyl)amino)phenyl)-2-methylchromeno[7,8-d]imidazol-6(3H)-one to 7,8-diamino-2-(4-((17-azido-3,6,9,12,15-pentoxaheptadecyl)(methyl)amino)phenyl)-4H-chromeno-4-one (700 mg, 1.28 mmol, 1 equivalent) in acetonitrile (15 1,1,1-trimethoxyethane (169.55 mg, 1.41 mmol, 1.1 equivalent) and iodine (32.56 mg, 128.29 μmol, 25.84 μL, 0.1 equivalent) were added to a solution in mL. The mixture was stirred at 25 °C for 1 hour, and then quenched by adding an aqueous solution of NaHSO3 (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic extracts were washed with brine (40 mL x 1), dried over anhydrous Na2SO4, filtered, concentrated, and subjected to rapid silica gel chromatography (ISCO®; 20 g SepaFlash® silica rapid column, 100 mL x ...Purification was performed using a 0–15% MeOH / DCM gradient elution at a flow rate of mL / min to obtain the title compound (470 mg, 64%) as a brown gel.

[0412] MS ES+: 570.2 Step 2: 8-(4-((17-chloro-3,6,9,12,15-pentoxaheptadecyl)(methyl)amino)phenyl)-2-methylchromone[7,8-d]imidazol-6(3H)-one was added to a solution of 8-(4-((17-azido-3,6,9,12,15-pentoxaheptadecyl)(methyl)amino)phenyl)-2-methylchromone[7,8-d]imidazol-6(3H)-one (400 mg, 702.19 μol, 1 equivalent) in DCM (6 mL) with SOCl2 (835.40 mg, 7.02 mmol, 509.39 μL, 10 equivalent). The mixture was stirred at 25°C for 4 hours and then poured into a saturated aqueous solution of NaHCO3 (40 mL) and extracted with ethyl acetate (40 mL x 3). The combined organic extracts were washed with brine (80 mL x 1), dried over anhydrous Na2SO4, filtered, and concentrated to give the title compound (320 mg, 71%) as a mixture of tautomers in a brown gel-like form. MS ES+: 588.3 H NMR (400 MHz, DMSO-d6) δ = 8.08 - 7.85 (m, 2H), 7.76 (d, J = 8.5 Hz, 1H), 7.50 (br d, J = 8.3 Hz, 1H), 6.87 (br d , J = 8.9 Hz, 2H) , 6.79 (s, 1H) , 3.70 ‑ 3.66 (m, 2H) , 3.66 ‑ 3.60 (m, 6H) , 3.54 ‑ 3.47 (m, 16H) , 3.05 (s, 3H) , 2.61 (s, 3H). Instructions for Use, Pages 112 / 151, CN 121335980 A

[0414] Step 3: 8-(4-((17-azido-3,6,9,12,15-pentoxaheptadecyl)(methyl)amino)phenyl)-2-methylchromone[7,8-d]imidazol-6(3H)-one (310 mg, 0.527 mmol, 1 equivalent) and sodium azide (171 mg, 2.63 mmol, 1 equivalent) in dried DMF (2 mL)The mixture was heated at 70 °C for 12 hours (5 equivalents). The mixture was cooled, diluted with water (20 mL), and extracted with DCM (100 mL). The organic extract was dried over Na2SO4, filtered, concentrated, and purified by column chromatography (0-20% MeOH / DCM) to give the title compound (120 mg, 38%) in the form of a tautomer mixture of deep orange gels in a 1:2 (30:70) form with a purity >95%.

[0415] LCMS m / z = 595 (M+1) The tautomer structures were confirmed by 1H NMR: isomer 1, in which the 7-NH proton appears at a further low field δ13.38; and isomer 2, in which the 9-NH proton appears at a high field δ12.98. The tautomer mixture of isomer 1 (80 mg) was further purified by rapid column chromatography to give pure 2 (50 mg) in the form of a deep orange gel.

[0416] Isomer 1: 1H NMR: (499 MHz, DMSO-d6) δ 13.38, 12.85 (2s, 1H), 8.09, 7.94 (d, J = 8.7 Hz, 2H), 7.77, 7.72 (d, J = 8.5 Hz, 1H), 7.54, 7.47 (d, J = 8.5 Hz, 1H), 6.88, 6.85 (d, J = 9.0 Hz, 2H), 6.81, 6.79 (s, 1H), 3.67 – 3.62 (m, 2H), 3.58 – 3.54 (m, 2H), 3.54 – 3.45 (m, 16H), 3.38 – 3.35 (m, 2H), 3.06, 3.05 (s, 3H), 2.63, 2.60 (s, 3H).

[0417] Isomer 2: ¹H NMR (499 MHz, DMSO-d⁶) δ 12.98 (s, ¹H), 7.98 (d, J = 8.7 Hz, 2H), 7.76 (d, J = 8.5 Hz, ¹H), 7.50 (d, J = 8.5 Hz, 1H), 6.87 (d, J = 9.0 Hz, 2H), 6.80 (s, ¹H), 3.62 (m, 4H), 3.58 – 3.54 (m, 2H), 3.54 – 3.45 (m, ¹⁶H), 3.40 – 3.34 (m, 2H), 3.05 (s, 3H), 2.61 (s, 3H).

[0418] Example 5: Preparation of (S)-3-(4-(5-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)phenyl)-2-(3,5-dichloroisonicotinamide)propionic acid

[0419] Step 1: tert-butyl (S)-2-(3,5-dichloroisonicotinamide)-3-(4-(5-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)phenyl)propionic acid specification 113 / 151 pages 123 CN 121335980 A A solution of tert-butyl propionate (S)-2-(3,5-dichloroisonicotinamide)-3-(4-(2-methyl-3-oxo-5-((1-phenyl-2,5,8,11-tetraoxadecatridecyl-13-yl)oxy)-2,3-dihydropyridazin-4-yl)phenyl)propionate (as described in Gong et al., "Synthesis and Biological Evaluation of Novel Pyridazinone-Based α4 Integrin Receptor Antagonists", J. Med. Chem., 2006, 49, 11, 3402-3411, 0.81 g, 1.02 mmol) in methanol (17 ml) was stirred for 2 hours under a hydrogen atmosphere (1 atm) in the presence of Pd / C (0.11 g, 1.02 mmol). The catalyst was removed by filtration, and the filtrate was concentrated and purified by silica gel column chromatography using 0-5% MeOH in DCM to give the compound (0.47 g, 66%).

[0420] MS (ESI) m / z 696.6 [M+H]+ Step 2: (S)-2-(3,5-dichloroisonicotinamide)-3-(4-(2-methyl-5-(2-(2-(2-(2-(((methylsulfonyl)oxy)ethoxy)ethoxy)ethoxy)ethoxy)3-oxo-2,3-dihydropyridazin-4-yl)phenyl)tert-butyl propionate was dissolved in DCM (1.4 ml) at 0°C in 17 μl of methanesulfonyl chloride (0.216 g). 0.144 mmol) of tert-butyl propionate (0.10 g, 0.144 mmol) was added dropwise to a solution of (S)-2-(3,5-dichloroisonicotinamide)-3-(4-(5-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)phenyl)propionate (0.4 ml) in pyridine. The reaction mixture was stirred at room temperature for 16 h and then quenched by adding water (10 ml) and treated with DCM.Extraction (3 x 10 ml). The organic layers were washed with saturated NaHCO3 solution (10 ml) and brine (10 ml). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated to give the title compound (0.11 g, quantified) as a brown oil.

[0421] MS (ESI) m / z 773.5 [M+H]+ Step 3: Add NaN3 (21 mg, 0.143 mmol) to a solution of (S)-3-(4-(5-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)phenyl)-2-(3,5-dichloroisonicotinamide)propionate tert-butyl ester (0.11 mg, 0.143 mmol) in DMF (2.3 ml). 0.316 mmol), followed by 1 drop of water. The mixture was stirred at 80 °C for 6 hours and then cooled to room temperature, and partitioned between ethyl acetate (20 ml) and water (20 ml). The organic phase was separated, and the aqueous phase was extracted twice with ethyl acetate (2 x 15 ml). The combined organic extracts were washed with brine (x2), dried, filtered, concentrated, and purified by silica gel column chromatography using a gradient of 0–100% ethyl acetate in hexane to give the compound (85 mg, 82%) as a clear oil.

[0422] MS (ESI) m / z 721.6 [M+H]+ Step 4: (S)-3-(4-(5-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)phenyl)-2-(3,5-dichloroisonicotinamide)propionic acid TFA (0.14 ml) was added dropwise at 0°C to a solution of (S)-3-(4-(5-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)phenyl)-2-(3,5-dichloroisonicotinamide)propionic acid tert-butyl propionate (25 mg, 0.035 mmol) in DCM (0.3 ml). The cooling bath was removed, the mixture was stirred at room temperature for 17 hours and then concentrated and purified by silica gel column chromatography using a 0-100% methanol gradient in DCM to give the title product (16 mg, 69%).

[0423] MS (ESI) m / z 687.8 [M+Na]+ 1H NMR (500 MHz, DMSO-d6) δ 12.95(s, 1H), 9.31 (d, J = 10 Hz, 1H), 8.63 (s, 2H), 8.20 (s, 1H), 7.42 (d, J = 10 Hz, 2H), 7.29 (d, J = 10 Hz, 2H), 4.78–4.72 (m, 1H), 4.36–4.32 (m, 2H), 3.66 (s, 5H), 3.57 (t, J = 5 Hz, 2H), 3.36 (t, J = 5 Hz, 2H), 3.53–3.47 (m, ... (Instruction manual 114 / 151 pages 124 CN 121335980 AJ = 5 Hz, 2H) 8H), 3.20 (dd, J = 10, 5 Hz, 1H), 2.93 (q, J = 10 Hz, 1H) Example 6: Preparation of (3S)-3-(2-(4-(14-azido-3-methyl-6,9,12-trioxa-3-azatetradecyl)-2-oxopyridin-1(2H)-yl)-5-methylhexamido)-3-(2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propionic acid

[0424] Step 1: Ethyl (E)-2-(4-(2-ethoxyvinyl)-2-oxopyridin-1(2H)-yl)-5-methylhexanoate was added at room temperature to a stirred solution of ethyl 2-(4-bromo-2-oxopyridin-1-yl)-5-methylhexanoate (prepared according to the procedure described in WO2021076890, 4.8 g, 14.54 mmol) and 2-[(E)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxoborane (5.76 g, 29.081 mmol) in dioxane (50 ml) and water (5 ml) with K2CO3 (4.02 g, 29.10 mmol) and Pd(PPh3)4 (1.68 g, 1.45 mmol). The resulting mixture was stirred overnight at 70°C under a nitrogen atmosphere. The mixture was cooled to room temperature, quenched by adding water, and then extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered, concentrated, and purified by silica gel column chromatography with PE / EA (1:1) elution to give the title product (containing pinacol). The residue was further purified by reversed-phase rapid chromatography (C18 silica gel column; mobile phase, acetonitrile in water, 10-100% gradient over 25 min; detector, UV 254 nm) to give the title compound (4 g, 86%) as a brown oil.

[0425] MS (ESI) m / z 322.1 [M+H]+ 1H NMR(300 MHz, CDCl3) δ 7.16 (m,J= 19.4, 10.1 Hz, 2H), 6.37 (s, 1H), 6.19 (d,J= 7.4 Hz, 1H), 5.60 (d,J= 13.0 Hz, 1H), 5 .54 (m,J= 10.2, 5.6 Hz, 1H), 4.19 (q,J= 7.2 Hz, 2H), 3.94 (q,J= 7.1 Hz, 2H), 2.29 – 2.03 (m, 1H), 1.86 (d ,J= 12.3 Hz, 1H), 1.57 (m, J = 13.3, 6.8 Hz, 1H), 1.35 (t, J = 7.0 Hz, 3H), 1.24 (m, J = 8.5, 7.8 Hz, 4H), 1.14 – 1.04 (m, 1H), 0.87 (m, J = 6.8, 3.0 Hz, 6H) Step 2: Ethyl 5-methyl-2-(2-oxo-4-(2-oxoethyl)pyridin-1(2H)-yl)hexanoate (E)-2-(4-(2-ethoxyvinyl)-2-oxopyridin-1(2H)-yl)-5-methylhexanoate (3.9 g, 12.134 1 mmol) and TFA (40 ml) were stirred overnight at room temperature. The resulting mixture was concentrated and purified by silica gel column chromatography (eluting with PE / EA, 1 / 2) to give the title compound (1.9 g, 53%) as a yellow oil. MS (ESI) m / z 294.2 H NMR (300 MHz, chloroform-d) δ 9.76 (t, J= 2.0 Hz, 1H), 7.35 (d, J= 7.1 Hz, 1H), 6.54 – 6.47 (m, 1H), 6.14 (m, J= 7.2, 2.0 Hz, 1H), 5.56 (m,J= 10.1, 5.6 Hz, 1H), 4.21 (q,J= 7.1 Hz, 2H), 3.56 (d,J= 2.0, 0.8 Hz, 2H), 2.19 (m ,J= 14.0, 11.1, 5.5 Hz, 1H), 1.88 (m,J= 18.8, 10.4, 4.8 Hz, 1H), 1.59 (m,J= 13.3,6.7 Hz, 1H), 1.34 – 1.16 (m, 4H), 1.16 – 0.98 (m, 1H), 0.88 (q, J = 6.6, 3.1 Hz, 6H) Step 3: Ethyl 5-methyl-2-(2-oxo-4-(2,2,3,3,16-pentamethyl-4,7,10,13-tetraoxa-16-aza-3-silazoctadecane-18-yl)pyridin-1(2H)-yl)hexanoate was added to stirred ethyl 5-methyl-2-(2-oxo-4-(2-oxoethyl)pyridin-1(2H)-yl)hexanoate (1.8 g, 6.136 mmol) in DCM (27 15,15,16,16-tetramethyl-5,8,11,14-tetraoxa-2-aza-15-silazappaheptadecane (1.97 g, 6.127 mmol) and STAB (2.60 g, 12.268 mmol) were added to a solution in ml. The resulting mixture was stirred at room temperature for 2 hours, quenched by the addition of water (100 ml), and extracted with DCM (3 x 120 ml). The combined organic extracts were washed with brine (2 x 50 ml), dried over anhydrous Na2SO4, filtered, concentrated, and purified by silica gel column chromatography (eluting with DCM / MeOH (10:1)) to give the title compound (1.6 g, 44%) as a yellow-brown oil. MS (ESI) m / z 599.3 [M+H]+ HNMR (300 MHz, acetonitrile-d3) δ 7.25 (d, J= 7.1 Hz, 1H), 6.20 (s, 1H), 6.11 (m, J= 7.1, 2.0 Hz, 1H), 5.08 (m,J= 10.2, 5.4 Hz, 1H) , 4.08 (q,J= 7.1 Hz, 2H) , 3.66 (m,J= 5.7, 4.4 Hz, 2H) , 3.57 – 3.47 (m, 11H) , 3.47 – 3.37 (m, 3H) , 2.68 – 2.48 (m, 4H) , 2.24 (s, 3H) , 2.15 – 1.99 (m, 1H) , 1.90 (m, 1H) , 1.48 (m,J= 13.4, 6.8...

Claims

1. A compound comprising a modified oligonucleotide of 14 to 30 linked nucleosides, said modified oligonucleotide having a nucleonucleotide sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 adjacent nucleosides of any nucleobase sequence comprising any nucleobase sequence of SEQ ID NO: 11-18, 28-106, 184-187, 196-202, or 214-223.

2. A compound comprising a modified oligonucleotide of 14 to 23 linked nucleosides, said modified oligonucleotide having a nucleobase sequence comprising any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202 or 214-223.

3. A compound comprising a modified oligonucleotide having a nucleobase sequence selected from the group consisting of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202 and 214-223.

4. The compound of any one of claims 1-3, wherein the modified oligonucleotide is at least 80%, at least 85%, at least 90%, or at least 95% complementary to SEQ ID NO:1 or 2.

5. The compound of any one of claims 1-4, wherein the modified oligonucleotide comprises at least one modification selected from modified nucleoside linkages, modified sugars, and modified nucleobases.

6. The compound according to any one of claims 1-5, wherein the compound is double-stranded.

7. A compound comprising a first modified oligonucleotide of 14 to 23 linked nucleosides, the first modified oligonucleotide having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 adjacent nucleosides comprising any nucleobase sequence of SEQ ID NO: 11-223; and a second modified oligonucleotide of 14 to 23 linked nucleosides, the second modified oligonucleotide having a region complementary to the first modified oligonucleotide.

8. A compound comprising a first modified oligonucleotide having 14 to 23 linked nucleosides, the first modified oligonucleotide having a nucleobase sequence comprising any one of SEQ ID NO: 11-223; and a second modified oligonucleotide having 14 to 23 linked nucleosides, the second modified oligonucleotide having a region complementary to the first modified oligonucleotide.

9. A compound comprising a first modified oligonucleotide having a nucleobase sequence selected from any of SEQ ID NO: 11-223; and a second modified oligonucleotide having a length of 19 to 23 linked nucleosides having a region complementary to the first modified oligonucleotide.

10. The compound of any one of claims 7-9, wherein the first modified oligonucleotide has at least 80%, at least 85%, at least 90%, or at least 95% complementarity or identity in length with SEQ ID NO: 1 or 2.

11. The compound of any one of claims 7-10, wherein the first modified oligonucleotide has at least one, at least two, or at least three mismatches with the region of the same length as the first modified oligonucleotide in SEQ ID NO: 1 or 2.

12. The compound of any one of claims 7-11, wherein the length of the complementary region between the first modified oligonucleotide and the second modified oligonucleotide is 14 to 23 linked nucleosides.

13. The compound of any one of claims 7-11, wherein the length of the complementary region between the first modified oligonucleotide and the second modified oligonucleotide is 19 to 23 linked nucleosides.

14. The compound of any one of claims 7-11, wherein the length of the complementary region between the first modified oligonucleotide and the second modified oligonucleotide is 21 to 23 linked nucleosides.

15. The compound of any one of claims 7-11, wherein the first modified oligonucleotide is completely complementary to the second modified oligonucleotide.

16. The compound of any one of claims 7-15, wherein the first modified oligonucleotide comprises at least one modification selected from modified nucleoside linkages, modified sugars, and modified nucleobases.

17. The compound of any one of claims 7-16, wherein the second modified oligonucleotide comprises at least one modification selected from the group consisting of modified nucleoside linkages, modified sugars, and modified nucleobases.

18. The compound of any one of claims 5, 16 and 17, wherein the modified nucleoside linkage is a thiophosphate nucleoside linkage or a methylphosphonate nucleoside linkage.

19. The compound of claim 18, wherein the thiophosphate nucleoside link or the methylphosphonate nucleoside link is located at the 3' end of the first modified oligonucleotide or the second modified oligonucleotide, or at the 5' end of the first modified oligonucleotide.

20. The compound of any one of claims 5, 16 and 17, wherein the modified sugar comprises a modification selected from the group consisting of halogens, alkoxy groups and bicyclic sugars.

21. The compound of claim 20, wherein the modified sugar comprises 2'-F modification.

22. The compound of claim 20, wherein the modified sugar comprises 2'-OMe modification.

23. The compound of any one of claims 7-15, wherein each nucleoside of the first modified oligonucleotide comprises a modified sugar.

24. The compound of any one of claims 7-15, wherein each nucleoside of the second modified oligonucleotide comprises a modified sugar.

25. The compound of claim 23 or 24, wherein the modified sugar comprises a modification selected from the group consisting of halogens, alkoxy groups, and bicyclic sugars or combinations thereof.

26. The compound of claim 25, wherein the modified sugar comprises a modification selected from the group consisting of LNA, cEt, 2'-MOE, 2'-F, 2'-OMe and 2'-deoxy or combinations thereof.

27. The compound of claim 26, wherein the first modified oligonucleotide comprises no more than ten 2'-F sugar modifications.

28. The compound of claim 27, wherein the second modified oligonucleotide comprises no more than five 2'-F sugar modifications.

29. The compound as claimed in any of the preceding claims, comprising a conjugated group.

30. The compound of claim 29, wherein the conjugating group is attached to the 5' end of the modified oligonucleotide.

31. The compound of claim 29 or 30, wherein the conjugating group comprises a targeting portion.

32. The compound of claim 31, wherein the targeting portion comprises one or more ligands selected from one or more tropomyosin receptor B (TrkB) ligands, one or more type 1 cannabinoid receptor (CB1) ligands, and one or more α4β ligands. 1 / 7 Integrin ligands and one or more N Ligands of the methyl-D-aspartate receptor (NMDA).

33. The compound of claim 32, wherein the modified oligonucleotide is the second modified oligonucleotide.

34. The compound of claim 33, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are present. 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 5' end of the modified oligonucleotide.

35. The compound of claim 33, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are present. 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 3' end of the modified oligonucleotide.

36. The compound of claim 33, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are present. 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 5' and 3' ends of the modified oligonucleotide.

37. The compound according to any one of claims 32-36, wherein: The one or more TrkB ligands are selected from any one of formulas I-XX, XXV and XXX; The one or more CB1 ligands are of formula XXVI; The one or more α4β 1 / 7 Integrin ligands are selected from any one of formulas XXVII, XXVIII, XXXI, and XXXII; and The one or more NMDA ligands are of formula XXIX.

38. The compound of any one of claims 29-37, wherein the conjugating group comprises one or more lipids.

39. The compound of claim 38, wherein the modified oligonucleotide is the second modified oligonucleotide.

40. The compound of claim 38 or 39, wherein one or more lipids are attached to the nucleoside internucleotide of the modified oligonucleotide.

41. The compound of claim 40, wherein the internucleotide linking of the modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV.

42. The compound of any one of claims 32-41, wherein the modified oligonucleotide comprises: One or more TrkB ligands, one or more CB1 ligands, one or more α4β 1 / 7 Integrin ligands or one or more NMDA ligands; and One or more lipids.

43. The compound of claim 42, wherein the modified oligonucleotide is the second modified oligonucleotide.

44. The compound of claim 42, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are present. 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 5' end of the modified oligonucleotide.

45. The compound of claim 42, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are present. 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 3' end of the modified oligonucleotide.

46. ​​The compound of claim 42, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are present. 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 5' and 3' ends of the modified oligonucleotide.

47. The compound of claim 42, wherein: The one or more TrkB ligands are selected from any one of formulas I-XX, XXV and XXX; The one or more CB1 ligands are of formula XXVI; The one or more α4β 1 / 7 Integrin ligands are selected from any one of formulas XXVII, XXVIII, XXXI, and XXXII; and The one or more NMDA ligands are of formula XXIX.

48. The compound of any one of claims 42-47, wherein the one or more lipids are attached to the nucleoside internucleotide of the modified oligonucleotide.

49. The compound of claim 48, wherein the internucleotide linking of the modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV.

50. The compound of any one of claims 1-49, wherein the modified oligonucleotide comprises one or more substituted or unsubstituted alkyl or alkenyl groups.

51. The compound of claim 50, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C4-C6 groups. 30 Hydrocarbon chain.

52. The compound of claim 51, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C5-C6 groups. 20 Hydrocarbon chain, optionally wherein one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C24 groups. 14 -C 20 Hydrocarbon chain.

53. The compound of claim 52, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C. 16 Hydrocarbon chain, saturated or unsaturated C 17 Hydrocarbon chain, saturated or unsaturated C 18 Hydrocarbon chain, either saturated or unsaturated C 22 Hydrocarbon chain.

54. The compound of any one of claims 50-53, wherein one or more substituted or unsubstituted alkyl or alkenyl groups are attached to the nucleoside internucleotide of the modified oligonucleotide.

55. The compound of claim 54, wherein the nucleoside-to-nucleotide linkage of the modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV.

56. The compound of any one of claims 1-6, wherein the modified oligonucleotide comprises a 5'-phosphonate modification.

57. The compound of any one of claims 7-55, wherein the first modified oligonucleotide comprises a 5'-phosphonate modification.

58. The compound of claim 56 or 57, wherein the 5'-phosphonate modification is a 5'-vinylphosphonate modification or a 5'-ethylidenephosphonate modification.

59. A compound comprising: A first modified oligonucleotide containing a 5'-phosphonate modification, wherein the first modified oligonucleotide is at least 80% complementary to the region of SEQ ID NO: 1 or 2; and A second modified oligonucleotide containing one or more ligands.

60. The compound of claim 59, wherein the first modified oligonucleotide comprises a 5'-terminal nucleoside containing the 5'-phosphonate modification.

61. The compound of claim 59 or 60, wherein the 5'-phosphonate modification is a 5'-vinylphosphonate modification or a 5'-ethylidenephosphonate modification.

62. The compound of any one of claims 59-61, wherein the 5'-phosphonate modification is a 5'-vinylphosphonate modification.

63. The compound of any one of claims 59-61, wherein the 5'-phosphonate modification is a 5'-ethylidene phosphonate modification.

64. The compound of any one of claims 59-63, wherein the second modified oligonucleotide comprises one or more ligands selected from one or more TrkB ligands, one or more CB1 ligands, and one or more α4β ligands. 1 / 7 Integrin ligands and ligands of one or more NMDA ligands.

65. The compound of claim 64, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are... 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 5' end of the second modified oligonucleotide.

66. The compound of claim 64, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are present. 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 3' end of the second modified oligonucleotide.

67. The compound of claim 64, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are present. 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 5' and 3' ends of the second modified oligonucleotide.

68. The compound of claim 64, wherein: The one or more TrkB ligands are selected from any one of formulas I-XX, XXV and XXX; The one or more CB1 ligands are of formula XXVI; The one or more α4β 1 / 7 Integrin ligands are selected from any one of formulas XXVII, XXVIII, XXXI, and XXXII; and The one or more NMDA ligands are of formula XXIX.

69. The compound of any one of claims 59-68, wherein the second modified oligonucleotide comprises one or more TrkB ligands.

70. The compound of claim 69, wherein one or more TrkB ligands are selected from any one of formulas I-XX, XXV, and XXX.

71. The compound of claim 69 or 70, wherein the second modified oligonucleotide comprises a TrkB ligand.

72. The compound of claim 69 or 70, wherein the second modified oligonucleotide comprises at least two TrkB ligands.

73. The compound of claim 72, wherein the at least two TrkB ligands are identical.

74. The compound of claim 72, wherein the at least two TrkB ligands are different.

75. The compound of any one of claims 59-68, wherein the second modified oligonucleotide comprises one or more CB1 ligands.

76. The compound of claim 75, wherein one or more CB1 ligands are of formula XXVI.

77. The compound of claim 75 or 76, wherein the second modified oligonucleotide comprises a CB1 ligand.

78. The compound of claim 75 or 76, wherein the second modified oligonucleotide comprises at least two CB1 ligands.

79. The compound of claim 78, wherein the at least two CB1 ligands are identical.

80. The compound of claim 78, wherein the at least two CB1 ligands are different.

81. The compound of any one of claims 59-68, wherein the second modified oligonucleotide comprises one or more α4β 1 / 7 Integrin ligands.

82. The compound of claim 81, wherein one or more α4β 1 / 7 The integrin ligand is selected from any one of formulas XXVII, XXVIII, XXXI, and XXXII.

83. The compound of claim 81 or 82, wherein the second modified oligonucleotide comprises an α4β 1 / 7 Integrin ligands.

84. The compound of claim 81 or 82, wherein the second modified oligonucleotide comprises at least two α4β groups. 1 / 7 Integrin ligands.

85. The compound of claim 84, wherein the at least two α4β compounds are... 1 / 7 The integrin ligands are the same.

86. The compound of claim 84, wherein the at least two α4β compounds are... 1 / 7 Integrin ligands are different.

87. The compound of any one of claims 59-68, wherein the second modified oligonucleotide comprises one or more NMDA ligands.

88. The compound of claim 87, wherein one or more NMDA ligands are of formula XXIX.

89. The compound of claim 87 or 88, wherein the second modified oligonucleotide comprises an NMDA ligand.

90. The compound of claim 87 or 88, wherein the second modified oligonucleotide comprises at least two NMDA ligands.

91. The compound of claim 90, wherein the at least two NMDA ligands are identical.

92. The compound of claim 90, wherein the at least two NMDA ligands are different.

93. The compound of any one of claims 59-92, wherein the second modified oligonucleotide comprises one or more lipids.

94. The compound of any one of claims 59-93, wherein the second modified oligonucleotide comprises one or more substituted or unsubstituted alkyl or alkenyl groups.

95. The compound of claim 94, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C4-C6 groups. 30 Hydrocarbon chain.

96. The compound of claim 95, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C5-C6 groups. 20 Hydrocarbon chain, optionally wherein one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C24 groups. 14 -C 20 Hydrocarbon chain.

97. The compound of claim 96, wherein the one or more substituted or unsubstituted alkyl or alkenyl groups comprise saturated or unsaturated C. 16 Hydrocarbon chain, saturated or unsaturated C 17 Hydrocarbon chain, saturated or unsaturated C 18 Hydrocarbon chain, either saturated or unsaturated C 22 Hydrocarbon chain.

98. The compound of any one of claims 94-97, wherein one or more substituted or unsubstituted alkyl or alkenyl groups are attached to the nucleoside internucleotide of the second modified oligonucleotide.

99. The compound of claim 98, wherein the internucleotide link of the second modified oligonucleotide is selected from any one of formulas XXI-XXIV and XXXIII-XXXV.

100. The compound of any one of claims 59-99, wherein the first modified oligonucleotide has a length of 14 to 30 linked nucleosides.

101. The compound of any one of claims 59-100, wherein the second modified oligonucleotide is 14 to 30 linked nucleosides in length and has a region complementary to the first modified oligonucleotide.

102. The compound of any one of claims 59-101, wherein the first modified oligonucleotide has a nucleobase sequence comprising at least 14 adjacent nucleobases of any one of SEQ ID NO: 11-18, 28-106, 184-187, 196-202 or 214-223.

103. The compound of any one of claims 59-102, wherein the second modified oligonucleotide has a nucleobase sequence comprising at least 14 adjacent nucleobases of any one of SEQ ID NO: 19-27, 107-183, 188-195 and 203-213.

104. The compound of any one of claims 59-103, wherein the first modified oligonucleotide is selected from any one of IA Ref ID NO in Table 3.

105. The compound of any one of claims 59-104, wherein the second modified oligonucleotide is selected from any one of IS Ref ID NO in Table 3.

106. A compound comprising a first modified oligonucleotide selected from any one of the groups IA Ref ID NO in Table 3, and a second modified oligonucleotide of 14 to 21 linked nucleosides that are completely complementary to the first modified oligonucleotide.

107. A compound comprising a first modified oligonucleotide selected from any one of the groups IA Ref ID NO in Table 3, and a second modified oligonucleotide selected from any one of the groups IS Ref ID NO in Table 3.

108. A compound comprising a first modified oligonucleotide selected from any one of the groups IA Ref ID NO in Table 3, and a second modified oligonucleotide selected from any one of the groups IS Ref ID NO in Table 3.

109. The compound of claim 106, 107 or 108, comprising a conjugating group.

110. The compound of claim 109, wherein the conjugation group is attached to the 5' end of the modified oligonucleotide.

111. The compound of claim 109 or 110, wherein the conjugating group comprises a targeting portion.

112. The compound of claim 111, wherein the targeting portion comprises one or more ligands selected from one or more tropomyosin receptor B (TrkB) ligands, one or more type 1 cannabinoid receptor (CB1) ligands, and one or more α4β ligands. 1 / 7 Integrin ligands and ligands of one or more NMDA ligands.

113. The compound of claim 112, wherein the modified oligonucleotide is the second modified oligonucleotide.

114. The compound of claim 112 or 113, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are... 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 5' end of the modified oligonucleotide.

115. The compound of claim 112 or 113, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are present. 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 3' end of the modified oligonucleotide.

116. The compound of claim 112 or 113, wherein the one or more TrkB ligands, the one or more CB1 ligands, and the one or more α4β ligands are... 1 / 7 An integrin ligand or one or more NMDA ligands are attached to the 5' and 3' ends of the modified oligonucleotide.

117. The compound according to any one of claims 112-116, wherein: The one or more TrkB ligands are selected from any of formulas I-XX XXV and XXX; The one or more CB1 ligands are of formula XXVI; The one or more α4β 1 / 7 Integrin ligands are selected from any one of formulas XXVII, XXVIII, XXXI, and XXXII; and The one or more NMDA ligands are of formula XXIX.

118. The compound of any one of claims 1-117, wherein the compound is in a pharmaceutically acceptable salt form.

119. The compound of claim 118, wherein the pharmaceutically acceptable salt is a sodium salt.

120. The compound of claim 118, wherein the pharmaceutically acceptable salt is a potassium salt.

121. A composition comprising any of the compounds of the preceding claims and a pharmaceutically acceptable carrier.

122. A composition for use in therapy comprising any of the compounds claimed in the preceding claims.

123. A method of treating, preventing, or improving an individual’s SOD1-related disease, condition, or disorder, comprising administering to the individual a compound targeting SOD1 to treat, prevent, or improve the disease, condition, or disorder.

124. A method of administering to an individual the compound of any one of claims 1-120 or the composition of claim 122.

125. The method of claim 123 or 124, wherein the disease, symptom, or disorder is a neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death.

126. The method of any one of claims 123-125, wherein application of the compound can inhibit or alleviate or improve symptoms of neurodegenerative diseases, ALS, or such as loss of motor function or neuronal death.

127. A method for inhibiting SOD1 expression in cells, comprising contacting the cells with a compound targeting SOD1 to inhibit SOD1 expression in the cells.

128. The method of claim 127, wherein the cell is in the brain of an individual.

129. The method of claim 128, wherein the individual suffers from or is at risk of suffering from a neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death.

130. A method for alleviating or suppressing a neurodegenerative disease in an individual, said neurodegenerative disease including ALS or its symptoms such as loss of motor function or neuronal death, said method comprising administering to the individual a compound targeting SOD1, thereby alleviating or suppressing the individual's neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death.

131. The method of claim 130, wherein the individual suffers from or is at risk of suffering from a neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death.

132. The method of any one of claims 123-131, wherein the compound is a compound targeting SOD1.

133. The method of any one of claims 123-132, wherein the compound is the compound of any one of claims 1-120 or the composition of claim 122.

134. The method of claim 133, wherein the compound or the composition is administered parenterally.

135. The method of claim 133, wherein the compound or the composition is administered via intrathecal application.

136. Use of compounds targeting SOD1 for the treatment, prevention or improvement of diseases, conditions or disorders related to SOD1.

137. The use as claimed in claim 136, wherein the disease, condition, or ailment is a neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death.

138. The use as described in claim 136 or 137, wherein the compound is a compound targeting SOD1.

139. The use according to any one of claims 136-138, wherein the compound or the modified oligonucleotide is the compound according to any one of claims 1-120 or the composition according to claim 122.

140. Use of compounds targeting SOD1 in the manufacture of pharmaceutical agents for the treatment, prevention or improvement of diseases, conditions or disorders related to SOD1.

141. The use as claimed in claim 140, wherein the disease is a neurodegenerative disease, including ALS or its symptoms such as loss of motor function or neuronal death.

142. The use as described in claim 140 or 141, wherein the compound is a compound targeting SOD1.

143. The use according to any one of claims 140-142, wherein the compound or the modified oligonucleotide is the compound of any one of claims 1-120 or the composition of claim 122.

144. The method or use as claimed in any of the preceding claims, wherein the compound or composition is administered to an individual about once every three months to about once a year.

145. The method or use as claimed in any of the preceding claims, wherein the compound or composition is administered to an individual about once every three months, about once every six months, or about once a year.

146. A method for delivering a therapeutic oligonucleotide to the brain of a subject, comprising administering to the subject the compound of any one of claims 1-120 or a stereoisomer, tautomer, prodrug, or salt thereof or the composition of claim 122.

147. The method of claim 146, wherein the therapeutic oligonucleotide is delivered to one or more brain regions selected from the group consisting of: striatum, cerebellum, brainstem, hippocampus, frontal cortex, and spinal cord.

148. A method for treating or improving a disease, condition, or symptom of a subject, comprising administering to the subject a compound of any one of claims 1-120 or a stereoisomer, tautomer, prodrug, or salt thereof, or a composition of claim 122.

149. The method of claim 148, wherein the disease, condition or symptom is a central nervous system (CNS) disease, condition or symptom.

150. The method of claim 148 or 149, wherein the disease, condition or symptom is Alzheimer's disease or a symptom thereof.

151. The method of any one of claims 146-150, wherein the administration is intrathecal or intraventricular (ICV) administration.

152. A method of delivering one or more cargo molecules into the living cells or tissues of a subject, comprising administering to the subject a compound of any one of claims 1-120 or a composition of claim 122.

153. The method of claim 152, wherein the cell or tissue is a CNS cell or tissue.